WO2024035864A1 - Combination of quercetin and pathenolide as anti-inflammatory agents for use in the treatment of dermatitis - Google Patents
Combination of quercetin and pathenolide as anti-inflammatory agents for use in the treatment of dermatitis Download PDFInfo
- Publication number
- WO2024035864A1 WO2024035864A1 PCT/US2023/029963 US2023029963W WO2024035864A1 WO 2024035864 A1 WO2024035864 A1 WO 2024035864A1 US 2023029963 W US2023029963 W US 2023029963W WO 2024035864 A1 WO2024035864 A1 WO 2024035864A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- flavonoid
- sesquiterpene lactone
- composition
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 title claims description 176
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 title claims description 124
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 title claims description 88
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 title claims description 88
- 235000005875 quercetin Nutrition 0.000 title claims description 88
- 229960001285 quercetin Drugs 0.000 title claims description 88
- 238000011282 treatment Methods 0.000 title abstract description 38
- 201000004624 Dermatitis Diseases 0.000 title description 15
- 239000002260 anti-inflammatory agent Substances 0.000 title description 15
- 229940121363 anti-inflammatory agent Drugs 0.000 title description 15
- UIMHJAOZYISGTJ-UHFFFAOYSA-N Pathenolide Natural products CC1=C/CCC2(C)OC2C3CC(=O)C(=C)C3CC1 UIMHJAOZYISGTJ-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 202
- 230000004054 inflammatory process Effects 0.000 claims abstract description 77
- 206010061218 Inflammation Diseases 0.000 claims abstract description 76
- 229930003935 flavonoid Natural products 0.000 claims description 361
- 235000017173 flavonoids Nutrition 0.000 claims description 361
- 150000002215 flavonoids Chemical class 0.000 claims description 358
- 229930009674 sesquiterpene lactone Natural products 0.000 claims description 321
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 claims description 318
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 claims description 311
- 150000003839 salts Chemical class 0.000 claims description 213
- 150000001875 compounds Chemical class 0.000 claims description 143
- 239000001257 hydrogen Substances 0.000 claims description 138
- 229910052739 hydrogen Inorganic materials 0.000 claims description 138
- 210000004027 cell Anatomy 0.000 claims description 129
- 239000000203 mixture Substances 0.000 claims description 115
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 105
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 84
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 claims description 68
- 229940069510 parthenolide Drugs 0.000 claims description 68
- -1 C(O)-C2-C6 alkenyl Chemical group 0.000 claims description 55
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 claims description 52
- 210000001519 tissue Anatomy 0.000 claims description 46
- 150000002431 hydrogen Chemical class 0.000 claims description 40
- HRYLQFBHBWLLLL-UHFFFAOYSA-N (+)-costunolide Natural products C1CC(C)=CCCC(C)=CC2OC(=O)C(=C)C21 HRYLQFBHBWLLLL-UHFFFAOYSA-N 0.000 claims description 38
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims description 36
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 claims description 34
- 206010020751 Hypersensitivity Diseases 0.000 claims description 33
- 208000026935 allergic disease Diseases 0.000 claims description 32
- 230000009610 hypersensitivity Effects 0.000 claims description 31
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims description 28
- 210000000056 organ Anatomy 0.000 claims description 25
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 claims description 24
- 125000000623 heterocyclic group Chemical group 0.000 claims description 22
- 210000003491 skin Anatomy 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 21
- CUGKULNFZMNVQI-UHFFFAOYSA-N Costunolid I Natural products CC1=CCC=C(/C)CCC2C(C1)OC(=O)C2=C CUGKULNFZMNVQI-UHFFFAOYSA-N 0.000 claims description 20
- MMTZAJNKISZWFG-UHFFFAOYSA-N costunolide Natural products CC1CCC2C(CC(=C/C=C1)C)OC(=O)C2=C MMTZAJNKISZWFG-UHFFFAOYSA-N 0.000 claims description 20
- NOZAJYKZMCFNFG-WULVTUHRSA-N Onopordopicrin Chemical compound OCC(=C)C(=O)O[C@H]1CC(/C)=C/CC\C(CO)=C\[C@H]2OC(=O)C(=C)[C@@H]21 NOZAJYKZMCFNFG-WULVTUHRSA-N 0.000 claims description 19
- 125000004432 carbon atom Chemical group C* 0.000 claims description 19
- CHIQPSWMOMNTPF-UHFFFAOYSA-N onopordopicrin Natural products CC1=C/CCC(=CC2OC(=O)C(=C)C2C(C1)OC(=O)C(=O)CO)CO CHIQPSWMOMNTPF-UHFFFAOYSA-N 0.000 claims description 19
- PDEJECFRCJOMEN-UHFFFAOYSA-N 4-hydroxy-3alpha,4,5,8,9,11alpha-hexahydro-6,10-dimethyl-3-methylene-cyclodeca[b]furan-2(3H)-one Natural products OC1CC(C)=CCCC(C)=CC2OC(=O)C(=C)C21 PDEJECFRCJOMEN-UHFFFAOYSA-N 0.000 claims description 18
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims description 18
- PDEJECFRCJOMEN-OURLZOILSA-N eupatolide Chemical compound O[C@@H]1CC(/C)=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]21 PDEJECFRCJOMEN-OURLZOILSA-N 0.000 claims description 18
- PDEJECFRCJOMEN-MGPQQGTHSA-N eupatolide Natural products CC1=CCCC(C)=C[C@H]2OC(=O)C(=C)[C@@H]2[C@H](O)C1 PDEJECFRCJOMEN-MGPQQGTHSA-N 0.000 claims description 18
- 235000008777 kaempferol Nutrition 0.000 claims description 18
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims description 18
- 235000009498 luteolin Nutrition 0.000 claims description 18
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims description 18
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims description 18
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 claims description 17
- KQNGHARGJDXHKF-UHFFFAOYSA-N dihydrotamarixetin Natural products C1=C(O)C(OC)=CC=C1C1C(O)C(=O)C2=C(O)C=C(O)C=C2O1 KQNGHARGJDXHKF-UHFFFAOYSA-N 0.000 claims description 17
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 claims description 17
- 235000007743 myricetin Nutrition 0.000 claims description 17
- 229940116852 myricetin Drugs 0.000 claims description 17
- 241000124008 Mammalia Species 0.000 claims description 16
- HRYLQFBHBWLLLL-AHNJNIBGSA-N costunolide Chemical compound C1CC(/C)=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]21 HRYLQFBHBWLLLL-AHNJNIBGSA-N 0.000 claims description 16
- 125000000810 parthenolide group Chemical group 0.000 claims description 16
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 14
- 241000282414 Homo sapiens Species 0.000 claims description 14
- 201000008937 atopic dermatitis Diseases 0.000 claims description 14
- 210000001508 eye Anatomy 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000556 agonist Substances 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 235000011990 fisetin Nutrition 0.000 claims description 12
- 210000004072 lung Anatomy 0.000 claims description 12
- 201000004681 Psoriasis Diseases 0.000 claims description 11
- 230000002500 effect on skin Effects 0.000 claims description 11
- 230000000699 topical effect Effects 0.000 claims description 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 10
- 210000002216 heart Anatomy 0.000 claims description 9
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 claims description 8
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 claims description 8
- 210000003734 kidney Anatomy 0.000 claims description 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 7
- 210000004556 brain Anatomy 0.000 claims description 7
- 210000004400 mucous membrane Anatomy 0.000 claims description 7
- 230000009885 systemic effect Effects 0.000 claims description 7
- KDDXOGDIPZSCTM-UHFFFAOYSA-N 2-[1H-indol-3-yl(oxo)methyl]-4-thiazolecarboxylic acid methyl ester Chemical compound COC(=O)C1=CSC(C(=O)C=2C3=CC=CC=C3NC=2)=N1 KDDXOGDIPZSCTM-UHFFFAOYSA-N 0.000 claims description 6
- 101150023417 PPARG gene Proteins 0.000 claims description 6
- 210000000278 spinal cord Anatomy 0.000 claims description 5
- 210000002429 large intestine Anatomy 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 210000005013 brain tissue Anatomy 0.000 claims description 3
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 210000000232 gallbladder Anatomy 0.000 claims description 3
- 210000005003 heart tissue Anatomy 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 210000004923 pancreatic tissue Anatomy 0.000 claims description 3
- 210000005084 renal tissue Anatomy 0.000 claims description 3
- 210000000813 small intestine Anatomy 0.000 claims description 3
- 210000000952 spleen Anatomy 0.000 claims description 3
- 210000005092 tracheal tissue Anatomy 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 abstract description 165
- 239000003814 drug Substances 0.000 abstract description 27
- 229940124597 therapeutic agent Drugs 0.000 abstract description 21
- 238000000034 method Methods 0.000 description 468
- 235000002639 sodium chloride Nutrition 0.000 description 199
- 108090000695 Cytokines Proteins 0.000 description 74
- 102000004127 Cytokines Human genes 0.000 description 73
- 208000024891 symptom Diseases 0.000 description 56
- 241000196324 Embryophyta Species 0.000 description 47
- 230000003110 anti-inflammatory effect Effects 0.000 description 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 43
- 230000002757 inflammatory effect Effects 0.000 description 38
- 239000000126 substance Substances 0.000 description 37
- 201000010099 disease Diseases 0.000 description 28
- 230000001965 increasing effect Effects 0.000 description 27
- 239000003550 marker Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 239000003981 vehicle Substances 0.000 description 20
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 17
- 102000004889 Interleukin-6 Human genes 0.000 description 16
- 108090001005 Interleukin-6 Proteins 0.000 description 16
- 230000006378 damage Effects 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 15
- 108090000174 Interleukin-10 Proteins 0.000 description 14
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
- 102100040247 Tumor necrosis factor Human genes 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 108090000978 Interleukin-4 Proteins 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 208000010668 atopic eczema Diseases 0.000 description 12
- 229960003957 dexamethasone Drugs 0.000 description 12
- 108700012920 TNF Proteins 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 210000002540 macrophage Anatomy 0.000 description 11
- 230000002195 synergetic effect Effects 0.000 description 11
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 208000007882 Gastritis Diseases 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 150000001721 carbon Chemical group 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 206010016654 Fibrosis Diseases 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 206010037660 Pyrexia Diseases 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 206010006451 bronchitis Diseases 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 210000005069 ears Anatomy 0.000 description 8
- 230000004761 fibrosis Effects 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 238000007911 parenteral administration Methods 0.000 description 8
- 230000036559 skin health Effects 0.000 description 8
- 201000004415 tendinitis Diseases 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 208000011231 Crohn disease Diseases 0.000 description 7
- 208000009329 Graft vs Host Disease Diseases 0.000 description 7
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 7
- 208000019695 Migraine disease Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 208000003251 Pruritus Diseases 0.000 description 7
- 208000000491 Tendinopathy Diseases 0.000 description 7
- 206010043255 Tendonitis Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 208000006673 asthma Diseases 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 208000024908 graft versus host disease Diseases 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 208000002551 irritable bowel syndrome Diseases 0.000 description 7
- 210000001503 joint Anatomy 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 206010006811 Bursitis Diseases 0.000 description 6
- 206010009900 Colitis ulcerative Diseases 0.000 description 6
- 208000017604 Hodgkin disease Diseases 0.000 description 6
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 6
- 206010040070 Septic Shock Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 description 6
- 238000002648 combination therapy Methods 0.000 description 6
- 208000007565 gingivitis Diseases 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000008297 liquid dosage form Substances 0.000 description 6
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 6
- 239000007909 solid dosage form Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 206010043778 thyroiditis Diseases 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 5
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 5
- 208000032467 Aplastic anaemia Diseases 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 201000008482 osteoarthritis Diseases 0.000 description 5
- 201000006292 polyarteritis nodosa Diseases 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 5
- LCAWNFIFMLXZPQ-UHFFFAOYSA-N 4',7-dihydroxyflavone Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=CC=C(O)C=C2O1 LCAWNFIFMLXZPQ-UHFFFAOYSA-N 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 206010010741 Conjunctivitis Diseases 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 206010020850 Hyperthyroidism Diseases 0.000 description 4
- 108090000176 Interleukin-13 Proteins 0.000 description 4
- 210000004322 M2 macrophage Anatomy 0.000 description 4
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 4
- 208000001647 Renal Insufficiency Diseases 0.000 description 4
- 208000024780 Urticaria Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- OJPDLGRQQOMYQL-JSGCOSHPSA-N costunolide group Chemical group CC1=C2[C@H]3OC(=O)C(=C)[C@@H]3CCC(C)=C2CC1 OJPDLGRQQOMYQL-JSGCOSHPSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 201000006370 kidney failure Diseases 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 206010027599 migraine Diseases 0.000 description 4
- 206010028417 myasthenia gravis Diseases 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 208000005987 polymyositis Diseases 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 201000003068 rheumatic fever Diseases 0.000 description 4
- 208000013220 shortness of breath Diseases 0.000 description 4
- 206010041232 sneezing Diseases 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 210000001685 thyroid gland Anatomy 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 208000027496 Behcet disease Diseases 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 3
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 3
- 101150019209 IL13 gene Proteins 0.000 description 3
- 101150012417 IL1B gene Proteins 0.000 description 3
- 101150081923 IL4 gene Proteins 0.000 description 3
- 101150101999 IL6 gene Proteins 0.000 description 3
- 101150029237 Il11 gene Proteins 0.000 description 3
- 206010023232 Joint swelling Diseases 0.000 description 3
- 206010023421 Kidney fibrosis Diseases 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
- 206010039085 Rhinitis allergic Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 101150033527 TNF gene Proteins 0.000 description 3
- 206010044248 Toxic shock syndrome Diseases 0.000 description 3
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 201000010105 allergic rhinitis Diseases 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 229940096118 ella Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 229960004584 methylprednisolone Drugs 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 201000000306 sarcoidosis Diseases 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- PVFGJHYLIHMCQD-UHFFFAOYSA-N 2-(3,4-dihydroxyphenyl)-7-hydroxychromen-4-one Chemical compound C=1C(O)=CC=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 PVFGJHYLIHMCQD-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- FMEHGPQTMOPUGM-UHFFFAOYSA-N 3,3'-dimethylquercetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC)=C1 FMEHGPQTMOPUGM-UHFFFAOYSA-N 0.000 description 2
- DANYIYRPLHHOCZ-UHFFFAOYSA-N 5,7-dihydroxy-4'-methoxyflavone Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 DANYIYRPLHHOCZ-UHFFFAOYSA-N 0.000 description 2
- HHGPYJLEJGNWJA-UHFFFAOYSA-N 5-hydroxy-3,3',4',7-tetramethoxyflavone Chemical compound C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HHGPYJLEJGNWJA-UHFFFAOYSA-N 0.000 description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
- MQGPSCMMNJKMHQ-UHFFFAOYSA-N 7-hydroxyflavone Chemical compound C=1C(O)=CC=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 MQGPSCMMNJKMHQ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 2
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010008469 Chest discomfort Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 208000003164 Diplopia Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 2
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- RRRSSAVLTCVNIQ-UHFFFAOYSA-N Luteolin 7-methyl ether Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 RRRSSAVLTCVNIQ-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010027603 Migraine headaches Diseases 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 241000669298 Pseudaulacaspis pentagona Species 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- DLXIJJURUIXRFK-UHFFFAOYSA-N Retusin(Dalbergia) Natural products C1=CC(OC)=CC=C1C1=COC2=C(O)C(O)=CC=C2C1=O DLXIJJURUIXRFK-UHFFFAOYSA-N 0.000 description 2
- GXAPLLMJHZBIPX-UHFFFAOYSA-N Retusine Natural products O1C(=O)C(C)C(C)C(C)(O)C(=O)OCC2CCN3C2C1CC3 GXAPLLMJHZBIPX-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 2
- 208000007587 Transfusion-Related Acute Lung Injury Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 206010047924 Wheezing Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 235000008714 apigenin Nutrition 0.000 description 2
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 2
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 2
- 229940117893 apigenin Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- BGSOJVFOEQLVMH-VWUMJDOOSA-N cortisol phosphate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 BGSOJVFOEQLVMH-VWUMJDOOSA-N 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000003568 cytokine secretion assay Methods 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 208000029444 double vision Diseases 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- WIQOUTANBFOBPB-PLJDJVMKSA-N elephantoin Chemical compound CC(=C)C(=O)O[C@H]([C@H]1C(=C)C(=O)O[C@@H]1[C@@H]1O[C@]1(C)C1)CC2=C[C@@H]1OC2=O WIQOUTANBFOBPB-PLJDJVMKSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002118 epoxides Chemical group 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- VCCRNZQBSJXYJD-UHFFFAOYSA-N galangin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=CC=C1 VCCRNZQBSJXYJD-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 210000004247 hand Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 230000005722 itchiness Effects 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960003464 mefenamic acid Drugs 0.000 description 2
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- BWORNNDZQGOKBY-UHFFFAOYSA-N ombuin Chemical compound C=1C(OC)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(OC)C(O)=C1 BWORNNDZQGOKBY-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229940124641 pain reliever Drugs 0.000 description 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- SQVXWIUVAILQRH-UHFFFAOYSA-N pratol Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=CC=C(O)C=C2O1 SQVXWIUVAILQRH-UHFFFAOYSA-N 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- VJZLQIPZNBPASX-OJJGEMKLSA-L prednisolone sodium phosphate Chemical compound [Na+].[Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 VJZLQIPZNBPASX-OJJGEMKLSA-L 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 229930008691 retusin Natural products 0.000 description 2
- 208000004124 rheumatic heart disease Diseases 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- IRZVHDLBAYNPCT-UHFFFAOYSA-N tectochrysin Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 IRZVHDLBAYNPCT-UHFFFAOYSA-N 0.000 description 2
- 239000005495 thyroid hormone Substances 0.000 description 2
- 229940036555 thyroid hormone Drugs 0.000 description 2
- 208000005057 thyrotoxicosis Diseases 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical class CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- GSVWPONNFJXHJL-UHFFFAOYSA-N 11betaH-dihydroparthenolide Natural products C1CC(C)=CCCC2(C)OC2C2OC(=O)C(C)C21 GSVWPONNFJXHJL-UHFFFAOYSA-N 0.000 description 1
- GSVWPONNFJXHJL-IOCBBESTSA-N 11β,13-dihydro-parthenolide Chemical group C1C\C(C)=C\CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)[C@@H](C)[C@@H]21 GSVWPONNFJXHJL-IOCBBESTSA-N 0.000 description 1
- VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 description 1
- HRGUSFBJBOKSML-UHFFFAOYSA-N 3',5'-di-O-methyltricetin Chemical compound COC1=C(O)C(OC)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 HRGUSFBJBOKSML-UHFFFAOYSA-N 0.000 description 1
- SCZVLDHREVKTSH-UHFFFAOYSA-N 4',5,7-trihydroxy-3'-methoxyflavone Chemical compound C1=C(O)C(OC)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 SCZVLDHREVKTSH-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- QTQGHKVYLQBJLO-UHFFFAOYSA-N 4-methylbenzenesulfonate;(4-methyl-1-oxo-1-phenylmethoxypentan-2-yl)azanium Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)CC(N)C(=O)OCC1=CC=CC=C1 QTQGHKVYLQBJLO-UHFFFAOYSA-N 0.000 description 1
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 description 1
- 101710135882 50S ribosomal protein L25 Proteins 0.000 description 1
- VHRSUDSXCMQTMA-UWKORSIYSA-N 6-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1C(C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-UWKORSIYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- RZUCCKARTVHQBW-UHFFFAOYSA-N 9beta-hydroxyparthenolide Natural products C1C(O)C(C)=CCCC2(C)OC2C2OC(=O)C(=C)C21 RZUCCKARTVHQBW-UHFFFAOYSA-N 0.000 description 1
- RZUCCKARTVHQBW-ZFDNOKKTSA-N 9α-hydroxyparthenolide Chemical group C1[C@@H](O)C(/C)=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]21 RZUCCKARTVHQBW-ZFDNOKKTSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108010093667 ALX-0061 Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- UPQPVJDISPFHEA-UHFFFAOYSA-N Apigenin dimethyl ether Natural products COC1=CC=CC(C=2OC3=CC(OC)=CC(O)=C3C(=O)C=2)=C1 UPQPVJDISPFHEA-UHFFFAOYSA-N 0.000 description 1
- 241000209524 Araceae Species 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 206010003504 Aspiration Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 206010006803 Burns third degree Diseases 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 241000219357 Cactaceae Species 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 1
- 208000031973 Conjunctivitis infective Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 206010060902 Diffuse alveolar damage Diseases 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 208000003870 Drug Overdose Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 206010015216 Erythema marginatum Diseases 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000221017 Euphorbiaceae Species 0.000 description 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
- VWFJDQUYCIWHTN-UHFFFAOYSA-N Farnesyl pyrophosphate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- SDTOABMYDICPQU-UHFFFAOYSA-N Genkwanin Natural products C=1C(C)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 SDTOABMYDICPQU-UHFFFAOYSA-N 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- 206010018374 Glomerulonephritis minimal lesion Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 1
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- HHZQLQREDATOBM-CODXZCKSSA-M Hydrocortisone Sodium Succinate Chemical compound [Na+].O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC([O-])=O)[C@@H]4[C@@H]3CCC2=C1 HHZQLQREDATOBM-CODXZCKSSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- DZUKXCCSULKRJA-UHFFFAOYSA-N Isopratol Natural products C=1C(OC)=CC=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 DZUKXCCSULKRJA-UHFFFAOYSA-N 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ODYJJNFWFYUXSS-CTSUEIOESA-N Lipiferolide Chemical group CC(=O)O[C@@H]1C\C(C)=C\CC[C@@]2(C)OC2[C@H]2OC(=O)C(=C)[C@H]12 ODYJJNFWFYUXSS-CTSUEIOESA-N 0.000 description 1
- 208000004883 Lipoid Nephrosis Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100436483 Mus musculus Atp7a gene Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010052437 Nasal discomfort Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033296 Overdoses Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- IDDMFNIRSJVBHE-UHFFFAOYSA-N Piscigenin Natural products COC1=C(O)C(OC)=CC(C=2C(C3=C(O)C=C(O)C=C3OC=2)=O)=C1 IDDMFNIRSJVBHE-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 206010037884 Rash pruritic Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 206010070774 Respiratory tract oedema Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000020312 Thickened skin Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 206010044314 Tracheobronchitis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 235000009962 acacetin Nutrition 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940119059 actemra Drugs 0.000 description 1
- 201000001028 acute contagious conjunctivitis Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 229940060236 ala-cort Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 150000001453 anthocyanidins Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- LZERJKGWTQYMBB-UHFFFAOYSA-N apigenin 7,4'-dimethyl ether Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC)C=C2O1 LZERJKGWTQYMBB-UHFFFAOYSA-N 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 150000001789 chalcones Chemical class 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 235000015838 chrysin Nutrition 0.000 description 1
- 229940043370 chrysin Drugs 0.000 description 1
- 229940090100 cimzia Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 229950001565 clazakizumab Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229940026692 decadron Drugs 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229940027008 deltasone Drugs 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 229940087410 dexasone Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 231100000725 drug overdose Toxicity 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- SBHXYTNGIZCORC-ZDUSSCGKSA-N eriodictyol Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-ZDUSSCGKSA-N 0.000 description 1
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 description 1
- 235000011797 eriodictyol Nutrition 0.000 description 1
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- CIPSYTVGZURWPT-UHFFFAOYSA-N galangin Natural products OC1=C(Oc2cc(O)c(O)cc2C1=O)c3ccccc3 CIPSYTVGZURWPT-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- JPMYFOBNRRGFNO-UHFFFAOYSA-N genkwanin Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 JPMYFOBNRRGFNO-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229950000785 hydrocortisone phosphate Drugs 0.000 description 1
- 229960004204 hydrocortisone sodium phosphate Drugs 0.000 description 1
- 229960001401 hydrocortisone sodium succinate Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 150000002596 lactones Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 208000010729 leg swelling Diseases 0.000 description 1
- ODYJJNFWFYUXSS-UHFFFAOYSA-N lipiferolide Natural products CC(=O)OC1CC(C)=CCCC2(C)OC2C2OC(=O)C(=C)C12 ODYJJNFWFYUXSS-UHFFFAOYSA-N 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229940087412 maxidex Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940064748 medrol Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960001293 methylprednisolone acetate Drugs 0.000 description 1
- PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 description 1
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960005170 moexipril Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000013315 neuromuscular junction disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229950010006 olokizumab Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940003515 orapred Drugs 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940097097 pediapred Drugs 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- SUYJZKRQHBQNCA-UHFFFAOYSA-N pinobanksin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=CC=C1 SUYJZKRQHBQNCA-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940096112 prednisol Drugs 0.000 description 1
- 229940096111 prelone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 230000003304 psychophysiological effect Effects 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000001350 reed-sternberg cell Anatomy 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229960001886 rilonacept Drugs 0.000 description 1
- 108010046141 rilonacept Proteins 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229950006348 sarilumab Drugs 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 229940068638 simponi Drugs 0.000 description 1
- 229950006094 sirukumab Drugs 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 229940088542 solu-cortef Drugs 0.000 description 1
- 229940087854 solu-medrol Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- IVDHYUQIDRJSTI-UHFFFAOYSA-N sorafenib tosylate Chemical compound [H+].CC1=CC=C(S([O-])(=O)=O)C=C1.C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 IVDHYUQIDRJSTI-UHFFFAOYSA-N 0.000 description 1
- 229960000487 sorafenib tosylate Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 201000002516 toxic megacolon Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- ARSRJFRKVXALTF-UHFFFAOYSA-N tricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 ARSRJFRKVXALTF-UHFFFAOYSA-N 0.000 description 1
- CMPNIWQMRYYTMK-UHFFFAOYSA-O tricetinidin Natural products [O+]=1C2=CC(O)=CC(O)=C2C=CC=1C1=CC(O)=C(O)C(O)=C1 CMPNIWQMRYYTMK-UHFFFAOYSA-O 0.000 description 1
- BMCJATLPEJCACU-UHFFFAOYSA-N tricin Natural products COc1cc(OC)c(O)c(c1)C2=CC(=O)c3c(O)cc(O)cc3O2 BMCJATLPEJCACU-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002568 urticarial effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
- 229940002005 zometa Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Definitions
- the present disclosure features a method of treating inflammation or an inflammatory disease or disorder (e.g., a dermatological condition) in a subject comprising administering a combination of a flavonoid (e.g., quercetin) and a sesquiterpene lactone (e.g., parthenolide) to the subject.
- administering a combination of a flavonoid (e.g., quercetin) and a sesquiterpene lactone (e.g., parthenolide) to a subject results in a beneficial effect in the subject, e.g., compared with administering the flavonoid and/or sesquiterpene lactone individually.
- administering a combination of a flavonoid and a sesquiterpene lactone to a cell or subject may result in one or more of: (i) reducing the level of an inflammatory cytokine (e.g., IL-6, IL-1b, and TNF-a) in a cell or subject; (ii) increasing the level of an anti-inflammatory cytokine (e.g., IL-4 and IL-10) in a cell or subject; (iii) reducing the level of a hypersensitivity marker (e.g., IL-13, IL-14, INF-g, and serum IgE) in a cell or subject; (iv) inducing expression of an anti-inflammatory macrophage (e.g., M2 macrophage) in a cell or subject; (v) improving skin health in a cell or subject; (vi) improving a symptom of a dermatological condition (e.g., atopic dermatitis, psoriasis, and dermal hypersensitivity
- FIG.1 is a graph depicting ear thickness measurements of oxazolone-stimulated ears or unstimulated control ears after topical treatment with either vehicle, dexamethasone (control), or parthenolide + quercetin.
- FIGS.2A-2C are graphs showing the levels of certain cytokines (FIG.2A - MIP1-beta, FIG.2B - CXCL1, FIG.2C - TNFa) in mice pre-injected for 1 hour with vehicle, dexamethasone (control), or parthenolide + quercetin, then injected with LPS.
- compositions comprising (i) a flavonoid or a pharmaceutically acceptable salt thereof and (ii) a sesquiterpene lactone or a pharmaceutically acceptable salt thereof, as well as compositions and methods of using the same.
- administering a combination of a flavonoid and a sesquiterpene lactone to a subject results in a beneficial effect in the subject, e.g., compared with administering the flavonoid and/or the sesquiterpene lactone individually.
- a combination of a flavonoid and a sesquiterpene lactone may result reducing the level of an inflammatory cytokine in a cell or subject, or treatment of a dermatological condition in a cell or subject.
- a description of exemplary embodiments of the disclosure is provided herein. Definitions As used herein, the articles “a” and “an” refer to one or to more than one (e.g., to at least one) of the grammatical object of the article. “About” and “approximately” shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Exemplary degrees of error are within 20 percent (%), typically, within 10%, and more typically, within 5% of a given value or range of values.
- a physical entity e.g., a sample, e.g., blood sample or liver biopsy specimen
- a value e.g., a numerical value
- Directly acquiring a value includes performing a process that includes a physical change in a sample or another substance, e.g., performing an analytical process which includes a physical change in a substance, e.g., a sample, performing an analytical method, e.g., a method as described herein, e.g., by sample analysis of a cell titer or a bodily fluid, e.g., via mass spectroscopy (e.g. LC-MS) or PCR (e.g., RT-PCR).
- an analytical method e.g., a method as described herein, e.g., by sample analysis of a cell titer or a bodily fluid, e.g., via mass spectroscopy (e.g. LC-MS) or PCR (e.g., RT-PCR).
- “Co-administration”, “co-administering”, “co-providing”, “in combination” and “a combination of” as used herein in the context of the administration of a flavonoid and a sesquiterpene lactone refers to administration at the same time or administration of one therapy before (e.g., immediately before, less than about 5, about 10, about 15, about 30, about 45, about 60 minutes, about 1, about 2, about 3, about 4, about 6, about 8, about 10, about 12, about 16, about 20, about 24, about 48, about 72 or more hours before) administration of a secondary therapy.
- the therapies to be co-administered are formulated in a single composition. In other embodiments, the therapies to be co-administered are formulated separately.
- ranges for the amount of a therapy administered per day, are provided herein.
- the range includes both endpoints.
- the range excludes one or both endpoints.
- the range can exclude the lower endpoint.
- a range of 250 to 400 mg/day, excluding the lower endpoint would cover an amount greater than 250 that is less than or equal to 400 mg/day.
- the term “comprise” is intended to mean “include”. Where a term is provided in the singular, it also contemplates aspects of the invention described by the plural of that term.
- the term “and/or” where used herein is to be taken as specific disclosure of each of the multiple specified features or components with or without another.
- the term “and/or” as used in a phrase such as “A and/or B” herein is intended to include “A and B,” “A or B,” “A” (alone), and “B” (alone).
- the term “and/or” as used in a phrase such as “A, B, and/or C” is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
- a “course” or “course of therapy,” as referred to herein, comprises one or more separate administrations of a therapeutic agent or a combination of therapeutic agents (e.g., a flavonoid and/or a sesquiterpene lactone).
- a course of therapy can comprise one or more cycles of a therapeutic agent.
- a therapeutic agent is administered to a subject at least once, at least twice, at least three times, at least four times, or more over a course of treatment.
- a subject may be administered with one or more courses of treatment.
- rest periods may be interposed between courses of treatment.
- a rest period may be about 1, about 2, about 4, about 6, about 8, about 10, about 12, about 16, about 20, or about 24 hours; or about 1, about 2, about 3, about 4, about 5, about 6, or about 7 days; or about 1, about 2, about 3, about 4 or more weeks in length.
- the first and second or subsequent cycles are the same in terms of one or both of duration and periodic administration. In embodiments, a first and second or subsequent cycle differs in terms of one or both of duration and periodic administration. Rest periods may be interposed between cycles.
- a rest cycle may be about 1, about 2, about 4, about 6, about 8, about 10, about 12, about 16, about 20, or about 24 hours; or about 1, about 2, about 3, about 4, about 5, about 6, or about 7 days; or about 1, about 2, about 3, about 4 or more weeks in length.
- a therapeutic agent or combination of therapeutic agents refers to the ability of a therapeutic agent or a combination of therapeutic agents to effect a desirable treatment outcome, such as (i) reducing the level of an inflammatory cytokine (e.g., IL-6, IL-1b, and TNF-a) in a cell or subject; (ii) increasing the level of an anti- inflammatory cytokine (e.g., IL-4 and IL-10) in a cell or subject; (iii) reducing the level of a hypersensitivity marker (e.g., IL-13, IL-14, INF-g, and serum IgE) in a cell or subject; (iv) inducing expression of an anti-inflammatory macrophage (e.g., M2 macrophage) in a cell or subject; (v) improving skin health in a cell or subject; (vi) improving a symptom of a dermatological condition (e.g., atopic dermatitis
- the terms “increasing” and “decreasing” refer to modulating that results in, respectively, greater or lesser amounts of function, expression, or activity of a particular metric relative to a reference.
- the amount of a marker of a metric e.g., cell viability, level of a cytokine
- the amount of a marker of a metric may be increased or decreased by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98%, 2X, 3X, 5X, 10X or more relative to the amount of the marker prior to administration or relative to the effect of a negative control agent.
- the metric may be measured subsequent to administration at a time that the administration has had the recited effect, e.g., at least 12 hours, 24 hours, one week, one month, 3 months, or 6 months, after a treatment has begun.
- the terms “prevent” or “preventing” as used in the context of a disease or disorder described herein refer to administration of a flavonoid in combination with a sesquiterpene lactone to a subject, e.g., the administration of parthenolide and quercetin, such that the onset of at least one symptom of the disorder or disease is delayed as compared to what would be seen in the absence of administration of said combination.
- the term “subject” is intended to include human and non-human animals.
- exemplary human subjects include a human patient having a disease or disorder, e.g., a disorder described herein (e.g., inflammation or an inflammatory disease or disorder), or a healthy subject.
- a disease or disorder e.g., a disorder described herein (e.g., inflammation or an inflammatory disease or disorder)
- non-human animals includes all vertebrates, e.g., non-mammals (such as chickens, amphibians, reptiles) and mammals, such as non-human primates, domesticated and/or agriculturally useful animals, e.g., sheep, dogs, cats, cows, pigs, etc.
- an amount of a compound, conjugate, or substance effective to treat a disease or disorder refers to an amount of the compound or composition which is effective, upon single or multiple dose administration(s) to a subject, in treating a subject, or in curing, alleviating, relieving or improving a subject with inflammation or an inflammatory disease or disorder beyond that expected in the absence of such treatment.
- the terms “treat” or “treating” as used in the context of a disease or disorder described herein refer to administration of a flavonoid in combination with a sesquiterpene lactone to a subject, e.g., the administration of parthenolide and quercetin, such that at least one symptom of the disorder or disease is cured, healed, alleviated, relieved, altered, remedied, ameliorated, or improved. Treating includes administering an amount effective to alleviate, relieve, alter, remedy, ameliorate, improve or affect the disorder or disease, or the symptoms of the disorder or disease.
- the treatment may inhibit deterioration or worsening of a symptom of a disorder or disease.
- treating includes preventing.
- treating does not include preventing.
- Therapeutic Agents Described herein are flavonoids administered in combination with sesquiterpene lactones to provide a therapeutic benefit to a cell or subject, e.g., treating inflammation or an inflammatory disease or disorder.
- Flavonoids are class of polyphenolic compounds containing at least one heterocyclic ring comprising a heteroatom, such as an oxygen atom. Flavonoids may be derived from plants, where they carry out multiple functions. For example, flavonoids play a role in plant pigmentation, UV filtration, nitrogen fixation, and certain metabolic pathways.
- flavonoids may be further classified into subgroups such as anthocyanidins, chalcones, flavonols, flavanones, and isoflavonoids.
- the flavonoid is a compound of Formula (A): a pharmaceutically acceptable salt thereof, wherein each of R 1 , hydrogen or -OR A ; R A is hydrogen, C 1 -C 6 alkyl, or cycloalkyl; and “ ” is a single or double bond.
- the flavonoid is a compound of Formula (A-i): a pharmaceutically acceptable salt thereof, wherein each of or -OR A ; R 3 is hydrogen or -OR A ; R 4 is hydrogen or -OR A ; or and “ ” is a single or double bond.
- R 1 is -OR A .
- R 1 is -OH.
- R 2 is - hydrogen.
- R 3 is -OR A .
- R 3 is -OH.
- R 4 is -OR A .
- R 4 is -OH.
- the flavonoid is a compound of Formula (A-ii): ii) or a pharmaceutically acceptable salt thereof, wherein each of or -OR A ; R 4 is hydrogen or -O A A R ; and R is hydrogen, C 1 -C 6 alkyl, or cycloalkyl.
- R 1 is -OR A ; R 2 is hydrogen; and R 4 is -OR A .
- R 1 is -OH ; R 2 is hydrogen; and R 4 is -OH.
- the flavonoid is a compound of Formula (A-iii): iii) or a pharmaceutically acceptable salt thereof, R 4 is hydrogen or -OR A ; and R A is hydrogen, C 1 -C 6 alkyl, or cycloalkyl.
- R 1 is -OR A and R 4 is -OR A .
- R 1 is -OH and R 4 is -OH.
- the flavonoid is a compound shown in Table 1. Table 1.
- Exemplary flavonoids Compound Structure Luteolin Attorney Docket No.: M2199-7017WO Apigenin Attorney Docket No.: M2199-7017WO 4',7- Dihydroxyflavone Attorney Docket No.: M2199-7017WO Retusin Attorney Docket No.: M2199-7017WO Tricin
- the flavonoid is quercetin or a pharmaceutically acceptable salt thereof.
- the flavonoid is myricetin or a pharmaceutically acceptable salt thereof.
- the flavonoid is taxifolin or a pharmaceutically acceptable salt thereof.
- the flavonoid is fisetin or a pharmaceutically acceptable salt thereof.
- the flavonoid is kaempferol or a pharmaceutically acceptable salt thereof.
- the flavonoid is apigenin or a pharmaceutically acceptable salt thereof.
- the flavonoid is tricetin or a pharmaceutically acceptable salt thereof.
- the flavonoid is isohamnetin or a pharmaceutically acceptable salt thereof.
- the flavonoid is eriodictyol or a pharmaceutically acceptable salt thereof.
- the flavonoid is dihydromyricetin or a pharmaceutically acceptable salt thereof.
- the flavonoid is chryseriol or a pharmaceutically acceptable salt thereof.
- the flavonoid is 7,3',4'-trihydroxyflavone or a pharmaceutically acceptable salt thereof.
- the flavonoid is 4',7-dihydroxyflavone or a pharmaceutically acceptable salt thereof.
- the flavonoid is hesperitin or a pharmaceutically acceptable salt thereof.
- the flavonoid is galangin or a pharmaceutically acceptable salt thereof.
- the flavonoid is chrysin or a pharmaceutically acceptable salt thereof.
- the flavonoid is 7-O-methylluteolin or a pharmaceutically acceptable salt thereof.
- the flavonoid is genkwanin or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is acacetin or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is retusin or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is 7-hydroxyflavone or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is apigenin 7,4'- dimethyl ether or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is Pratol or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is ombuin Attorney Docket No.: M2199-7017WO or a pharmaceutically acceptable salt thereof.
- the flavonoid is quercetin 3,3'- dimethyl ether or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is tectochrysin or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is luteolin or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid such as quercetin, myricetin, taxifolin, fistein, or kaempferol. In an embodiment, the flavonoid is quercetin or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid such as luteolin, myricetin, taxifolin, fistein, or kaempferol.
- the flavonoid is myricetin or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid such as quercetin, luteolin, taxifolin, fistein, or kaempferol.
- the flavonoid is taxifolin or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid such as quercetin, myricetin, luteolin, fistein, or kaempferol.
- the flavonoid is fisetin or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid such as quercetin, myricetin, taxifolin, luteolin, or kaempferol.
- the flavonoid is kaempferol or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid such as quercetin, myricetin, taxifolin, fistein, or luteolin.
- the flavonoid is luteolin or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid shown in Table 1.
- the flavonoid is quercetin or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid shown in Table 1.
- the flavonoid is myricetin or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid shown in Table 1.
- the flavonoid is taxifolin or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid s shown in Table 1.
- the flavonoid is fisetin or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid shown in Table 1.
- the flavonoid is kaempferol or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid s shown in Table 1.
- the flavonoid or a pharmaceutically acceptable salt thereof is provided as a substantially pure compound, for example, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.9% pure, measured, e.g, by HPLC analysis.
- the flavonoid is quercetin or a pharmaceutically acceptable salt thereof and is provided as a Attorney Docket No.: M2199-7017WO substantially pure compound, for example, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.9% pure, measured, e.g, by HPLC analysis.
- the flavonoid is provided with less than 10%, 7.5%, 5%, 2.5%, 1%, 0.5%, or 0.1% of another flavonoid, e.g., in the absence of another flavonoid.
- the flavonoid is quercetin and is provided with less than 10%, 7.5%, 5%, 2.5%, 1%, 0.5%, or 0.1% of another flavonoid, e.g., in the absence of another flavonoid. In an embodiment, the flavonoid is quercetin and is provided with less than 10%, 7.5%, 5%, 2.5%, 1%, 0.5%, or 0.1% of quercetin present, e.g., in the absence of luteolin. In an embodiment, the flavonoid is provided with less than 10%, 7.5%, 5%, 2.5%, 1%, 0.5%, or 0.1% of another plant-derived substance, such as a plant metabolite, plant lipid, or plant fiber.
- another plant-derived substance such as a plant metabolite, plant lipid, or plant fiber.
- the flavonoid is quercetin and is provided with less than 10%, 7.5%, 5%, 2.5%, 1%, 0.5%, or 0.1% of plant- derived substance, such as a plant metabolite, plant lipid, or plant fiber.
- a composition useful for the treatment of inflammation or an inflammatory disease or disorder may contain a flavonoid (e.g., quercetin) or a plurality of flavonoids.
- a composition comprising a flavonoid may comprise quercetin, e.g., synthetically prepared or extracted from a natural source, in the absence of another flavonoid.
- a composition comprising a flavonoid may also contain a combination of quercetin and a closely related analog or variant thereof, e.g., a flavonoid shown in Table 1, e.g., quercetin.
- Sesquiterpene Lactones Sesquiterpene lactones are class of colorless, lipophilic sesquiterpenoid compounds that comprise a lactone ring. These compounds are one of the most prevalent classes of secondary metabolites present in plants, and are most commonly found in plant families such as Asteraceae, Cactaceae, Solanaceae, Araceae, and the Euphorbiaceae. polyphenol compounds commonly found in higher plants, fungi, and lichens.
- the sesquiterpene lactone is a compound of Formula (B): Attorney Docket No.: M2199-7017WO a pharmaceutically acceptable salt thereof, wherein each of R 1a and C1-C6 alkyl, or C1-C6 heteroalkyl, or R 1a and R 1b , taken together they are attached, form C2-C6 alkenyl or C2-C6 alkynyl; R 2 is hydrogen or C 1 -C 6 alkyl; R 3 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl or -OR A ; each of R 4 and R 5 is independently absent, hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or -OR A , or R 4 and R 5 , taken together with
- the sesquiterpene lactone is a compound of Formula (B-i): a pharmaceutically acceptable salt thereof, wherein each of R 1a and C -C alkyl, or C -C h 1a 1b 1 6 1 6 eteroalkyl, or R and R , taken together with the carbon atom to which they are attached, form C 2 -C 6 alkenyl or C 2 -C 6 alkynyl;
- R 2 is hydrogen or C1-C6 alkyl;
- R 3 is hydrogen or C1-C6 alkyl;
- each of R 4 and R 5 is independently absent, hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or -OR A , or R 4 and R 5 , taken together with the carbon atoms to which they are attached, form a heterocyclyl ring;
- R 6 is hydrogen, C 1 -C 6 alkyl, C1-C6 heteroalkyl, or -OR A ;
- R 7 is
- R 1a and R 1b are taken together to form C 2 -C 6 alkenyl.
- R 2 is C1-C6 alkyl.
- R 3 is C1-C6 alkyl.
- R 4 and R 5 are taken together to form a heterocyclyl ring (e.g., an epoxide ring). -OH.
- R 4 is -OR A .
- R 4 is -OH.
- R 6 is hydrogen or - OR A .
- R 7 is hydrogen or -OR A .
- R 2 and R7 are taken together to form a heterocyclyl ring.
- “ ” is a single bond. In an embodiment, “ ” is a double bond. In an embodiment, R 1a and R 1b are taken together with the carbon atom to which they are attached to form a C2-C6 alkenyl; R 2 is C1-C6 alkyl; R 3 is C1-C6 alkyl; R 4 and R 5 , taken together with the carbon atoms to which they are attached, form a heterocyclyl ring; R 6 is hydrogen; R 7 is hydrogen; and “ ” is a single bond.
- R 1a and R 1b are taken together with the carbon atom to which they are attached to form ethenyl; R 2 is methyl; R 3 is methyl; R 4 and R 5 , taken together with the carbon atoms to which they are attached, form an epoxide ring; R 6 is hydrogen; R 7 is hydrogen; and “ ” is a single bond.
- R 1a and R 1b are taken together with the carbon atom to which they are attached to form a C 2 -C 6 alkenyl; R 2 is C 1 -C 6 alkyl; R 3 is C 1 -C 6 alkyl; each of R 4 and R 5 is independently absent; R 6 is hydrogen; R 7 is hydrogen; and “ ” is a double bond.
- the sesquiterpene lactone is a compound of Formula (B-ii): ii) or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen or or C 1 -C 6 alkyl; R 6 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, or - OR A ; R 7 is hydrogen or -OR A , or R 2 and R 7 , taken together with the carbon atoms to which they are attached, form a heterocyclyl ring; and R A is hydrogen, C1-C6 alkyl, -C(O)-C1-C6 alkyl, C(O)-C 2 -C 6 alkenyl, or cycloalkyl.
- R 2 is hydrogen or or C 1 -C 6 alkyl
- R 6 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, or - OR A
- R 7 is hydrogen or -OR A , or R 2 and R 7 ,
- R 2 is C 1 -C 6 alkyl; R 3 is C 1 -C 6 alkyl; R 6 is hydrogen; and R 7 is hydrogen.
- R 2 is methyl; R 3 is methyl; R 6 is hydrogen; and R 7 is hydrogen.
- the sesquiterpene lactone is a compound of Formula (B-iii): Attorney Docket No.: M2199-7017WO iii) or a pharmaceutically acceptable salt thereof, wherein R 2 is is hydrogen or C1-C6 alkyl; R 6 is hydrogen, C1-C6 alkyl, C1-C6 or - hydrogen or -OR A , or R 2 and R 7 , taken together with the carbon atoms to which they are attached, form a heterocyclyl ring; and R A is hydrogen, C 1 -C 6 alkyl, - C(O)-C1-C6 alkyl, C(O)-C2-C6 alkenyl, or cycloalkyl.
- R 2 is hydrogen or C1-C6 alkyl
- R 6 is hydrogen, C1-C6 alkyl, C1-C6 or - hydrogen or -OR A , or R 2 and R 7 , taken together with the carbon atoms to which they are attached, form
- R 2 is C1-C6 alkyl; R 3 is C1-C6 alkyl; R 6 is hydrogen; and R 7 is hydrogen.
- R 2 is methyl; R 3 is methyl; R 6 is hydrogen; and R 7 is hydrogen.
- R 2 is C1-C6 alkyl; R 3 is C1-C6 alkyl; R 6 is -OR A ; R 7 is hydrogen; and R A is hydrogen.
- R 2 is methyl; R 3 is methyl; R 6 is -OR A ; R 7 is hydrogen; and R A is hydrogen.
- the sesquiterpene lactone is a compound shown in Table 2.
- Table 2 Exemplary sesquiterpene lactones Compound Structure Attorney Docket No.: M2199-7017WO Onopordopicrin Attorney Docket No.: M2199-7017WO Elephantoin
- the sesquiterpene lactone is costunolide or a pharmaceutically acceptable salt thereof.
- the sesquiterpene lactone is eupatolide or a pharmaceutically acceptable salt thereof.
- the sesquiterpene lactone is onopordopicrin or a pharmaceutically acceptable salt thereof.
- the sesquiterpene lactone is deoxyelepantopin or a pharmaceutically acceptable salt thereof. In an embodiment, the sesquiterpene lactone is 9alpha-hydroxyparthenolide or a pharmaceutically acceptable salt thereof. In an embodiment, the sesquiterpene lactone is 11beta,13-dihydroparthenolide or a pharmaceutically acceptable salt thereof. In an embodiment, the sesquiterpene lactone is lipiferolide or a pharmaceutically acceptable salt thereof. In an embodiment, the sesquiterpene lactone is elephantoin or a pharmaceutically acceptable salt thereof.
- the sesquiterpene lactone is parthenolide or a pharmaceutically acceptable salt thereof, substantially free of costunolide, eupatolide, onopordopicrin, and deoxyelepantopin.
- the sesquiterpene lactone is costunolide or a pharmaceutically acceptable salt thereof, substantially free of parthenolide, eupatolide, onopordopicrin, and deoxyelepantopin.
- the sesquiterpene lactone is eupatolide or a pharmaceutically acceptable salt thereof, substantially free of costunolide, parthenolide, onopordopicrin, and deoxyelepantopin.
- the sesquiterpene lactone is onopordopicrin or a pharmaceutically acceptable salt thereof, substantially free of costunolide, eupatolide, parthenolide, and deoxyelepantopin. In an embodiment, the sesquiterpene lactone is deoxyelepantopin or a pharmaceutically acceptable salt thereof, substantially free of costunolide, eupatolide, onopordopicrin, and parthenolide. In an embodiment, the sesquiterpene lactone is parthenolide or a pharmaceutically acceptable salt thereof, substantially free of another compound shown in Table 2.
- the sesquiterpene lactone is costunolide or a pharmaceutically acceptable salt thereof, substantially free of another compound shown in Table 2.
- the sesquiterpene lactone is eupatolide or a pharmaceutically acceptable salt thereof, substantially free of another compound shown in Table 2.
- the sesquiterpene lactone is onopordopicrin or a pharmaceutically acceptable salt thereof, substantially free of c another compound shown in Table 2.
- the sesquiterpene lactone is deoxyelepantopin or a pharmaceutically acceptable salt thereof, substantially free of another compound shown in Table 2.
- the sesquiterpene lactone or a pharmaceutically acceptable salt thereof is provided as a substantially pure compound, for example, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.9% pure, measured, e.g, by HPLC analysis.
- the sesquiterpene lactone is parthenolide or a pharmaceutically acceptable salt thereof, and is provided as a substantially pure compound, for example, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.9% pure, measured, e.g, by HPLC analysis.
- the sesquiterpene lactone is provided with less than 10%, 7.5%, 5%, 2.5%, 1%, 0.5%, or 0.1% of another sesquiterpene lactone present. In an embodiment, the sesquiterpene lactone is parthenolide and is provided with less than 10%, 7.5%, 5%, 2.5%, 1%, 0.5%, or 0.1% of another sesquiterpene lactone present. In an embodiment, the sesquiterpene lactone is parthenolide and is provided with less than 10%, 7.5%, 5%, 2.5%, 1%, 0.5%, or 0.1% of costunolide present.
- the sesquiterpene lactone is provided with less than 10%, 7.5%, 5%, 2.5%, 1%, 0.5%, or 0.1% of another plant material, such as a plant metabolite or plant lipid.
- the sesquiterpene lactone is parthenolide and is provided with less than 10%, 7.5%, 5%, 2.5%, 1%, 0.5%, or 0.1% of another plant material, such as a plant metabolite or plant lipid.
- a composition useful for the treatment of inflammation or an inflammatory disease or disorder may contain a sesquiterpene lactone (e.g., parthenolide) or a plurality of sesquiterpene lactones.
- compositions comprising a sesquiterpene lactone may contain only parthenolide, e.g., synthetically prepared or extracted from a natural source, in the absence of another sesquiterpene lactone.
- a composition comprising a sesquiterpene lactone may Attorney Docket No.: M2199-7017WO also contain a combination of parthenolide and a closely related analog or variant thereof, e.g., a sesquiterpene lactone shown in Table 1, e.g., costunolide.
- the flavonoids and sesquiterpene lactones provided herein may contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. Further, the flavonoids and sesquiterpene lactones may exist as one of many tautomeric forms. All such isomeric and tautomeric forms of these compounds are expressly included within the scope. Unless otherwise indicated when a compound is named or depicted by a structure without specifying the stereochemistry and has one or more chiral centers or tautomeric structures, it is understood to represent all possible stereoisomers or tautomers of the compound.
- the compounds provided herewith may also contain linkages (e.g., carbon-carbon bonds, phosphorus-oxygen bonds, or phosphorus-sulfur bonds) or substituents that can restrict bond rotation, e.g., restriction resulting from the presence of a ring or double bond.
- Inflammatory Diseases and Disorders Described herein are methods for treating inflammation or an inflammatory disease or disorder in a subject, tissue, or cell, e.g., by administration of a sesquiterpene lactone and a flavonoid.
- the cell is an isolated cell (e.g., a cell in a cell culture or a cell isolated from a tissue or intact organism).
- the cell is located in a tissue or organ.
- An inflammatory disease or disorder relates to any disease or disorder that affects the immune system and may result in a modulation of the inflammatory pathway.
- exemplary inflammatory diseases and disorders include dermatological conditions (e.g., psoriasis, dermal hypersensitivity, eczema, burns, atopic dermatitis, or abnormal proliferation of hair follicle cells), fibrosis (e.g., kidney or lung fibrosis), allergic rhinitis, respiratory distress syndrome, asthma, bronchitis, tendinitis, bursitis, fever, migraine headaches, gastrointestinal conditions (e.g., inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome, colitis and colorectal cancer), vascular diseases (e.g., atherosclerosis), periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's Disease, rheumatic fever, osteoarthritis, autoimmune diseases (e.g.,
- Psoriasis is a chronic skin disorder that afflicts about 2 percent of the population.
- the disease is associated with the rapid turnover of skin cells (hyperproliferation) accompanied by a loss of differentiation so that silvery white scales form on the surface of the skin. Additionally, the capillaries become tortuous and dilated and an inflammatory reaction occurs, so that the skin reddens.
- the elevated silvery white scales on a contrasting red background produce the unsightly lesions characteristic of psoriasis.
- Psoriasis most commonly appears on the scalp, knees, elbows, hands and feet, but can affect any part of the skin.
- the inflammatory disease or disorder comprises psoriasis.
- Dermal hypersensitivity is a nonspecific histological reaction pattern that may be seen in multiple clinical conditions. Symptoms may include pruritis, lesions, and in idiopathic cases, urticarial or eczematous papules or plaques.
- the inflammatory disease or disorder comprises dermal hypersensitivity.
- Eczema is a general term for many types of skin inflammation, also known as dermatitis. The most common form of eczema is atopic eczema or dermatitis.
- Eczema occurs in people of all races and can affect people of any age, although the condition is most common in infants, and about 85% of people have an onset prior to five years of age. Typically, eczema will permanently resolve by age three in only about one-half of affected infants. In others, the condition tends to recur throughout life. People with eczema often have a family history of the condition or a family history of other allergic conditions, such as asthma and/or hay fever. While eczema is not known to be contagious, it is believed to be at least partially inherited. In an embodiment, the inflammatory disease or disorder comprises eczema. Approximately 140 million people suffer burns per year in the United States alone.
- a burn is an injury to the skin or other tissue caused by heat, cold, electricity, chemicals, friction, or radiation. Most burns are caused by heat generated by hot liquids (burns), solids, or fire.
- the skin is composed of three Attorney Docket No.: M2199-7017WO major tissue layers: epidermis, dermis, and subcutaneous tissue. Burns that affect only the outermost skin are called superficial or first-order burns. They appear red, free of blisters, and pain usually lasts for about three days. When the damage extends to some underlying skin layer, it is called a local thickness or secondary burn. Blisters often occur and are often painful. Healing may take up to eight weeks and scarring may occur.
- the inflammatory disease or disorder comprises burns.
- Atopic dermatitis is the most common form of eczema. It is a condition that causes dry, itchy and inflamed skin. It is common in young children but can occur at any age. Atopic dermatitis is a chronic condition that can cause flare ups throughout a patient’s life and is not contagious.
- atopic dermatitis People with atopic dermatitis are at risk of developing food allergies, hay fever, and asthma. Symptoms of atopic dermatitis may include dry, cracked skin, itchiness (pruritis), small, raised bumps, thickened skin, darkening of the skin around the eyes, and raw, sensitive skin.
- the inflammatory disease or disorder comprises atopic dermatitis. Fibrosis is a process characterized by an excessive accumulation of the extracellular matrix as a response to different types of tissue injuries, which leads to organ dysfunction. The process can be initiated by multiple and different stimuli and pathogenic factors which trigger the cascade of reparation converging in molecular signals responsible of initiating and driving fibrosis.
- fibrosis can play a defensive role, in several circumstances at a certain stage, it can progressively become an uncontrolled irreversible and self-maintained process, named pathological fibrosis.
- Such fibrosis can occur in any organ in the body, e.g., in the kidney(s) (kidney fibrosis), or in the lung(s) (lung fibrosis).
- the inflammatory disease or disorder comprises fibrosis, e.g., kidney fibrosis and lung fibrosis.
- Allergic rhinitis also called hay fever, is an allergic reaction that causes sneezing, congestion, itchy nose and sore throat. Pollen, pet dander, mold and insects can lead to hay fever symptoms.
- Symptoms of hay fever include sneezing, nasal congestion and irritation of the nose, throat, mouth and eyes.
- the inflammatory disease or disorder comprises allergic rhinitis.
- Respiratory distress syndrome is a disease involving increased pulmonary capillary permeability. The consequent accumulation of protein-rich fluid inside the alveoli is the result of the damage to the capillary endothelium and alveolar epithelium; this causes the release of cytokines, producing diffuse alveolar damage.
- ARDS ARDS ARDS
- ARDS ARDS ARDS
- the characteristic pathological features of ARDS have classically been described by three overlapping phases: an exudative or inflammatory phase, a proliferative phase, and a fibrotic phase.
- the inflammatory disease or disorder comprises respiratory distress syndrome.
- Asthma is a chronic inflammatory disease of the airways characterized by airway hyper responsiveness, acute and chronic bronchoconstriction, airway edema, and mucus plugging.
- the inflammation component of asthma is thought to involve many cell types, including mast cells, eosinophils, T lymphocytes, neutrophils, and epithelial cells, and their biological products. Patients with asthma most often present with symptoms of wheezing, shortness of breath, cough, and chest tightness.
- the inflammatory disease or disorder comprises asthma.
- Bronchitis is an inflammation of the mucous membrane of the trachea and bronchi caused by bacterial and viral infections or irritations caused by physical and chemical factors. As a rule, this disease is mainly characterized by cough, sputum, discomfort or pain behind the sternum, shortness of breath and the usual cold symptoms that accompany them.
- bronchitis In accordance with the duration of bronchitis can be divided into two forms: acute tracheobronchitis and chronic bronchitis.
- Chronic bronchitis is bronchitis which lasts more than two months and worsens for two consecutive years or lasts three consecutive months for one year, causing inflammation of the mucous membrane and peripheral tissues. Most patients are adults, and the incidence of bronchitis increases in the winter and spring.
- the inflammatory disease or disorder comprises bronchitis.
- Tendinitis is a tendon inflammation referring to the inflammatory changes of the tendon tissue. It often results in degenerative changes of the tissue affected, possibly including calcium deposits at a later time. In general, tendinitis can affect any tendon of the body.
- tendinitis is mainly caused by mechanical stress (sports), tendinitis affects in particular certain body regions, such as e.g., in the region of the shoulder, the tibia, or the foot. Tendinitis can also occur in the Attorney Docket No.: M2199-7017WO context of inflammatory rheumatoid diseases (in particular Reiter's syndrome, spondylitis ankylosans, and arthritis psoriatica).
- the inflammatory disease or disorder comprises tendinitis.
- Bursitis is an inflammation of a bursa or protecting sac that is located in or near the patients joints.
- Bursitis can be acute resulting in a sudden, sharp pain following an injury, or it can be chronic as a result of a recurrent inflammation in the same area. Most commonly, bursitis is caused by trauma, infection and crystal deposits. Bursitis typically results from overuse or injury of a joint as a consequence of intensive working or playing, poor conditioning before exercising or sporting, systematic incorrect posture at work or rest, or an abnormal positioned joint as a result of for instance arthritis or bone length differences that stress soft tissue structures in the human or animal body.
- the inflammatory disease or disorder comprises bursitis.
- Fever is a commonly used medical indicator characterized by elevation of body temperature above a normal range.
- the inflammatory disease or disorder comprises fever.
- Migraine comprises a complex, common neurological condition that is characterized by severe, episodic attacks of headache and associated features, which may include nausea, vomiting, sensitivity to light, sound or movement. In some patients, the headache is preceded or accompanied by sensory warning signs or symptoms (i.e., auras). The headache pain may be severe and may also be unilateral in certain patients. Migraine attacks are disruptive to daily life and cost billions of dollars each year in missed work days and impaired performance. Migraine is a highly prevalent disease worldwide with approximately 15% of the European population and 12% of the United States population suffering from migraine attacks. Additionally, migraines have been found to be associated with a number of psychiatric and medical comorbidities such as depression and vascular disorders. In an embodiment, the inflammatory disease or disorder comprises migraine headaches.
- IBD Inflammatory bowel disease
- GI gastrointestinal
- CD Crohn's disease
- UC ulcerative colitis
- CD Crohn's disease
- Both conditions are characterized clinically by frequent bowel motions, malnutrition, and dehydration, Attorney Docket No.: M2199-7017WO with disruption in the activities of daily living.
- CD is frequently complicated by the development of malabsorption, strictures, and fistulae and may require repeated surgery.
- UC less frequently, may be complicated by severe bloody diarrhea and toxic megacolon, also requiring surgery.
- the inflammatory disease or disorder comprises inflammatory bowel disease (e.g., Crohn’s disease or ulcerative colitis).
- Gastritis is a general term for a group of conditions comprising inflammation of the stomach lining. The inflammation of gastritis is most often the result of infection with the same bacterium that causes most stomach ulcers or the regular use of certain pain relievers. Drinking too much alcohol also can contribute to gastritis. Gastritis may occur suddenly (acute gastritis) or appear slowly over time (chronic gastritis).
- the inflammatory disease or disorder comprises gastritis.
- IBS Irritable bowel syndrome
- IBS is the most common of all gastrointestinal disorders, affecting 11-14% of adults and accounting for more than 50% of all patients with digestive complaints. It is thought that only a minority of people with IBS actually seek medical treatment. Patients with IBS present with disparate symptoms, for example, abdominal pain predominantly related to defecation, alternating diarrhea and constipation, abdominal distention, gas, and excessive mucus in the stool. A number of possible causes for IBS have been proposed, but none has been fully accepted.
- the inflammatory disease or disorder comprises IBS.
- Colorectal cancer also known as bowel cancer, colon cancer, or rectal cancer, is the development of cancer from the colon or rectum (parts of the large intestine). Signs and symptoms may include blood in the stool, a change in bowel movements, weight loss, and fatigue. Most colorectal cancers are due to old age and lifestyle factors, with only a small number of cases due to underlying genetic disorders. Risk factors include diet, obesity, smoking, and lack of physical activity. Another risk factor is inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis.
- the inherited genetic disorders that can cause colorectal Attorney Docket No.: M2199-7017WO cancer include familial adenomatous polyposis and hereditary non-polyposis colon cancer; however, these represent less than 5% of cases. It typically starts as a benign tumor, often in the form of a polyp, which over time becomes cancerous.
- the inflammatory disease or disorder comprises colorectal cancer.
- Atherosclerosis is a chronic disease that causes thickening of the innermost layer (intima) of the aorta or middle artery. This reduces blood flow and can cause ischemia and tissue destruction in organs supplied by affected blood vessels.
- Atherosclerosis is a major cause of heart disease including myocardial infarction, stroke and surrounding arterial disease.
- the disease begins with the accumulation of lipoproteins, mainly low density lipoprotein (LDL), in the extracellular matrix of blood vessels. These LDL particles aggregate and promote oxidative modification. Oxidized LDL is toxic and causes vascular damage.
- Atherosclerosis represents a response to this wound in the form of inflammation and fibrosis.
- the inflammatory disease or disorder comprises atherosclerosis.
- PAN Polyarteritis nodosa
- PAN is a systemic necrotizing inflammation of blood vessels (vasculitis) affecting medium-sized muscular arteries, typically involving the arteries of the kidneys and other internal organs but generally sparing the lungs' circulation.
- the inflammatory disease or disorder comprises periarteritis nodosa.
- Thyroiditis is the inflammation of the thyroid gland. There are many different signs and symptoms for thyroiditis, none of which are exclusively limited to this disease. Many of the signs imitate symptoms of other diseases, so thyroiditis can sometimes be difficult to diagnose. Common hypothyroid symptoms manifest when thyroid cell damage is slow and chronic, and may include fatigue, weight gain, feeling "fuzzy headed", depression, dry skin, and constipation.
- the inflammatory disease or disorder comprises thyroiditis.
- Aplastic anemia is a severe hematologic condition in which the body fails to make blood cells in sufficient numbers.
- Aplastic anemia is associated with cancer and various cancer syndromes. Blood cells are produced in the bone marrow by stem cells that reside there.
- Aplastic anemia causes a deficiency of all blood cell types: red blood cells, white blood cells, and platelets. It occurs most frequently in people in their teens and twenties but is also common among the elderly. It can be caused by heredity, immune disease, or exposure to chemicals, drugs, or radiation. However, in about half of cases, the cause is unknown.
- the inflammatory disease or disorder comprises aplastic anemia.
- Hodgkin’s disease also known as Hodgkin’s lymphoma (HL) is a type of lymphoma in which cancer originates from a specific type of white blood cell called lymphocytes, where multinucleated Reed–Sternberg cells (RS cells) are present in the patient's lymph nodes. Symptoms may include fever, night sweats, and weight loss. Often, nonpainful enlarged lymph nodes occur in the neck, under the arm, or in the groin. About half of cases of Hodgkin lymphoma are due to Epstein–Barr virus (EBV) and these are generally the classic form. Other risk factors include a family history of the condition and having HIV/AIDS.
- the inflammatory disease or disorder comprises Hodgkin’s disease.
- Rheumatic fever is an inflammatory disease that can involve the heart, joints, skin, and brain.
- the disease typically develops two to four weeks after a streptococcal throat infection. Signs and symptoms include fever, multiple painful joints, involuntary muscle movements, and occasionally a characteristic non-itchy rash known as erythema marginatum.
- the heart is involved in about half of the cases. Damage to the heart valves, known as rheumatic heart disease (RHD), usually occurs after repeated attacks but can sometimes occur after one. The damaged valves may result in heart failure, atrial fibrillation and infection of the valves.
- the inflammatory disease or disorder comprises rheumatic fever.
- Osteoarthritis is a type of degenerative joint disease that results from breakdown of joint cartilage and underlying bone which affects 1 in 7 adults in the United States. It is believed to be the fourth leading cause of disability in the world. The most common symptoms are joint pain and stiffness. Other symptoms may include joint swelling, decreased range of motion, and, when the back is affected, weakness or numbness of the arms and legs. The most Attorney Docket No.: M2199-7017WO commonly involved joints are the two near the ends of the fingers and the joint at the base of the thumbs, the knee and hip joints, and the joints of the neck and lower back. Unlike some other types of arthritis, only the joints, not internal organs, are affected. In an embodiment, the inflammatory disease or disorder comprises osteoarthritis.
- Type 1 diabetes formerly known as juvenile diabetes, is an autoimmune disease that originates when cells that make insulin (beta cells) are destroyed by the immune system, resulting in high blood sugar levels.
- the common symptoms of this elevated blood sugar are frequent urination, increased thirst, increased hunger, weight loss, and other serious complications. Additional symptoms may include blurry vision, tiredness, and slow wound healing. Symptoms typically develop over a short period of time, often a matter of weeks. The underlying mechanism involves an autoimmune destruction of the insulin-producing beta cells in the pancreas.
- the inflammatory disease or disorder comprises Type I diabetes.
- Myasthenia gravis (MG) is a long-term autoimmune neuromuscular junction disease that leads to varying degrees of skeletal muscle weakness.
- the inflammatory disease or disorder comprises myasthenia gravis.
- Rheumatoid arthritis is a long-term autoimmune disorder that primarily affects joints. It typically results in warm, swollen, and painful joints. Pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. The disease may also affect other parts of the body, including skin, eyes, lungs, heart, nerves and blood.
- the inflammatory disease or disorder comprises rheumatoid arthritis.
- Lupus technically known as systemic lupus erythematosus (SLE)
- SLE systemic lupus erythematosus
- Symptoms vary among people and may be mild to severe. Common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, feeling tired, and a red rash which is most commonly on the face.
- the inflammatory disease or disorder comprises systemic lupus erythematosus.
- MS Multiple sclerosis
- This damage disrupts the ability of parts of the nervous system to transmit signals, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems.
- Specific symptoms can include double vision, visual loss, muscle weakness, and trouble with sensation or coordination.
- the inflammatory disease or disorder comprises multiple sclerosis.
- Sarcoidosis is a disease involving abnormal collections of inflammatory cells that form lumps known as granulomata. The disease usually begins in the lungs, skin, or lymph nodes. Less commonly affected are the eyes, liver, heart, and brain, though any organ can be affected. The signs and symptoms depend on the organ involved. Often, no, or only mild, symptoms are seen.
- the inflammatory disease or disorder comprises sarcoidosis.
- Nephrotic syndrome is a collection of symptoms due to kidney damage. This includes protein in the urine, low blood albumin levels, high blood lipids, and significant swelling. Other symptoms may include weight gain, feeling tired, and foamy urine.
- Complications may include blood clots, infections, and high blood pressure.
- Causes include a number of kidney diseases such as focal segmental glomerulosclerosis, membranous nephropathy, and minimal change disease. It may also occur as a complication of diabetes or lupus.
- the inflammatory disease or disorder comprises nephrotic syndrome.
- Kidney failure also known as end-stage kidney disease, is a medical condition in which the kidneys can no longer adequately filter waste products from the blood, functioning at less than 15% of normal levels. Kidney failure is classified as either acute kidney failure, which Attorney Docket No.: M2199-7017WO develops rapidly and may resolve; and chronic kidney failure, which develops slowly and can often be irreversible. Symptoms may include leg swelling, feeling tired, vomiting, loss of appetite, and confusion.
- the inflammatory disease or disorder comprises renal failure.
- Behçet's disease (BD) is a type of inflammatory disorder which affects multiple parts of the body. The most common symptoms include painful sores on the mucous membranes of the mouth and other parts of the body, inflammation of parts of the eye, and arthritis.
- the sores can last from a few days, up to a week or more. Less commonly there may be inflammation of the brain or spinal cord, blood clots, aneurysms, or blindness. Often, the symptoms come and go.
- the inflammatory disease or disorder comprises Behcet’s disease.
- Polymyositis is a type of chronic inflammation of the muscles (inflammatory myopathy) related to dermatomyositis and inclusion body myositis.
- the inflammation of polymyositis is mainly found in the endomysial layer of skeletal muscle, whereas dermatomyositis is characterized primarily by inflammation of the perimysial layer of skeletal muscles.
- the inflammatory disease or disorder comprises polymyositis.
- Gingivitis is a non-destructive disease that causes inflammation of the gums.
- the most common form of gingivitis, and the most common form of periodontal disease overall, is in response to bacterial biofilms (also called plaque) that is attached to tooth surfaces, termed plaque-induced gingivitis.
- Most forms of gingivitis are plaque-induced.
- the inflammatory disease or disorder comprises gingivitis.
- Graft-versus-host disease is a syndrome, characterized by inflammation in different organs. GVHD is commonly associated with bone marrow transplants and stem cell transplants.
- the inflammatory disease or disorder comprises GVHD.
- Conjunctivitis also known as pink eye, is inflammation of the outermost layer of the white part of the eye and the inner surface of the eyelid. It makes the eye appear pink or Attorney Docket No.: M2199-7017WO reddish.
- the inflammatory disease or disorder comprises conjunctivitis.
- Myocardial ischemia involves the reduction of blood flow to the heart muscle due to build-up of atherosclerotic plaque in the arteries of the heart. It is the most common of the cardiovascular diseases. A common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck, or jaw. Occasionally it may feel like heartburn.
- the inflammatory disease or disorder comprises myocardial ischemia.
- Endotoxin shock syndrome also known as toxic shock syndrome (TSS)
- TSS-1 poisonous endotoxin
- the inflammatory disease or disorder comprises endotoxin shock syndrome.
- the inflammatory disease or disorder is a dermatological condition.
- the dermatological disease or disorder may be atopic dermatitis, psoriasis, eczema, or dermal hypersensitivity.
- the dermatological condition is atopic dermatitis.
- the dermatological condition is psoriasis.
- the dermatological condition is eczema. In an embodiment, the dermatological condition is dermal hypersensitivity.
- Combination Therapies Attorney Docket No.: M2199-7017WO Described herein are combination therapies comprising a flavonoid and a sesquiterpene lactone useful for the treatment of inflammation or an inflammatory disease or disorder.
- the combination therapy may be administered as a single formulation or as separate formulations.
- the flavonoid and sesquiterpene lactone are administered as a single pharmaceutical composition.
- the flavonoid and sesquiterpene lactone are administered as separate pharmaceutical compositions. In the case of separate formulations, the flavonoid and sesquiterpene lactone may be administered concomitantly or sequentially.
- the flavonoid and sesquiterpene lactone are administered concomitantly. In an embodiment, the flavonoid and sesquiterpene lactone are administered sequentially. For example, the flavonoid may be administered prior to the sesquiterpene lactone or subsequent to the sesquiterpene lactone. In some embodiments, the administration of the flavonoid and sesquiterpene lactone has a synergistic or additive effect. For example, the administration of the flavonoid and sesquiterpene lactone may have an additive effect, in which the therapeutic effect of the flavonoid and sesquiterpene lactone is the total sum of the effects of each of the components individually.
- the administration of the flavonoid and sesquiterpene lactone may have a synergistic effect, in which the therapeutic effect of the flavonoid and sesquiterpene lactone is greater than the sum of the individual components.
- the synergistic effect of the combination of the flavonoid and sesquiterpene lactone may be 0.1%, 0.25%.0.5%.0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%.90%.95%, or more than the total sum of the effects of the flavonoid and sesquiterpene lactone administered individually.
- the synergistic effect of the combination of flavonoid and sesquiterpene lactone is greater than between 5% and 75% of the total sum of the effects of the flavonoid and sesquiterpene lactone administered individually. In an embodiment, the synergistic effect of the combination of the flavonoid and sesquiterpene lactone is greater than 10% of the total sum of the effects of the flavonoid and sesquiterpene lactone administered individually. In an embodiment, the synergistic effect of the combination of the flavonoid and sesquiterpene lactone is greater than 25% of the total sum of the effects of the flavonoid and sesquiterpene lactone administered individually.
- the synergistic effect of the combination of the flavonoid and sesquiterpene lactone is greater than 50% of the total sum of the effects of the flavonoid and sesquiterpene lactone Attorney Docket No.: M2199-7017WO administered individually. In an embodiment, the synergistic effect of the combination of the flavonoid and sesquiterpene lactone is greater than 75% of the total sum of the effects of flavonoid and sesquiterpene lactone administered individually.
- the synergistic effect of the combination of the flavonoid and sesquiterpene lactone may be 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 40-fold, 50-fold, 75-fold, 100-fold, 200-fold, 500-fold greater or more than the total sum of the effects of the flavonoid and sesquiterpene lactone administered individually.
- the synergistic effect of the combination of the flavonoid and sesquiterpene lactone is greater than between 2-fold and 100-fold of the total sum of the effects of the flavonoid and sesquiterpene lactone administered individually.
- the synergistic effect of the combination of the flavonoid and sesquiterpene lactone is greater than between 5- fold and 50-fold of the total sum of the effects of the flavonoid and sesquiterpene lactone administered individually.
- the amount of the flavonoid and the amount of the sesquiterpene lactone are selected such that the molar concentration of the flavonoid is greater than the molar concentration of the sesquiterpene lactone.
- the molar concentration of the flavonoid is greater than 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15- fold, 20-fold, 25-fold, 30-fold, 40-fold, 50-fold, 75-fold, 100-fold, 200-fold, or 500-fold greater than the molar concentration of the sesquiterpene lactone.
- the molar concentration of the flavonoid is greater than 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7- fold, 8-fold, 9-fold, or 10-fold greater than the molar concentration of the sesquiterpene lactone.
- the molar concentration of the flavonoid is between 2-fold and 20-fold greater than the molar concentration of the sesquiterpene lactone. In an embodiment, the molar concentration of the flavonoid is between 5-fold and 10-fold greater than the molar concentration of the sesquiterpene lactone. In an embodiment, the molar concentration of the flavonoid is about 5-fold greater than the molar concentration of the sesquiterpene lactone. In an embodiment, the molar concentration of the flavonoid is about 10-fold greater than the molar concentration of the sesquiterpene lactone. In an embodiment, the molar concentration of the flavonoid is about 15- fold greater than the molar concentration of the sesquiterpene lactone.
- the combination of the flavonoid with a sesquiterpene lactone results in reducing inflammation (e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a) Attorney Docket No.: M2199-7017WO in a subject or cell.
- inflammation e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a
- administration of a combination of the flavonoid with a sesquiterpene lactone may result reducing inflammation (e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a) in a subject or cell, compared with the inflammation (e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a) that results when the sesquiterpene lactone is administered to the subject or cell individually.
- inflammation e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a
- the inflammation e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a
- the inflammation is reduced upon administration of the sesquiterpene lactone in combination with a flavonoid, e.g., by about 0.1%, 0.25%.0.5%.0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%.90%.95%, or more compared with the inflammation (e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a) that results when a sesquiterpene lactone is administered individually.
- the inflammation e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a
- the combination of the flavonoid with a sesquiterpene lactone results in reducing inflammation (e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a) in a subject or cell.
- inflammation e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a
- administration of a combination of the flavonoid with a sesquiterpene lactone may result in reducing the inflammation (e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a) in a subject or cell, compared with the inflammation (e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a) that results when the flavonoid is administered to the subject or cell individually.
- the inflammation e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a
- the inflammation e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a
- a sesquiterpene lactone in combination with a flavonoid, e.g., by about 0.1%, 0.25%.0.5%.0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%.90%.95%, or more compared with the inflammation (e.g., the level of an inflammatory cytokine) that results when the flavonoid is administered individually.
- the inflammation e.g., the level of an inflammatory cytokine
- the combination of the flavonoid with a sesquiterpene lactone results in increasing the level of an anti-inflammatory cytokine (e.g., IL-4 and IL-10) in a subject or cell.
- administration of a combination of the flavonoid with a sesquiterpene lactone may result increasing the level of an anti-inflammatory cytokine (e.g., IL-4 and IL-10) in a subject or cell, compared with the level of an anti-inflammatory cytokine (e.g., IL-4 and IL-10) that results when the sesquiterpene lactone is administered to the subject or cell individually.
- the level of an anti-inflammatory cytokine (e.g., IL-4 and IL-10) in a subject or cell Attorney Docket No.: M2199-7017WO is increased upon administration of the sesquiterpene lactone in combination with a flavonoid, e.g., by about 0.1%, 0.25%.0.5%.0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%.90%.95%, or more compared with the level of an anti-inflammatory cytokine (e.g., IL-4 and IL-10) that results when a sesquiterpene lactone is administered individually.
- an anti-inflammatory cytokine e.g., IL-4 and IL-10
- the combination of the flavonoid with a sesquiterpene lactone results in increasing the level of an anti-inflammatory cytokine (e.g., IL-4 and IL-10) in a subject or cell.
- an anti-inflammatory cytokine e.g., IL-4 and IL-10
- administration of a combination of the flavonoid with a sesquiterpene lactone may result in increasing the level of an anti-inflammatory cytokine (e.g., IL-4 and IL-10) in a subject or cell, compared with level of an anti-inflammatory cytokine that results when the flavonoid is administered to the subject or cell individually.
- the level of an anti- inflammatory cytokine (e.g., IL-4 and IL-10) in a subject or cell is increased upon administration of a sesquiterpene lactone in combination with a flavonoid, e.g., by about 0.1%, 0.25%.0.5%. 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%.90%.95%, or more compared with the level of an inflammatory cytokine hat results when the flavonoid is administered individually.
- a sesquiterpene lactone e.g., by about 0.1%, 0.25%.0.5%. 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%.90%.95%, or more compared with the level
- the flavonoid is administered at a dosage to provide a concentration of between 0.1 ⁇ M and 500 ⁇ M in a subject or cell. In an embodiment, the flavonoid is administered at a dosage to provide a concentration of between 0.5 ⁇ M and 100 ⁇ M in a subject or cell. In an embodiment, the flavonoid is administered at a dosage to provide a concentration of between 1 ⁇ M and 100 ⁇ M in a subject or cell. In an embodiment, the flavonoid is administered at a dosage to provide a concentration of between 1 ⁇ M and 50 ⁇ M in a subject or cell. In an embodiment, the flavonoid is administered at a dosage to provide a concentration of between 1 ⁇ M and 25 ⁇ M in a subject or cell.
- the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.01 ⁇ M and 50 ⁇ M in a subject or cell. In an embodiment, the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.1 ⁇ M and 25 ⁇ M in a subject or cell. In an embodiment, the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.1 ⁇ M and 10 ⁇ M in a subject or cell. In an embodiment, the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.1 ⁇ M and 5 ⁇ M in a subject or cell.
- the Attorney Docket No.: M2199-7017WO sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.1 ⁇ M and 2.5 ⁇ M in a subject or cell.
- the flavonoid is administered at a dosage to provide a concentration of between 0.1 ⁇ M and 500 ⁇ M and the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.01 ⁇ M and 50 ⁇ M in a subject or cell.
- the flavonoid is administered at a dosage to provide a concentration of to provide a concentration of between 1 ⁇ M and 100 ⁇ M and the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.1 ⁇ M and 25 ⁇ M in a subject or cell. In an embodiment, the flavonoid is administered at a dosage to provide a concentration of to provide a concentration of between 1 ⁇ M and 25 ⁇ M and the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.1 ⁇ M and 2.5 ⁇ M in a subject or cell.
- compositions features methods for treating a subject having inflammation or an inflammatory disease or disorder, the methods comprising administering a flavonoid, a sesquiterpene lactone, or a combination thereof. While it is possible for a flavonoid (e.g., a compound of Table 1) or a sesquiterpene lactone (e.g., a compound of Table 2) to be administered alone, it is preferable to administer said compound as a pharmaceutical composition or formulation, where the compounds are combined with one or more pharmaceutically acceptable diluents, excipients or carriers.
- the compounds according to the disclosure may be formulated for administration in any convenient way for use in human or veterinary medicine.
- the compounds included in the pharmaceutical preparation may be active itself, or may be a prodrug, e.g., capable of being converted to an active compound in a physiological setting.
- the compounds of the present disclosure which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present disclosure, are formulated into a pharmaceutically acceptable dosage form such as described below or by other conventional methods known to those of skill in the art.
- the amount and concentration of compounds of the present disclosure e.g., a flavonoid (e.g., a compound of Table 1) or a sesquiterpene lactone (e.g., a compound of Table 2) in the pharmaceutical compositions, as well as the quantity of the pharmaceutical composition Attorney Docket No.: M2199-7017WO administered to a subject, can be selected based on clinically relevant factors, such as medically relevant characteristics of the subject (e.g., age, weight, gender, other medical conditions, and the like), the solubility of compounds in the pharmaceutical compositions, the potency and activity of the compounds, and the manner of administration of the pharmaceutical compositions.
- a flavonoid e.g., a compound of Table 1
- a sesquiterpene lactone e.g., a compound of Table 2
- compositions comprising a therapeutically effective amount or prophylactically effective amount of a flavonoid (e.g., a compound of Table 1) or a sesquiterpene lactone (e.g., a compound of Table 2), formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents.
- a flavonoid e.g., a compound of Table 1
- a sesquiterpene lactone e.g., a compound of Table 2
- compositions of the present disclosure may be specially formulated for administration in solid or liquid form, including those adapted for oral or parenteral administration, for example, by oral dosage, or by subcutaneous, intramuscular or intravenous injection as, for example, a sterile solution or suspension.
- the subject compounds may be simply dissolved or suspended in sterile water.
- the pharmaceutical preparation is non-pyrogenic, i.e., does not elevate the body temperature of a patient.
- systemic administration means the administration of the compound other than directly into the central nervous system, such that it enters the patient’s system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
- pharmaceutically acceptable is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- pharmaceutically acceptable carrier means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, stabilizing agent, excipient, solvent or encapsulating material, involved in carrying or Attorney Docket No.: M2199-7017WO transporting the subject antagonists from one organ, or portion of the body, to another organ, or portion of the body.
- Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
- materials which can serve as pharmaceutically acceptable carriers include, but are not limited to: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide, such
- certain embodiments of the compounds described herein may contain a basic functional group, such as an amine, and are thus capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable acids.
- pharmaceutically acceptable salts refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the present disclosure. These salts can be prepared in situ during the final isolation and purification of the compounds of the disclosure, or by separately reacting a purified compound of the disclosure in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed.
- Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like (see, for example, Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci.66:1-19).
- the compounds of the present disclosure may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases.
- pharmaceutically acceptable salts refers to the relatively non-toxic, inorganic and organic base addition salts of the Attorney Docket No.: M2199-7017WO compound of the present disclosure (e.g. of a flavonoid (e.g., a compound of Table 1) or a sesquiterpene lactone (e.g., a compound of Table 2)).
- salts can likewise be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary or tertiary amine.
- a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary or tertiary amine.
- Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like.
- Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like (see, for example, Berge et al., supra).
- wetting agents such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
- antioxidants examples include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha- tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
- water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
- oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), le
- the pharmaceutically acceptable carriers as well as wetting agents, emulsifiers, lubricants, coloring agents, release agents, coating agents, sweetening, flavoring agents, perfuming agents, preservatives, antioxidants, and other additional components may be present in an amount between about 0.001% and 99% of the composition described herein.
- said pharmaceutically acceptable carriers as well as wetting agents, emulsifiers, lubricants, coloring agents, release agents, coating agents, sweetening, flavoring agents, perfuming agents, preservatives, antioxidants, and other additional components may be present from about 0.005%, about 0.01%, about 0.05%, about 0.1%, about 0.25%, about 0.5%, about 0.75%, about 1%, about 1.5%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 85%, about 90%, about 95%, or about 99% of the composition described herein.
- compositions of the present disclosure may be in a form suitable for oral administration, e.g., a liquid or solid oral dosage form.
- the liquid dosage form comprises a suspension, a solution, a linctus, an emulsion, a drink, an elixir, or a syrup.
- the solid dosage form comprises a capsule, tablet, powder, dragée, or powder.
- the pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages.
- compositions may comprise, in addition to of a flavonoid (e.g., a compound of Table 1) or a sesquiterpene lactone (e.g., a compound of Table 2), a pharmaceutically acceptable carrier, and may optionally further comprise one or more pharmaceutically acceptable excipients, such as, for example, stabilizers (e.g., a binder, e.g., polymer, e.g., a precipitation inhibitor, diluents, binders, and lubricants.
- the composition described herein comprises a liquid dosage form for oral administration, e.g., a solution or suspension.
- the composition described herein comprises a solid dosage form for oral administration capable of being directly compressed into a tablet.
- said tablet may include other medicinal or pharmaceutical agents, carriers, and or adjuvants.
- exemplary pharmaceutical compositions include compressed tablets (e.g., directly compressed tablets), e.g., comprising one or more of a flavonoid (e.g., a compound of Table 1) or a sesquiterpene lactone (e.g., a compound of Table 2) or a pharmaceutically acceptable salt thereof.
- Formulations of the present disclosure include those suitable for parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
- the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration.
- the amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about 99 percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.
- compositions of this disclosure suitable for parenteral administration comprise compounds of the disclosure in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable Attorney Docket No.: M2199-7017WO solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
- a compound of the present disclosure such as a flavonoid (e.g., a compound of Table 1), is provided as a composition in combination with a sesquiterpene lactone (e.g., a compound of Table 2).
- a flavonoid e.g., a compound of Table 1
- the fixed dose composition may be formulated for oral administration, e.g., as a solid dosage form or a liquid dosage form.
- the liquid dosage form comprises a suspension, a solution, a linctus, an emulsion, a drink, an elixir, or a syrup.
- the solid dosage form comprises a capsule, tablet, dragée, or powder.
- the combination therapy described herein may involve formulation of the component agents for different routes of administration or for the same route of administration.
- both the flavonoid and sesquiterpene lactone may be formulated for oral administration.
- the flavonoid is formulated for oral administration and the sesquiterpene lactone is formulated for parenteral administration.
- the flavonoid is formulated for parenteral administration and the sesquiterpene lactone is formulated for oral administration.
- the flavonoid and sesquiterpene lactone are formulated as a fixed dose combination (e.g., as a liquid dosage form or solid dosage form, e.g., a capsule or tablet). In some embodiments, the flavonoid and sesquiterpene lactone are formulated as a fixed dose combination (e.g., as a liquid dosage form or solid dosage form, e.g., a capsule or tablet) for oral administration.
- aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
- polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
- vegetable oils such as olive oil
- injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
- microorganisms Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, Attorney Docket No.: M2199-7017WO chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin.
- agents that delay absorption such as aluminum monostearate and gelatin.
- a compound of the present disclosure e.g., a flavonoid and sesquiterpene lactone
- delayed absorption of a parenterally administered form of the compound of the present disclosure is accomplished by dissolving or suspending compound in an oil vehicle.
- sustained absorption may be achieved by combining a compound of the present disclosure with other pharmaceutically acceptable ingredients, diluents, or carriers that slow its release properties into systemic circulation.
- Routes of Administration The flavonoids and sesquiterpene lactones described herein, as well as other agents and related compositions thereof used in the methods described herein may be administered to a subject in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art. Exemplary routes of administration of the compositions used in the methods described herein include topical, enteral, or parenteral applications.
- Topical applications include but are not limited to epicutaneous, inhalation, enema, eye drops, ear drops, and applications through mucous membranes in the body.
- Enteral applications include oral administration, rectal administration, vaginal administration, and gastric feeding tubes.
- Parenteral administration includes intravenous, intraarterial, intracapsular, intraorbital, intracardiac, intradermal, transtracheal, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, intrastemal, intraperitoneal, subcutaneous, intramuscular, transepithelial, Attorney Docket No.: M2199-7017WO nasal, intrapulmonary, intrathecal, rectal, and topical modes of administration.
- Parenteral administration may be by continuous infusion over a selected period of time.
- the compositions described herein comprising a flavonoid and sesquiterpene lactone are administered orally.
- the compositions described herein comprising a flavonoid and sesquiterpene lactone are administered systemically.
- the compositions described herein comprising a flavonoid and sesquiterpene lactone are administered topically.
- the compositions described herein comprising a flavonoid are administered orally.
- the compositions described herein comprising a sesquiterpene lactone are administered orally.
- compositions described herein comprising a flavonoid are administered systemically. In other embodiments of the disclosure, the compositions described herein comprising a sesquiterpene lactone are administered systemically. In certain embodiments of the disclosure, the compositions described herein comprising a flavonoid are administered topically. In certain embodiments of the disclosure, the compositions described herein comprising a sesquiterpene lactone are administered topically. In other embodiments of the disclosure, the compositions described herein comprising a flavonoid are administered intravenously. In other embodiments of the disclosure, the compositions described herein comprising a sesquiterpene lactone are administered intravenously.
- compositions described herein comprising quercetin is administered orally in combination with parthenolide. In an embodiment, the compositions described herein comprising quercetin is administered orally prior to or after oral administration of parthenolide. In other embodiments of the disclosure, the compositions described herein comprising quercetin is administered topically (e.g., dermally). In an embodiment, the compositions described herein comprising quercetin is administered topically in combination with parthenolide. In an embodiment, the compositions described herein comprising quercetin is administered systemically prior to or after administration of parthenolide.
- the composition For intravenous, intraperitoneal, or intrathecal delivery or direct injection, the composition must be sterile and fluid to the extent that the composition is deliverable by syringe.
- the carrier can be an isotonic buffered saline solution, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable Attorney Docket No.: M2199-7017WO mixtures thereof.
- Proper fluidity can be maintained, for example, by use of coating such as lecithin, by maintenance of required particle size in the case of dispersion and by use of surfactants.
- isotonic agents for example, sugars, polyalcohols such as mannitol or sorbitol, and sodium chloride in the composition.
- Long-term absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate or gelatin.
- the choice of the route of administration will depend on whether a local or systemic effect is to be achieved. For example, for local effects, the composition can be formulated for topical administration and applied directly where its action is desired. For systemic, long-term effects, the composition can be formulated for enteral administration and given via the digestive tract.
- the composition can be formulated for parenteral administration and given by routes other than through the digestive tract.
- Dosages The compositions of the flavonoids and sesquiterpene lactones as described herein may be formulated into acceptable dosage forms by conventional methods known to those of skill in the art.
- Actual dosage levels of the active ingredients in the compositions of the present disclosure e.g., a flavonoid or a sesquiterpene lactone, e.g., quercetin or parthenolide
- the selected dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present disclosure employed, the route of administration, the time of administration, the rate of absorption of the particular agent being employed, the duration of the treatment, other drugs, substances, and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the subject being treated, and like factors well known in the medical arts.
- a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the composition required.
- a suitable daily dose of a composition of the present disclosure will be that amount of the substance which is the lowest dose effective to produce a therapeutic effect.
- Such an effective dose will generally depend upon the factors described herein.
- the effective daily dose of a therapeutic composition may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
- Preferred therapeutic dosage levels are between about 0.1 mg/kg to about 1000 mg/kg (e.g., about 0.2 mg/kg, 0.5 mg/kg, 1.0 mg/kg, 1.5 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 60 mg/kg, 70 mg/kg, 80 mg/kg, 90 mg/kg, 100 mg/kg, 125 mg/kg, 150 mg/kg, 175 mg/kg, 200 mg/kg, 250 mg/kg, 300 mg/kg, 350 mg/kg, 400 mg/kg, 450 mg/kg, 500 mg/kg, 600 mg/kg, 700 mg/kg, 800 mg/kg, 900 mg/kg, or 1000 mg/kg) of the composition per day administered (e.g., orally or via injection) to a subject afflicted with a disease or disorder described herein
- Preferred prophylactic dosage levels are between about 0.1 mg/kg to about 1000 mg/kg (e.g., about 0.2 mg/kg, 0.5 mg/kg, 1.0 mg/kg, 1.5 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 60 mg/kg, 70 mg/kg, 80 mg/kg, 90 mg/kg, 100 mg/kg, 125 mg/kg, 150 mg/kg, 175 mg/kg, 200 mg/kg, 250 mg/kg, 300 mg/kg, 350 mg/kg, 400 mg/kg, 450 mg/kg, 500 mg/kg, 600 mg/kg, 700 mg/kg, 800 mg/kg, 900 mg/kg, or 1000 mg/kg) of the composition per day administered (e.g., orally, topically, or systemically) to a subject.
- mg/kg
- the dose may also be titrated (e.g., the dose may be escalated gradually until signs of toxicity appear, such as headache, diarrhea, or nausea).
- the frequency of treatment may also vary.
- the subject can be treated one or more times per day (e.g., once, twice, three, four or more times) or every so-many hours (e.g., about every 2, 4, 6, 8, 12, or 24 hours).
- the flavonoid and/or sesquiterpene lactone concentration can be administered 1 or 2 times per 24 hours.
- the time course of treatment may be of varying duration, e.g., for two, three, four, five, six, seven, eight, nine, ten, or more days, two weeks, 1 month, 2 months, 4 months, 6 months, 8 months, 10 months, or more than one year.
- the treatment can be twice a day for three days, twice a day for seven days, twice a day for ten days.
- Treatment cycles can be repeated at intervals, for example weekly, bimonthly or Attorney Docket No.: M2199-7017WO monthly, which are separated by periods in which no treatment is given.
- the treatment can be a single treatment or can last as long as the life span of the subject (e.g., many years).
- the dosage of a flavonoid is between about 5 mg/kg to about 100 mg/kg (e.g., about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 30 mg/kg, about 40 mg/kg, about 50 mg/kg, about 60 mg/kg, about 70 mg/kg, about 80 mg/kg, about 90 mg/kg, or about 100 mg/kg).
- the dosage of a flavonoid (e.g., a compound of Table 1) between about 10 mg/kg to about 50 mg/kg (e.g., about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, or about 50 mg/kg).
- the dosage of a flavonoid is about 0.1 mg to about 5 mg (e.g., about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, or about 5 mg).
- the dosage of a flavonoid is between about 0.01 mg/kg to about 10 mg/kg (e.g., about 0.01 mg/kg, about 0.025 mg/kg, about 0.05 mg/kg, about 0.1 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, or about 10 mg/kg).
- a flavonoid e.g., a compound of Table 1
- the dosage of a flavonoid is between about 0.01 mg/kg to about 10 mg/kg (e.g., about 0.01 mg/kg, about 0.025 mg/kg, about 0.05 mg/kg, about 0.1 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg
- the dosage of a flavonoid is between about 0.1 mg/kg to about 5 mg/kg (e.g., about 0.1 mg/kg, about 0.2 mg/kg, about 0.3 mg/kg, about 0.4 mg/kg, about 0.5 mg/kg, about 0.6 mg/kg, about 0.7 mg/kg, about 0.8 mg/kg, about 0.9 mg/kg, about 1 mg/kg, about 1.25 mg/kg, about 1.5 mg/kg, about 1.75 mg/kg, about 2 mg/kg, about 2.5 mg/kg, about 3 mg/kg, about 3.5 mg/kg, about 4 mg/kg, about 4.5 mg/kg, or about 5 mg/kg).
- a flavonoid e.g., a compound of Table 1 mg/kg
- 5 mg/kg e.g., about 0.1 mg/kg, about 0.2 mg/kg, about 0.3 mg/kg, about 0.4 mg/kg, about 0.5 mg/kg, about 0.6 mg/kg, about 0.7 mg/kg, about 0.8 mg/kg,
- a course of a flavonoid is between about 1 day to about 24 weeks.
- the course of a flavonoid e.g., a compound of Table 1 is administered at least weekly (e.g., once a week, twice a week, three times a week, four times a week, five times a week, six times a week, 7 times a week) throughout a course of treatment.
- the course of a flavonoid e.g., a compound of Table 1 is administered daily throughout a course of treatment.
- the dosage of a sesquiterpene lactone is between about 5 mg/kg to about 100 mg/kg (e.g., about 5 mg/kg, about 10 mg/kg, about 15 Attorney Docket No.: M2199-7017WO mg/kg, about 20 mg/kg, about 30 mg/kg, about 40 mg/kg, about 50 mg/kg, about 60 mg/kg, about 70 mg/kg, about 80 mg/kg, about 90 mg/kg, or about 100 mg/kg).
- the dosage of a sesquiterpene lactone is between about 10 mg/kg to about 50 mg/kg (e.g., about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, or about 50 mg/kg).
- the dosage of a sesquiterpene lactone is about 0.1 mg to about 5 mg (e.g., about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, or about 5 mg).
- the dosage of a sesquiterpene lactone is between about 0.01 mg/kg to about 10 mg/kg (e.g., about 0.01 mg/kg, about 0.025 mg/kg, about 0.05 mg/kg, about 0.1 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, or about 10 mg/kg).
- the dosage of a sesquiterpene lactone is between about 0.1 mg/kg to about 5 mg/kg (e.g., about 0.1 mg/kg, about 0.2 mg/kg, about 0.3 mg/kg, about 0.4 mg/kg, about 0.5 mg/kg, about 0.6 mg/kg, about 0.7 mg/kg, about 0.8 mg/kg, about 0.9 mg/kg, about 1 mg/kg, about 1.25 mg/kg, about 1.5 mg/kg, about 1.75 mg/kg, about 2 mg/kg, about 2.5 mg/kg, about 3 mg/kg, about 3.5 mg/kg, about 4 mg/kg, about 4.5 mg/kg, or about 5 mg/kg).
- a course of a sesquiterpene lactone is between about 1 day to about 24 weeks.
- the course of a sesquiterpene lactone e.g., a compound of Table 2 is administered at least weekly (e.g., once a week, twice a week, three times a week, four times a week, five times a week, six times a week, 7 times a week) throughout a course of treatment.
- the course of a sesquiterpene lactone e.g., a compound of Table 2 is administered daily throughout a course of treatment.
- a patient and/or subject can be selected for treatment using a flavonoid and a sesquiterpene lactone for the treatment of an inflammatory disease or disorder by first evaluating the patient and/or subject to determine Attorney Docket No.: M2199-7017WO whether the subject has an inflammatory disease or disorder.
- a subject can be evaluated as having an inflammatory disease or disorder using methods known in the art.
- the subject can also be monitored, for example, subsequent to administration of a compound described herein (e.g., a flavonoid and a sesquiterpene lactone) or a pharmaceutically acceptable salt thereof.
- the subject is a mammal. In some embodiments, the subject is a human. In some embodiments, the subject is an adult. In some embodiments, the subject has an acute form of inflammation or an inflammatory disease or disorder. In some embodiments, the subject has a chronic form of inflammation or an inflammatory disease or disorder. In some embodiments, the subject has been diagnosed with an inflammatory disease or disorder. In some embodiments, the subject is treatment na ⁇ ve. In some embodiments, the subject has previously been treated for inflammation or an inflammatory disease or disorder. For example, the subject may have received an immune therapy. In some embodiments, the subject is suffering from an inflammatory disease or disorder.
- the subject has been treated with an agent other than a flavonoid or sesquiterpene lactone described herein and is suffering from a relapsed inflammatory disease or disorder.
- the subject has a co-morbidity, such as heart disease, coronary artery disease, a cardiomyopathy, diabetes, obesity, high blood pressure, cancer, cerebrovascular disease, chronic kidney disease, chronic liver disease, cystic fibrosis, an immunodeficiency, and tuberculosis.
- the methods described herein further comprise analyzing or receiving analysis of a biopsy specimen from the subject at least once prior to the end of treatment.
- the biopsy specimen is analyzed for the levels of a cytokine, antibody, or other hypersensitivity marker.
- additional therapeutic agents may be administered with compositions of the present disclosure for the treatment of inflammation or an inflammatory disease or disorder, or any symptom or associated condition thereof.
- the additional therapeutic agent(s) can be administered as a separate formulation or may be combined with any of the compositions described herein.
- Attorney Docket No.: M2199-7017WO any of the methods described herein may further comprise the administration of a therapeutically effective amount of an additional agent in conjunction with a a flavonoid or a sesquiterpene lactone.
- Exemplary additional agents include an immune therapy, a vaccine, an anti-inflammatory agent, a pain reliever, a mucolytic agent, a cancer therapy, an antifungal agent, an antibacterial agent, a bronchodilator, or a vasodilator.
- the additional agent is an anti-inflammatory agent.
- the anti-inflammatory agent may be an angiotensin-converting enzyme 2 (ACE-2) inhibitor (e.g., lisinopril, benazepril, captopril, enalapril, fosinopril, moexipril, perindopril, or quinapril), a corticosteroid (e.g., cortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, or hydrocortisone) or a non-steroidal anti-inflammatory drug (NSAID) (e.g., ibuprofen, naproxen, diclofenac, celecoxib, mefenamic acid, etoricoxib, or indomethacin).
- ACE-2 angiotensin-converting enzyme 2
- NSAID non-steroidal anti-inflammatory drug
- the additional agent is a cancer therapy.
- the cancer therapy agent is selected from methotrexate, 5-fluorouracil, doxorubicin, vincristine, bleomycin, vinblastine, dacarbazine, toposide, cisplatin, epirubicin, and sorafenib tosylate.
- the compositions and methods described herein can comprise an immunomodulator.
- the immunomodulator is an anti-inflammatory agent described herein, e.g., for treating or preventing a disease or disorder, e.g., a cancer or a fibrotic disorder described herein.
- composition and method can include one, two, three or more anti-inflammatory agents, alone or in combination with one or more therapeutic agents described herein (e.g., an AHCM agent, a microenvironment modulator, an immune-checkpoint inhibitor, or an additional therapy, e.g., a cancer or anti-fibrotic therapy).
- the anti-inflammatory agent is an agent that blocks, inhibits, or reduces inflammation or signaling from an inflammatory signaling pathway.
- the anti-inflammatory agent inhibits or reduces the activity of one or more of any of the following: IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-18, IL-23, interferons (IFNs), e.g., TNF- ⁇ , TNF- ⁇ , TNF-RI, TNF-RII; CD23, CD30, CD40L, CXCL-1, EGF, G-CSF, GDNF, PDGF-BB, RANTES/CCL5, IKK, NF-kB, TLR2, TLR3, TLR4, TL5, TLR6, TLR7, TLR8, TLR8, TLR9, and/or any cognate receptors thereof.
- IFNs interferons
- the anti-inflammatory agent is an IL-1 or IL-1 receptor antagonist, such as anakinra (KINIRET®), rilonacept, or canakinumab. Attorney Docket No.: M2199-7017WO
- the anti-inflammatory agent is an IL-6 or IL-6 receptor antagonist, e.g., an anti-IL-6 antibody or an anti-IL-6 receptor antibody, such as tocilizumab (ACTEMRA®), olokizumab, clazakizumab, sarilumab, sirukumab, siltuximab, or ALX-0061.
- the anti-inflammatory agent is a TNF-a antagonist, e.g., an anti- TNFa antibody, such as infliximab (REMICADE®), golimumab (SIMPONI®), adalimumab (HUMIRA®), certolizumab pegol (CIMZIA®) or etanercept.
- the anti-inflammatory agent is a corticosteroid.
- corticosteroids include, but are not limited to, cortisone (hydrocortisone, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, ALA-CORT®, HYDROCORT ACETATE®, hydrocortone phosphate LANACORT®, SOLU-CORTEF®), decadron (dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate, DEXASONE®, DIODEX®, HEXADROL®, MAXIDEX®), methylprednisolone (6-methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, DURALONE®, MEDRALONE®, MEDROL®, M-PREDNISOL®, SOLU-MEDROL®), prednisolone (DELTA-CORTEF®, ORAPRED®, PEDIAPRED®, PRELONE®), and predni
- the anti-inflammatory agent is a non-steroidal anti-inflammatory drug (NSAID).
- NSAIDs non-steroidal anti-inflammatory drugs
- Exemplary anti-inflammatory agents include, but are not limited to, aspirin, ibuprofen, naproxen, celecoxib, , diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ketoprofen, ketorolac, mefenamic acid, meloxicam, nabumetone, oxaprozin, piroxicam, sulindac, and tolmetin.
- the anti-inflammatory agent is an immune selective anti-inflammatory derivative (ImSAID).
- EMBODIMENTS 1. A method of reducing the level of an inflammatory cytokine in a cell or subject, wherein the method comprises administering to the cell or subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, Attorney Docket No.: M2199-7017WO thereby reducing the level of the inflammatory cytokine in the cell or subject. 2.
- a method of reducing the level of an inflammatory cytokine in a cell comprising administering to the cell a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing the level of the inflammatory cytokine in the cell.
- the method comprises administering to the subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing the level of the inflammatory cytokine in the subject. 4. The method of any one of embodiments 1 or 3, wherein the subject is a mammal. 5.
- inflammatory cytokine is selected from IL-6, IL-1b, and TNF-a. 6. The method of any one of embodiments 1-3, wherein the inflammatory cytokine is IL-6. 7. The method of any one of embodiments 1-3, wherein the inflammatory cytokine is IL-1b. 8. The method of any one of embodiments 1-3, wherein the inflammatory cytokine is TNF- a. 9. The method of any one of embodiments 1-3 or 5-8, wherein the level of the inflammatory cytokine is reduced by about 10%, 25%, 50%, 75%, 90%, 95%, or more, e.g., relative to a reference standard.
- any one of embodiments 1-3 or 5-8 wherein the level of the inflammatory cytokine is reduced by about 75%, e.g., relative to a reference standard. 14. The method of any one of embodiments 1-3 or 5-8, wherein the level of the inflammatory cytokine is reduced by about 90%, e.g., relative to a reference standard. 15. The method of any one of embodiments 1-3 or 5-8, wherein the level of the inflammatory cytokine is reduced by about 95%, e.g., relative to a reference standard. 16.
- a method of increasing the level of an anti-inflammatory cytokine in a cell or subject comprising administering to the cell or subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing the level of an anti-inflammatory cytokine in the cell or subject. 17.
- a method of increasing the level of an anti-inflammatory cytokine in a cell wherein the method comprises administering to the cell a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing the level of an anti-inflammatory cytokine in the cell.
- a method of increasing the level of an anti-inflammatory cytokine in a subject comprising administering to the subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing the level of an anti-inflammatory cytokine in the subject. 19.
- the method of any one of embodiments 16-18, wherein the anti-inflammatory cytokine is selected from IL-4 and IL-10.
- any one of embodiments 16-18 or 20-22 wherein the level of the anti- inflammatory cytokine is increased by about 90%, e.g., relative to a reference standard.
- 30 The method of any one of embodiments 16-18 or 20-22, wherein the level of the anti- inflammatory cytokine is increased by about 95%, e.g., relative to a reference standard.
- 31 A method of reducing the level of a hypersensitivity marker in a cell or subject, wherein the method comprises administering to the cell or subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing the level of a hypersensitivity marker in the cell or subject. 32.
- a method of reducing the level of a hypersensitivity marker in a cell comprises administering to the cell a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing the level of a hypersensitivity marker in the cell.
- 33. A method of reducing the level of a hypersensitivity marker in a subject, wherein the method comprises administering to the subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing the level of a hypersensitivity marker in the subject.
- 34 The method of any one of claims 31 or 33, wherein the subject is a mammal. Attorney Docket No.: M2199-7017WO 35.
- the method of any one of embodiments 31-33, wherein the hypersensitivity marker is selected from IL-13, IL-14, INF-g, and serum IgE. 36.
- the method of any one of embodiments 31-33, wherein the hypersensitivity marker is IL- 13. 37.
- the method of any one of embodiments 31-33, wherein the hypersensitivity marker is IL- 14. 38.
- the method of any one of embodiments 31-33, wherein the hypersensitivity marker is INF-g. 39.
- the method of any one of embodiments 31-33, wherein the hypersensitivity marker is serum IgE. 40.
- any one of embodiments 31-33 or 35-39 wherein the level of the hypersensitivity marker is reduced by about 10%, 25%, 50%, 75%, 90%, 95%, or more, e.g., relative to a reference standard. 41. The method of any one of embodiments 31-33 or 35-39, wherein the level of the hypersensitivity marker is reduced by about 10%, e.g., relative to a reference standard. 42. The method of any one of embodiments 31-33 or 35-39, wherein the level of the hypersensitivity marker is reduced by about 25%, e.g., relative to a reference standard. 43.
- any one of embodiments 31-33 or 35-39 wherein the level of the hypersensitivity marker is reduced by about 50%, e.g., relative to a reference standard. 44.
- the method of any one of embodiments 31-33 or 35-39, wherein the level of the hypersensitivity marker is reduced by about 90%, e.g., relative to a reference standard. 46.
- a method of inducing expression of an anti-inflammatory macrophage in a cell or subject wherein the method comprises administering to the cell or subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby inducing expression of the anti-inflammatory macrophage in the cell or subject.
- a method of inducing expression of an anti-inflammatory macrophage in a cell comprising administering to the cell a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby inducing expression of the anti-inflammatory macrophage in the cell.
- the method comprises administering to the subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby inducing expression of the anti-inflammatory macrophage in the subject.
- the method of any one of embodiments 47-49, wherein the anti-inflammatory macrophage is an M2 macrophage.
- 53. A method of improving skin health in a cell or subject, wherein the method comprises administering to the cell or subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby improving skin health in the cell or subject. 54.
- a method of improving skin health in a cell comprising administering to the cell a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby improving skin health in the cell.
- a method of improving skin health in a subject wherein the method comprises administering to the subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby improving skin health in the subject.
- 56. The method of any one of embodiments 53 or 55, wherein the subject is a mammal. 57.
- a method of reducing inflammation in a cell or subject comprising administering to the cell or subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing inflammation in the cell or subject.
- the method comprises administering to the cell a combination of: Attorney Docket No.: M2199-7017WO (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing inflammation in the cell.
- a method of reducing inflammation in a subject comprising administering to the subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing inflammation in the subject.
- 60. The method of any one of embodiments 57 or 59, wherein the subject is a mammal.
- a method of treating a dermatological condition in a cell or subject comprising administering to the cell or subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby treating the dermatological condition in a cell or subject in a cell or subject.
- the method comprises administering to the cell a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby treating the dermatological condition in a cell or subject in a cell.
- a method of treating a dermatological condition in a subject comprising administering to the subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, Attorney Docket No.: M2199-7017WO thereby treating the dermatological condition in a cell or subject in a subject.
- 65. The method of any one of embodiments 62 or 64, wherein the subject is a mammal.
- 66. The method of any one of embodiments 62-64, wherein the dermatological condition is selected from atopic dermatitis, psoriasis, and dermal hypersensitivity. 67.
- a method of treating topical inflammation in a subject comprising administering to the subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby treating topical inflammation in a subject.
- the subject is a mammal.
- the topical inflammation comprises hives or a rash.
- a method of treating an inflammatory disease or disorder in a cell or subject wherein the method comprises administering to the cell or subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby treating an inflammatory disease or disorder in a cell or subject. 71.
- a method of treating an inflammatory disease or disorder in a cell comprising administering to the cell a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby treating an inflammatory disease or disorder in a cell.
- Attorney Docket No.: M2199-7017WO 72 A method of treating an inflammatory disease or disorder in a subject, wherein the method comprises administering to the subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby treating an inflammatory disease or disorder in a subject.
- 73 The method of any one of embodiments 70 or 72, wherein the subject is a mammal. 74.
- the inflammatory disease or disorder condition comprises rheumatoid arthritis.
- a method of reducing a symptom of inflammation or an inflammatory disease or disorder in a subject wherein the method comprises administering to the subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing a symptom of inflammation or an inflammatory disease or disorder in a subject.
- the method of embodiment 75, wherein the subject is a mammal.
- the symptom comprises swelling, irritation, redness, itching, hives, or sneezing. 78.
- the method of embodiment 77, wherein the symptom comprises swelling. 79.
- the method of embodiment 77, wherein the symptom comprises irritation. 80.
- the method of embodiment 77, wherein the symptom comprises redness.
- the method of embodiment 77, wherein the symptom comprises itching.
- the method of embodiment 77, wherein the symptom comprises hives.
- the method of embodiment 77, wherein the symptom comprises sneezing. 84.
- the method of any one of the preceding embodiments, wherein one of the flavonoid and the sesquiterpene lactone comprises an AHR agonist, an NRF2 agonist, or a PPARg agonist. 85.
- each of the flavonoid and the sesquiterpene lactone independently comprises an AHR agonist.
- each of the flavonoid and the sesquiterpene lactone independently comprises an NRF2 agonist.
- 91. The method of any one of the preceding embodiments, wherein each of the flavonoid and the sesquiterpene lactone independently comprises a PPARg agonist.
- the sesquiterpene lactone has the structure of Formula (B-i): a pharmaceutically acceptable salt thereof, wherein: hydrogen, C 1 -C 6 alkyl, or C 1 -C 6 heteroalkyl, or with the carbon atom to which they are attached, form C 2 - C6 alkenyl or C2-C6 alkynyl;
- R 2 is hydrogen or C1-C6 alkyl;
- R 3 is hydrogen or C 1 -C 6 alkyl; each of R 4 and R 5 is independently absent, hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or - OR A , or R 4 and R 5 , taken together with the carbon atoms to which they are attached, form a heterocyclyl ring;
- R 6 is hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or -OR A ;
- R 7 is hydrogen or -OR A , or R 2 and R 7 , taken together with
- each of R 1a and R 1b is independently hydrogen, C1-C6 alkyl, or C1-C6 heteroalkyl.
- each of R 1a and R 1b is independently hydrogen.
- each of R 1a and R 1b is independently C1-C6 alkyl.
- the method of embodiment 92, wherein each of R 1a and R 1b is independently C 1 -C 6 heteroalkyl. 97.
- each of R 1a and R 1b is independently hydrogen, C 1 -C 6 alkyl, or C 1 -C 6 heteroalkyl, or R 1a and R 1b , taken together with the carbon atom to which they are attached, form C2-C6 alkenyl or C2-C6 alkynyl.
- R 2 is hydrogen or C 1 -C 6 alkyl.
- R 2 is hydrogen.
- R 3 is hydrogen or C1-C6 alkyl.
- each of R 4 and R 5 is independently C 1 -C 6 heteroalkyl. 112.
- the method of embodiment 92, wherein each of R 4 and R 5 is independently -OR A .
- the method of embodiment 92, wherein R 4 and R 5 taken together with the carbon atoms to which they are attached, form a heterocyclyl ring.
- each of R 4 and R 5 is independently absent, hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or -OR A , or R 4 and R 5 , taken together with the carbon atoms to which they are attached, form a heterocyclyl ring.
- R A is hydrogen. 127.
- the method of embodiment 92, wherein R A is C1-C6 alkyl. 128.
- the method of embodiment 92, wherein R A is -C(O)-C 1 -C 6 alkyl. 129.
- the method of embodiment 92, wherein R A is C(O)-C 2 -C 6 alkenyl. 130.
- the method of embodiment 92, wherein “ ” is a single or double bond, provided that when “ ” is a double bond, each of R 4 and R 5 is independently absent.
- the method of embodiment 92, wherein “ ” is a single or double bond.
- the sesquiterpene lactone is a compound of Formula (C-iii): iii) or a pharmaceutically acceptable salt thereof, wherein R 2 is is hydrogen or C1-C6 alkyl; R 6 is hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or -OR A ; R 7 is hydrogen or -OR A , or R 2 and R 7 , taken together with the carbon Attorney Docket No.: M2199-7017WO atoms to which they are attached, form a heterocyclyl ring; and R A is hydrogen, C 1 -C 6 alkyl, - C(O)-C1-C6 alkyl, C(O)-C2-C6 alkenyl, or cycloalkyl.
- R 2 is hydrogen or C1-C6 alkyl
- R 6 is hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or -OR A
- R 7 is hydrogen or -OR A ,
- R A is C(O)-C2-C6 alkenyl. 187.
- R 2 is C1-C6 alkyl; R 3 is C1-C6 alkyl; R 6 is - OR A ; R 7 is hydrogen; and R A is hydrogen. 191.
- sesquiterpene lactone is costunolide or a pharmaceutically acceptable salt thereof.
- sesquiterpene lactone is eupatolide or a pharmaceutically acceptable salt thereof.
- sesquiterpene lactone is onopordopicrin or a pharmaceutically acceptable salt thereof.
- each of R 1 and R 2 is independently hydrogen or OR A ;
- R 3 is hydrogen or OR A ;
- R 4 is hydrogen or -OR A ;
- R A is hydrogen, C1-C6 alkyl, or cycloalkyl; and “ ” is a single or double bond.
- the method of embodiment 197, wherein each of R 1 and R 2 is independently hydrogen or OR A .
- 199. The method of embodiment 197, wherein each of R 1 and R 2 is independently hydrogen. 200.
- each of R 1 and R 2 is independently OR A .
- the flavonoid is quercetin or a pharmaceutically acceptable salt thereof.
- the flavonoid is luteolin or a pharmaceutically acceptable salt thereof.
- the flavonoid is myricetin or a pharmaceutically acceptable salt thereof.
- the flavonoid is taxifolin or a pharmaceutically acceptable salt thereof. 219.
- the method of any one of the preceding embodiments, wherein the flavonoid is fisetin, and kaempferol, or a pharmaceutically acceptable salt thereof. 220.
- the flavonoid is kaempferol or a pharmaceutically acceptable salt thereof. 221. The method of any one of the preceding embodiments, wherein the flavonoid is selected from quercetin, myricetin, taxifolin, fisetin, and kaempferol, or a pharmaceutically acceptable salt thereof. 222. The method of any one of the preceding embodiments, wherein the flavonoid is quercetin, luteolin, or a pharmaceutically acceptable salt thereof. Attorney Docket No.: M2199-7017WO 223.
- the efficacy of the combination is at least X 1 -fold greater than the efficacy of the flavonoid alone at the molar amount used in the combination, wherein X1 is 1.75. 228.
- the method of any one of the preceding embodiments, wherein the efficacy of the combination is at least X1-fold greater than the efficacy of the flavonoid alone at the molar amount used in the combination, wherein X1 is 2. 229.
- the method of any one of the preceding embodiments, wherein the efficacy of the combination is at least X1-fold greater than the efficacy of the flavonoid alone at the molar amount used in the combination, wherein X 1 is 2.5. 230.
- the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 99.9% of another compound. 246.
- the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 60% of another compound. 249. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 65% of another compound. 250. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 70% of another compound. 251. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 75% of another compound. 252.
- the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 80% of another compound. 253. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 85% of another compound. 254. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 90% of another compound. 255. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 95% of another compound. Attorney Docket No.: M2199-7017WO 256.
- the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 99% of another compound. 257.
- the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 50% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof.
- the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 55% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof.
- the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 60% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof.
- the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about Attorney Docket No.: M2199-7017WO 65% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof. 263.
- the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 70% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof.
- the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 75% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof. 265.
- the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 80% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof. 266.
- the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 85% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof. 267.
- the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 90% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof. 268.
- the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about Attorney Docket No.: M2199-7017WO 95% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof. 269.
- the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 99% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof.
- the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 99.9% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof.
- the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 99.9% of a plant-derived substance. 272.
- the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 60% of a plant-derived substance.
- Attorney Docket No.: M2199-7017WO 275 The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 65% of a plant-derived substance. 276.
- the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 75% of a plant-derived substance. 278. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 80% of a plant-derived substance. 279. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 85% of a plant-derived substance. 280. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 90% of a plant-derived substance. 281.
- the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 95% of a plant-derived substance. 282.
- the method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 99.5% of a plant-derived substance. 284.
- the method of embodiment 291, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided in the combination in the absence of myricetin or a pharmaceutically acceptable salt thereof. 295. The method of embodiment 291, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided in the combination in the absence of taxifolin or a pharmaceutically acceptable salt thereof. 296. The method of embodiment 291, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided in the combination in the absence of fisetin or a pharmaceutically acceptable salt thereof. 297. The method of embodiment 291, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided in the combination in the absence of kaempferol or a pharmaceutically acceptable salt thereof. 298.
- any one of embodiments 291-297 wherein the quercetin or a pharmaceutically acceptable salt thereof is provided as a pharmaceutical composition, and the pharmaceutical composition comprises less than about 95% of another compound in listed in Table 1 or a pharmaceutically acceptable salt thereof.
- 301 The method of any one of embodiments 291-297, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided as a pharmaceutical composition, and the pharmaceutical composition comprises less than about 99% of another compound in listed in Table 1 or a pharmaceutically acceptable salt thereof.
- 302. The method of any one of embodiments 291-297, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided as a pharmaceutical composition, and the pharmaceutical composition comprises less than about 99.9% of another compound in listed in Table 1 or a pharmaceutically acceptable salt thereof.
- the sesquiterpene lactone is a compound selected from Table 1 or a pharmaceutically acceptable salt thereof.
- the sesquiterpene lactone is substantially pure.
- the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 99.9% of another compound.
- the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 50% of another compound.
- the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 70% of another compound. 311. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 75% of another compound. 312. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 80% of another compound. 313. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 85% of another compound.
- sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 99.9% of another compound. 318.
- sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 50% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof.
- the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 55% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof.
- sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 60% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof.
- the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 65% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof. 323.
- sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 70% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof. 324.
- the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 75% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof. 325.
- sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 80% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof. 326.
- the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 85% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof.
- sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 90% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof.
- sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 95% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof.
- sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 99% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof.
- the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 99.9% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof.
- the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 99.9% of a plant- derived substance. 332.
- Attorney Docket No.: M2199-7017WO 333 The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 55% of a plant-derived substance.
- the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 75% of a plant-derived substance. 338.
- the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 90% of a plant-derived substance.
- the method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 99% of a plant-derived substance. 343.
- the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 99.9% of a plant-derived substance.
- the sesquiterpene lactone is provided in the combination in the absence of costunolide, eupatolide, onopordopicrin, and deoxyelepantopin, or a pharmaceutically acceptable salt thereof.
- the sesquiterpene lactone is provided in the combination in the absence of costunolide or a pharmaceutically acceptable salt thereof.
- the sesquiterpene lactone is parthenolide or a pharmaceutically acceptable salt thereof.
- the parthenolide or a pharmaceutically acceptable salt thereof is provided in the combination in the absence of costunolide, eupatolide, onopordopicrin, and deoxyelepantopin, or a pharmaceutically acceptable salt thereof.
- the parthenolide or a pharmaceutically acceptable salt thereof is provided in the combination in the absence of costunolide or a pharmaceutically acceptable salt thereof. 352.
- the flavonoid is administered at a dosage to provide a concentration of between 0.1 ⁇ M and 500 ⁇ M in the subject. 372. The method of any one of the preceding embodiments, wherein the flavonoid is administered at a dosage to provide a concentration of between 0.1 ⁇ M and 500 ⁇ M in a cell. Attorney Docket No.: M2199-7017WO 373. The method of any one of the preceding embodiments, wherein the flavonoid is administered at a dosage to provide a concentration of between 1 ⁇ M and 25 ⁇ M in the subject or a cell. 374.
- the flavonoid is administered at a dosage to provide a concentration of between 1 ⁇ M and 25 ⁇ M in the subject. 375. The method of any one of the preceding embodiments, wherein the flavonoid is administered at a dosage to provide a concentration of between 1 ⁇ M and 25 ⁇ M in a cell. 376. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.01 ⁇ M and 25 ⁇ M in the subject or a cell. 377.
- the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.01 ⁇ M and 25 ⁇ M in the subject.
- the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.01 ⁇ M and 25 ⁇ M in a cell.
- the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.1 ⁇ M and 5 ⁇ M in the subject or a cell. 380.
- the method of any one of the preceding embodiments, wherein the ratio of the amount of flavonoid to the sesquiterpene lactone in the combination is between 200:1 to 1:1. 383.
- the method of embodiment 382, wherein the ratio of the amount of flavonoid to the sesquiterpene lactone in the combination is between 50:1 to 1:1. 384.
- the method of any one of embodiments 382-383, wherein the ratio of the amount of flavonoid to the sesquiterpene lactone in the combination is between 50:1 to 2:1. 385.
- the method of any one of embodiments 382-384, wherein the ratio of the amount of flavonoid to the sesquiterpene lactone in the combination is between 25:1 to 2:1. 386.
- the flavonoid is quercetin or a pharmaceutically acceptable salt thereof;
- the sesquiterpene lactone is parthenolide or a pharmaceutically acceptable salt thereof; and
- the molar amount of the flavonoid in the combination is between 20-fold and 5-fold greater than the molar amount of the sesquiterpene lactone.
- the method of embodiment 389, wherein the inflamed organ is the eye. 395.
- the method of embodiment 389, wherein the inflamed organ is the skin. 396.
- the method of embodiment 389, wherein the inflamed organ is the lung. 397.
- the method of embodiment 389, wherein the inflamed organ is the large intestine. 398.
- the method of embodiment 389, wherein the inflamed organ is the small intestine. 399.
- the method of embodiment 389, wherein the inflamed organ is the stomach. 400.
- the method of embodiment 389, wherein the inflamed organ is the liver. 401.
- the method of embodiment 389, wherein the inflamed organ is the gall bladder. 402.
- the method of embodiment 389, wherein the inflamed organ is the kidney. 403.
- the method of embodiment 389, wherein the inflamed organ is the spleen.
- the method of embodiment 389, wherein the inflamed tissue is selected from the group consisting of lung tissue, tracheal tissue, intestinal tissue, skin tissue, pancreatic tissue, vascular tissue, mucosal tissue, kidney tissue, brain tissue, nervous tissue, or cardiac tissue. 405.
- the method of embodiment 389, wherein the inflamed tissue is lung tissue. 406.
- the method of embodiment 389, wherein the inflamed tissue is tracheal tissue. 407.
- the method of embodiment 389, wherein the inflamed tissue is intestinal tissue.
- the method of embodiment 389, wherein the inflamed tissue is skin tissue. 409. The method of embodiment 389, wherein the inflamed tissue is pancreatic tissue. 410. The method of embodiment 389, wherein the inflamed tissue is vascular tissue. 411. The method of embodiment 389, wherein the inflamed tissue is mucosal tissue 412. The method of embodiment 389, wherein the inflamed tissue is kidney tissue. 413. The method of embodiment 389, wherein the inflamed tissue is brain tissue. 414. The method of embodiment 389, wherein the inflamed tissue is nervous tissue. 415. The method of embodiment 389, wherein the inflamed tissue is cardiac tissue.
- Example 1 In vitro assay to determine anti-inflammatory properties of exemplary compounds - THP1 cytokine secretion assay AhR, NRF2, or PPARG agonism are known to lead to downstream inhibition of the secretion of various inflammatory cytokines (e.g., TNFa, IL6).
- cytokines e.g., TNFa, IL6
- the purpose of this example was to demonstrate the ability of quercetin and parthenolide, alone or in combination, to impact various downstream, functional inflammatory processes.
- Human THP-1 cells were plated and differentiated into macrophages through treatment with phorbol 12-myristate 13-acetate and beta-mercaptoethanol for 72 hours. Differentiated THP-1 macrophages were then stimulated with IFN-gamma (20 ng/mL) and LPS (50 ng/mL) to induce an inflammatory response and co-treated with Parthenolide and/or Quercetin at 0, 0.2, 0.5, 2, 5, 10 uM.
- Example 2 In vitro assay to determine anti-inflammatory properties of exemplary compounds .
- Primary T cell cytokine secretion assay CD4+CD25- T-responder cells T-cells can be isolated from human PBMC (STEMCELL Technologies, Cat# 70025) using the CD4+CD127lowCD25+ regulatory T-cell isolation kit (Cat# 18063, STEMCELL Technologies).
- CD4+ T-responder cell cytokine release cells can be seeded at 25000/well in a V-bottom 96-well plate and exposed to IL-2 (100 U/mL) to trigger cytokine secretion.
- Parthenolide and Quercetin (5 uM + 5 uM) ability to prevent cytokine secretion may be evaluated.
- a cytokine panel analysis may be performed using Ella Automated Immunoassay System (ProteinSimple). Attorney Docket No.: M2199-7017WO
- Example 3 Oxazolone-induced dermatitis mouse model: Experimental design and results The purpose of this example was to demonstrate the combinatorial, anti-inflammatory effects of a combination of parthenolide or quercetin applied topically on oxazolone-induced ear swelling in mice, a model of allergic contact dermatitis. Male BALB/c mice weighing 22 ⁇ 2 g are used and randomly divided into groups of 5 each.
- Sham treatment group receive no oxazolone sensitization and challenge, but PBS, plus treated with vehicle (Acetone:ethanol 1:1). All other groups’ animals were sensitized by applying oxazolone (100 ⁇ L, 1.5% in acetone) onto their preshaved abdominal surface on Day 0, and challenged by oxazolone (1%, 20 ⁇ L/ear) seven (7) days later.20 ⁇ L of either Vehicle, Dexamethasone (5 mg/mL; anti-inflammatory positive control), or a combination of Parthenolide (0.5 – 3 mg/mL) + Quercetin (1.8 – 10.8 mg/mL) were applied topically to the anterior and posterior surfaces of the right ear 30 minutes before and 15 minutes after oxazolone challenge.
- Left ear was unstimulated and treated as a control.
- the right and left ear thickness of each mouse were measured at 24 hours after oxazolone challenge as an index of inflammation.
- the right ear was harvested and snap frozen for cytokine gene expression analysis.
- Each compound was assessed by calculating the percentage of cytokine gene expression compared to the Vehicle control, with a lower percentage indicating greater anti-inflammatory action of the compound.
- Vehicle-treated ears exhibited oxazolone-stimulated increases in ear thickness to 0.42 mm.
- Dexamethasone-treated ears demonstrated a 29% reduction in thickness compared to the Vehicle-treated ears.
- Parthenolide + Quercetin-treated ears demonstrated a 20% reduction in thickness compared to the Vehicle-treated ears (FIG.1).
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present disclosure relates to therapeutic agents and combinations thereof (e.g., pharmaceutical compositions) for the treatment of inflammation and an inflammatory disease or disorder in a subject, tissue or cell.
Description
Attorney Docket No.: M2199-7017WO COMBINATION THERAPIES FOR TREATING INFLAMMATION CLAIM OF PRIORITY The present application claims priority to U.S. Provisional Application No.63/396,940, filed August 10, 2022; the contents of which are incorporated herein by reference in their entirety. BACKGROUND There is a need for therapeutic agents useful in modulating the inflammatory response in a cell or tissue, and treatment of inflammation and inflammatory diseases and disorders in a subject. SUMMARY The present disclosure relates to therapeutic agents and combinations thereof (e.g., pharmaceutical compositions) for the treatment of inflammation and inflammatory diseases and disorders in a subject, tissue or cell. In one aspect, the present disclosure features a method of treating inflammation or an inflammatory disease or disorder (e.g., a dermatological condition) in a subject comprising administering a combination of a flavonoid (e.g., quercetin) and a sesquiterpene lactone (e.g., parthenolide) to the subject. In an embodiment, administering a combination of a flavonoid (e.g., quercetin) and a sesquiterpene lactone (e.g., parthenolide) to a subject results in a beneficial effect in the subject, e.g., compared with administering the flavonoid and/or sesquiterpene lactone individually. For example, administering a combination of a flavonoid and a sesquiterpene lactone to a cell or subject may result in one or more of: (i) reducing the level of an inflammatory cytokine (e.g., IL-6, IL-1b, and TNF-a) in a cell or subject; (ii) increasing the level of an anti-inflammatory cytokine (e.g., IL-4 and IL-10) in a cell or subject; (iii) reducing the level of a hypersensitivity marker (e.g., IL-13, IL-14, INF-g, and serum IgE) in a cell or subject; (iv) inducing expression of an anti-inflammatory macrophage (e.g., M2 macrophage) in a cell or subject; (v) improving skin health in a cell or subject; (vi) improving a symptom of a dermatological condition (e.g., atopic dermatitis, psoriasis, and dermal hypersensitivity) in a cell or subject; and (vii) improving a symptom of inflammation or an inflammatory disease or disorder in a cell or subject.
Attorney Docket No.: M2199-7017WO BRIEF DESCRIPTION OF DRAWINGS FIG.1 is a graph depicting ear thickness measurements of oxazolone-stimulated ears or unstimulated control ears after topical treatment with either vehicle, dexamethasone (control), or parthenolide + quercetin. FIGS.2A-2C are graphs showing the levels of certain cytokines (FIG.2A - MIP1-beta, FIG.2B - CXCL1, FIG.2C - TNFa) in mice pre-injected for 1 hour with vehicle, dexamethasone (control), or parthenolide + quercetin, then injected with LPS. DESCRIPTION Described herein are compositions comprising (i) a flavonoid or a pharmaceutically acceptable salt thereof and (ii) a sesquiterpene lactone or a pharmaceutically acceptable salt thereof, as well as compositions and methods of using the same. In an embodiment, administering a combination of a flavonoid and a sesquiterpene lactone to a subject results in a beneficial effect in the subject, e.g., compared with administering the flavonoid and/or the sesquiterpene lactone individually. For example, a combination of a flavonoid and a sesquiterpene lactone may result reducing the level of an inflammatory cytokine in a cell or subject, or treatment of a dermatological condition in a cell or subject. A description of exemplary embodiments of the disclosure is provided herein. Definitions As used herein, the articles "a" and "an" refer to one or to more than one (e.g., to at least one) of the grammatical object of the article. "About" and "approximately" shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Exemplary degrees of error are within 20 percent (%), typically, within 10%, and more typically, within 5% of a given value or range of values. As used herein, the term “acquire” or “acquiring” as the terms are used herein, refer to obtaining possession of a physical entity (e.g., a sample, e.g., blood sample or liver biopsy specimen), or a value, e.g., a numerical value, by “directly acquiring” or “indirectly acquiring” the physical entity or value. “Directly acquiring” means performing a process (e.g., an analytical
Attorney Docket No.: M2199-7017WO method) to obtain the physical entity or value. “Indirectly acquiring” refers to receiving the physical entity or value from another party or source (e.g., a third party laboratory that directly acquired the physical entity or value). Directly acquiring a value includes performing a process that includes a physical change in a sample or another substance, e.g., performing an analytical process which includes a physical change in a substance, e.g., a sample, performing an analytical method, e.g., a method as described herein, e.g., by sample analysis of a cell titer or a bodily fluid, e.g., via mass spectroscopy (e.g. LC-MS) or PCR (e.g., RT-PCR). “Co-administration”, “co-administering”, “co-providing”, “in combination” and “a combination of” as used herein in the context of the administration of a flavonoid and a sesquiterpene lactone, refers to administration at the same time or administration of one therapy before (e.g., immediately before, less than about 5, about 10, about 15, about 30, about 45, about 60 minutes, about 1, about 2, about 3, about 4, about 6, about 8, about 10, about 12, about 16, about 20, about 24, about 48, about 72 or more hours before) administration of a secondary therapy. In some embodiments, the therapies to be co-administered are formulated in a single composition. In other embodiments, the therapies to be co-administered are formulated separately. Numerous ranges, e.g., ranges for the amount of a therapy administered per day, are provided herein. In some embodiments, the range includes both endpoints. In other embodiments, the range excludes one or both endpoints. By way of example, the range can exclude the lower endpoint. Thus, in such an embodiment, a range of 250 to 400 mg/day, excluding the lower endpoint, would cover an amount greater than 250 that is less than or equal to 400 mg/day. The term “comprise” is intended to mean “include”. Where a term is provided in the singular, it also contemplates aspects of the invention described by the plural of that term. The term “and/or” where used herein is to be taken as specific disclosure of each of the multiple specified features or components with or without another. Thus, the term “and/or” as used in a phrase such as “A and/or B” herein is intended to include “A and B,” “A or B,” “A” (alone), and “B” (alone). Likewise, the term “and/or” as used in a phrase such as “A, B, and/or C” is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
Attorney Docket No.: M2199-7017WO A “course” or “course of therapy,” as referred to herein, comprises one or more separate administrations of a therapeutic agent or a combination of therapeutic agents (e.g., a flavonoid and/or a sesquiterpene lactone). A course of therapy can comprise one or more cycles of a therapeutic agent. In some embodiments, a therapeutic agent is administered to a subject at least once, at least twice, at least three times, at least four times, or more over a course of treatment. A subject may be administered with one or more courses of treatment. In some embodiments, rest periods may be interposed between courses of treatment. For example, a rest period may be about 1, about 2, about 4, about 6, about 8, about 10, about 12, about 16, about 20, or about 24 hours; or about 1, about 2, about 3, about 4, about 5, about 6, or about 7 days; or about 1, about 2, about 3, about 4 or more weeks in length. A “cycle”, as used herein in the context of a cycle of administration of a therapeutic agent or a combination of therapeutic agents, refers to a period of time for which the therapeutic agent or combination of therapeutic agents is administered to a patient. For example, if a therapeutic agent is administered for a cycle of 4 weeks days, the periodic administration, e.g., daily or twice daily, is given for 4 weeks. A therapeutic agent or combination of therapeutic agents can be administered for more than one cycle. In some embodiments, the first and second or subsequent cycles are the same in terms of one or both of duration and periodic administration. In embodiments, a first and second or subsequent cycle differs in terms of one or both of duration and periodic administration. Rest periods may be interposed between cycles. A rest cycle may be about 1, about 2, about 4, about 6, about 8, about 10, about 12, about 16, about 20, or about 24 hours; or about 1, about 2, about 3, about 4, about 5, about 6, or about 7 days; or about 1, about 2, about 3, about 4 or more weeks in length. The term “efficacy,” as used herein in the context of a therapeutic agent or combination of therapeutic agents, refers to the ability of a therapeutic agent or a combination of therapeutic agents to effect a desirable treatment outcome, such as (i) reducing the level of an inflammatory cytokine (e.g., IL-6, IL-1b, and TNF-a) in a cell or subject; (ii) increasing the level of an anti- inflammatory cytokine (e.g., IL-4 and IL-10) in a cell or subject; (iii) reducing the level of a hypersensitivity marker (e.g., IL-13, IL-14, INF-g, and serum IgE) in a cell or subject; (iv) inducing expression of an anti-inflammatory macrophage (e.g., M2 macrophage) in a cell or subject; (v) improving skin health in a cell or subject; (vi) improving a symptom of a dermatological condition (e.g., atopic dermatitis, psoriasis, and dermal hypersensitivity) in a cell
Attorney Docket No.: M2199-7017WO or subject; and (vii) improving a symptom of inflammation or an inflammatory disease or disorder in a cell or subject. As used herein, the terms “increasing” and “decreasing” refer to modulating that results in, respectively, greater or lesser amounts of function, expression, or activity of a particular metric relative to a reference. For example, subsequent to administration to a cell, tissue or subject of a combination of a flavonoid and a sesquiterpene lactone described herein, the amount of a marker of a metric (e.g., cell viability, level of a cytokine) as described herein may be increased or decreased by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98%, 2X, 3X, 5X, 10X or more relative to the amount of the marker prior to administration or relative to the effect of a negative control agent. The metric may be measured subsequent to administration at a time that the administration has had the recited effect, e.g., at least 12 hours, 24 hours, one week, one month, 3 months, or 6 months, after a treatment has begun. As used herein, the terms “prevent” or “preventing” as used in the context of a disease or disorder described herein (e.g., inflammation or an inflammatory disease or disorder), refer to administration of a flavonoid in combination with a sesquiterpene lactone to a subject, e.g., the administration of parthenolide and quercetin, such that the onset of at least one symptom of the disorder or disease is delayed as compared to what would be seen in the absence of administration of said combination. As used herein, the term “subject” is intended to include human and non-human animals. Exemplary human subjects include a human patient having a disease or disorder, e.g., a disorder described herein (e.g., inflammation or an inflammatory disease or disorder), or a healthy subject. The term “non-human animals” includes all vertebrates, e.g., non-mammals (such as chickens, amphibians, reptiles) and mammals, such as non-human primates, domesticated and/or agriculturally useful animals, e.g., sheep, dogs, cats, cows, pigs, etc. As used herein, an amount of a compound, conjugate, or substance effective to treat a disease or disorder (e.g., inflammation or an inflammatory disease or disorder), “therapeutically effective amount,” “effective amount” or “effective course” refers to an amount of the compound or composition which is effective, upon single or multiple dose administration(s) to a subject, in treating a subject, or in curing, alleviating, relieving or improving a subject with inflammation or an inflammatory disease or disorder beyond that expected in the absence of such treatment.
Attorney Docket No.: M2199-7017WO As used herein, the terms “treat” or “treating” as used in the context of a disease or disorder described herein (e.g., inflammation or an inflammatory disease or disorder), refer to administration of a flavonoid in combination with a sesquiterpene lactone to a subject, e.g., the administration of parthenolide and quercetin, such that at least one symptom of the disorder or disease is cured, healed, alleviated, relieved, altered, remedied, ameliorated, or improved. Treating includes administering an amount effective to alleviate, relieve, alter, remedy, ameliorate, improve or affect the disorder or disease, or the symptoms of the disorder or disease. The treatment may inhibit deterioration or worsening of a symptom of a disorder or disease. In some embodiments, treating includes preventing. In some embodiments, treating does not include preventing. Therapeutic Agents Described herein are flavonoids administered in combination with sesquiterpene lactones to provide a therapeutic benefit to a cell or subject, e.g., treating inflammation or an inflammatory disease or disorder. Flavonoids Flavonoids are class of polyphenolic compounds containing at least one heterocyclic ring comprising a heteroatom, such as an oxygen atom. Flavonoids may be derived from plants, where they carry out multiple functions. For example, flavonoids play a role in plant pigmentation, UV filtration, nitrogen fixation, and certain metabolic pathways. Depending on their structure, flavonoids may be further classified into subgroups such as anthocyanidins, chalcones, flavonols, flavanones, and isoflavonoids. In an embodiment, the flavonoid is a compound of Formula (A): a pharmaceutically acceptable salt thereof, wherein each of R1,
hydrogen or -ORA; RA is hydrogen, C1-C6 alkyl, or cycloalkyl; and “ ” is a single or double bond.
Attorney Docket No.: M2199-7017WO In an embodiment, the flavonoid is a compound of Formula (A-i): a pharmaceutically acceptable salt thereof, wherein each of or -ORA; R3 is hydrogen or -ORA; R4 is hydrogen or -ORA;
or and “ ” is a single or double bond. In an embodiment, R1 is -ORA. In an embodiment, R1 is -OH. In an embodiment, R2 is - hydrogen. In an embodiment, R3 is -ORA. In an embodiment, R3 is -OH. In an embodiment, R4 is -ORA. In an embodiment, R4 is -OH. In an embodiment, is a double bond. In an embodiment, the flavonoid is a compound of Formula (A-ii): ii) or a pharmaceutically acceptable salt thereof, wherein each of or -ORA; R4 is hydrogen or -O A A
R ; and R is hydrogen, C1-C6 alkyl, or cycloalkyl. In an embodiment of Formula (A-i), R1 is -ORA ; R2 is hydrogen; and R4 is -ORA. In an embodiment of Formula (A-i), R1 is -OH ; R2 is hydrogen; and R4 is -OH. In an embodiment, the flavonoid is a compound of Formula (A-iii): iii) or a pharmaceutically acceptable salt thereof,
R4 is hydrogen or -ORA; and RA is hydrogen, C1-C6 alkyl, or cycloalkyl. In an embodiment of Formula (A-iii), R1 is -ORA and R4 is -ORA. In an embodiment of Formula (A-ii), R1 is -OH and R4 is -OH.
Attorney Docket No.: M2199-7017WO In an embodiment, the flavonoid is a compound shown in Table 1. Table 1. Exemplary flavonoids Compound Structure Luteolin
Attorney Docket No.: M2199-7017WO Apigenin
Attorney Docket No.: M2199-7017WO 4',7- Dihydroxyflavone
Attorney Docket No.: M2199-7017WO Retusin
Attorney Docket No.: M2199-7017WO Tricin In an embo
, p y ceptable salt thereof. In an embodiment, the flavonoid is quercetin or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is myricetin or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is taxifolin or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is fisetin or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is kaempferol or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is apigenin or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is tricetin or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is isohamnetin or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is eriodictyol or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is dihydromyricetin or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is chryseriol or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is 7,3',4'-trihydroxyflavone or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is 4',7-dihydroxyflavone or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is hesperitin or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is galangin or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is chrysin or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is 7-O-methylluteolin or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is genkwanin or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is acacetin or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is retusin or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is 7-hydroxyflavone or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is apigenin 7,4'- dimethyl ether or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is Pratol or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is ombuin
Attorney Docket No.: M2199-7017WO or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is quercetin 3,3'- dimethyl ether or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is tectochrysin or a pharmaceutically acceptable salt thereof. In an embodiment, the flavonoid is luteolin or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid such as quercetin, myricetin, taxifolin, fistein, or kaempferol. In an embodiment, the flavonoid is quercetin or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid such as luteolin, myricetin, taxifolin, fistein, or kaempferol. In an embodiment, the flavonoid is myricetin or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid such as quercetin, luteolin, taxifolin, fistein, or kaempferol. In an embodiment, the flavonoid is taxifolin or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid such as quercetin, myricetin, luteolin, fistein, or kaempferol. In an embodiment, the flavonoid is fisetin or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid such as quercetin, myricetin, taxifolin, luteolin, or kaempferol. In an embodiment, the flavonoid is kaempferol or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid such as quercetin, myricetin, taxifolin, fistein, or luteolin. In an embodiment, the flavonoid is luteolin or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid shown in Table 1. In an embodiment, the flavonoid is quercetin or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid shown in Table 1. In an embodiment, the flavonoid is myricetin or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid shown in Table 1. In an embodiment, the flavonoid is taxifolin or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid s shown in Table 1. In an embodiment, the flavonoid is fisetin or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid shown in Table 1. In an embodiment, the flavonoid is kaempferol or a pharmaceutically acceptable salt thereof, provided substantially free of another flavonoid s shown in Table 1. In an embodiment, the flavonoid or a pharmaceutically acceptable salt thereof is provided as a substantially pure compound, for example, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.9% pure, measured, e.g, by HPLC analysis. In an embodiment, the flavonoid is quercetin or a pharmaceutically acceptable salt thereof and is provided as a
Attorney Docket No.: M2199-7017WO substantially pure compound, for example, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.9% pure, measured, e.g, by HPLC analysis. In an embodiment, the flavonoid is provided with less than 10%, 7.5%, 5%, 2.5%, 1%, 0.5%, or 0.1% of another flavonoid, e.g., in the absence of another flavonoid. In an embodiment, the flavonoid is quercetin and is provided with less than 10%, 7.5%, 5%, 2.5%, 1%, 0.5%, or 0.1% of another flavonoid, e.g., in the absence of another flavonoid. In an embodiment, the flavonoid is quercetin and is provided with less than 10%, 7.5%, 5%, 2.5%, 1%, 0.5%, or 0.1% of quercetin present, e.g., in the absence of luteolin. In an embodiment, the flavonoid is provided with less than 10%, 7.5%, 5%, 2.5%, 1%, 0.5%, or 0.1% of another plant-derived substance, such as a plant metabolite, plant lipid, or plant fiber. In an embodiment, the flavonoid is quercetin and is provided with less than 10%, 7.5%, 5%, 2.5%, 1%, 0.5%, or 0.1% of plant- derived substance, such as a plant metabolite, plant lipid, or plant fiber. A composition useful for the treatment of inflammation or an inflammatory disease or disorder may contain a flavonoid (e.g., quercetin) or a plurality of flavonoids. For example, a composition comprising a flavonoid may comprise quercetin, e.g., synthetically prepared or extracted from a natural source, in the absence of another flavonoid. In contrast, a composition comprising a flavonoid may also contain a combination of quercetin and a closely related analog or variant thereof, e.g., a flavonoid shown in Table 1, e.g., quercetin. Sesquiterpene Lactones Sesquiterpene lactones are class of colorless, lipophilic sesquiterpenoid compounds that comprise a lactone ring. These compounds are one of the most prevalent classes of secondary metabolites present in plants, and are most commonly found in plant families such as Asteraceae, Cactaceae, Solanaceae, Araceae, and the Euphorbiaceae. polyphenol compounds commonly found in higher plants, fungi, and lichens. The biosynthesis of sesquiterpene lactones is will understood, and occurs from three isoprene units via farnesyl pyrophosphate in the endoplasmic reticulum of plant cells. In an embodiment, the sesquiterpene lactone is a compound of Formula (B):
Attorney Docket No.: M2199-7017WO a pharmaceutically acceptable salt thereof, wherein each of R1a and C1-C6 alkyl, or C1-C6 heteroalkyl, or R1a and R1b, taken together
they are attached, form C2-C6 alkenyl or C2-C6 alkynyl; R2 is hydrogen or C1-C6 alkyl; R3 is hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl or -ORA; each of R4 and R5 is independently absent, hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or -ORA, or R4 and R5, taken together with the carbon atoms to which they are attached, form a heterocyclyl ring; R6 is hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or -ORA; R7 is hydrogen or -ORA, or R2 and R7, taken together with the carbon atoms to which they are attached, form a heterocyclyl ring; R8 is hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl or -ORA; RA is hydrogen, C1-C6 alkyl, -C(O)-C1-C6 alkyl, C(O)-C2-C6 alkenyl, or cycloalkyl; and “ ” is a single or double bond, provided that when “ ” is a double bond, each of R4 and R5 is independently absent. In an embodiment, the sesquiterpene lactone is a compound of Formula (B-i): a pharmaceutically acceptable salt thereof, wherein each of R1a and C -C alkyl, or C -C h 1a 1b
1 6 1 6 eteroalkyl, or R and R , taken together with the carbon atom to which they are attached, form C2-C6 alkenyl or C2-C6 alkynyl; R2 is hydrogen or C1-C6 alkyl; R3 is hydrogen or C1-C6 alkyl; each of R4 and R5 is independently absent, hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or -ORA, or R4 and R5, taken together with the carbon atoms to which they are attached, form a heterocyclyl ring; R6 is hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or -ORA; R7 is hydrogen or -ORA, or R2 and R7, taken together with the carbon atoms to which they are attached, form a heterocyclyl ring; RA is hydrogen, C1-C6 alkyl, - C(O)-C1-C6 alkyl, C(O)-C2-C6 alkenyl, or cycloalkyl; and “ ” is a single or double bond, provided that when “ ” is a double bond, each of R4 and R5 is independently absent.
Attorney Docket No.: M2199-7017WO In an embodiment, R1a and R1b are taken together to form C2-C6 alkenyl. In an embodiment, R2 is C1-C6 alkyl. In an embodiment, R3 is C1-C6 alkyl. In an embodiment, R4 and R5 are taken together to form a heterocyclyl ring (e.g., an epoxide ring). -OH. In an embodiment, R4 is -ORA. In an embodiment, R4 is -OH. In an embodiment, R6 is hydrogen or - ORA. In an embodiment, R7 is hydrogen or -ORA. In an embodiment, R2 and R7 are taken together to form a heterocyclyl ring. In an embodiment, “ ” is a single bond. In an embodiment, “ ” is a double bond. In an embodiment, R1a and R1b are taken together with the carbon atom to which they are attached to form a C2-C6 alkenyl; R2 is C1-C6 alkyl; R3 is C1-C6 alkyl; R4 and R5, taken together with the carbon atoms to which they are attached, form a heterocyclyl ring; R6 is hydrogen; R7 is hydrogen; and “ ” is a single bond. In an embodiment, R1a and R1b are taken together with the carbon atom to which they are attached to form ethenyl; R2 is methyl; R3 is methyl; R4 and R5, taken together with the carbon atoms to which they are attached, form an epoxide ring; R6 is hydrogen; R7 is hydrogen; and “ ” is a single bond. In an embodiment, R1a and R1b are taken together with the carbon atom to which they are attached to form a C2-C6 alkenyl; R2 is C1-C6 alkyl; R3 is C1-C6 alkyl; each of R4 and R5 is independently absent; R6 is hydrogen; R7 is hydrogen; and “ ” is a double bond. In an embodiment, the sesquiterpene lactone is a compound of Formula (B-ii): ii) or a pharmaceutically acceptable salt thereof, wherein R2 is hydrogen or
or C1-C6 alkyl; R6 is hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or - ORA; R7 is hydrogen or -ORA, or R2 and R7, taken together with the carbon atoms to which they are attached, form a heterocyclyl ring; and RA is hydrogen, C1-C6 alkyl, -C(O)-C1-C6 alkyl, C(O)-C2-C6 alkenyl, or cycloalkyl. In an embodiment, of Formula (C-i), R2 is C1-C6 alkyl; R3 is C1-C6 alkyl; R6 is hydrogen; and R7 is hydrogen. In an embodiment, of Formula (C-i), R2 is methyl; R3 is methyl; R6 is hydrogen; and R7 is hydrogen. In an embodiment, the sesquiterpene lactone is a compound of Formula (B-iii):
Attorney Docket No.: M2199-7017WO iii) or a pharmaceutically acceptable salt thereof, wherein R2 is is hydrogen or C1-C6 alkyl; R6 is hydrogen, C1-C6 alkyl, C1-C6
or - hydrogen or -ORA, or R2 and R7, taken together with the carbon atoms to which they are attached, form a heterocyclyl ring; and RA is hydrogen, C1-C6 alkyl, - C(O)-C1-C6 alkyl, C(O)-C2-C6 alkenyl, or cycloalkyl. In an embodiment, of Formula (B-iii), R2 is C1-C6 alkyl; R3 is C1-C6 alkyl; R6 is hydrogen; and R7 is hydrogen. In an embodiment, of Formula (C-ii), R2 is methyl; R3 is methyl; R6 is hydrogen; and R7 is hydrogen. In an embodiment, of Formula (B-iii), R2 is C1-C6 alkyl; R3 is C1-C6 alkyl; R6 is -ORA; R7 is hydrogen; and RA is hydrogen. In an embodiment, of Formula (C-ii), R2 is methyl; R3 is methyl; R6 is -ORA; R7 is hydrogen; and RA is hydrogen. In an embodiment, the sesquiterpene lactone is a compound shown in Table 2. Table 2: Exemplary sesquiterpene lactones Compound Structure
Attorney Docket No.: M2199-7017WO Onopordopicrin
Attorney Docket No.: M2199-7017WO Elephantoin In an e
, q p p p aceutically acceptable salt thereof. In an embodiment, the sesquiterpene lactone is costunolide or a pharmaceutically acceptable salt thereof. In an embodiment, the sesquiterpene lactone is eupatolide or a pharmaceutically acceptable salt thereof. In an embodiment, the sesquiterpene lactone is onopordopicrin or a pharmaceutically acceptable salt thereof. In an embodiment, the sesquiterpene lactone is deoxyelepantopin or a pharmaceutically acceptable salt thereof. In an embodiment, the sesquiterpene lactone is 9alpha-hydroxyparthenolide or a pharmaceutically acceptable salt thereof. In an embodiment, the sesquiterpene lactone is 11beta,13-dihydroparthenolide or a pharmaceutically acceptable salt thereof. In an embodiment, the sesquiterpene lactone is lipiferolide or a pharmaceutically acceptable salt thereof. In an embodiment, the sesquiterpene lactone is elephantoin or a pharmaceutically acceptable salt thereof. In an embodiment, the sesquiterpene lactone is parthenolide or a pharmaceutically acceptable salt thereof, substantially free of costunolide, eupatolide, onopordopicrin, and deoxyelepantopin. In an embodiment, the sesquiterpene lactone is costunolide or a pharmaceutically acceptable salt thereof, substantially free of parthenolide, eupatolide, onopordopicrin, and deoxyelepantopin. In an embodiment, the sesquiterpene lactone is eupatolide or a pharmaceutically acceptable salt thereof, substantially free of costunolide, parthenolide, onopordopicrin, and deoxyelepantopin. In an embodiment, the sesquiterpene lactone is onopordopicrin or a pharmaceutically acceptable salt thereof, substantially free of costunolide, eupatolide, parthenolide, and deoxyelepantopin. In an embodiment, the sesquiterpene lactone is deoxyelepantopin or a pharmaceutically acceptable salt thereof, substantially free of costunolide, eupatolide, onopordopicrin, and parthenolide. In an embodiment, the sesquiterpene lactone is parthenolide or a pharmaceutically acceptable salt thereof, substantially free of another compound shown in Table 2. In an
Attorney Docket No.: M2199-7017WO embodiment, the sesquiterpene lactone is costunolide or a pharmaceutically acceptable salt thereof, substantially free of another compound shown in Table 2. In an embodiment, the sesquiterpene lactone is eupatolide or a pharmaceutically acceptable salt thereof, substantially free of another compound shown in Table 2. In an embodiment, the sesquiterpene lactone is onopordopicrin or a pharmaceutically acceptable salt thereof, substantially free of c another compound shown in Table 2. In an embodiment, the sesquiterpene lactone is deoxyelepantopin or a pharmaceutically acceptable salt thereof, substantially free of another compound shown in Table 2. In an embodiment, the sesquiterpene lactone or a pharmaceutically acceptable salt thereof is provided as a substantially pure compound, for example, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.9% pure, measured, e.g, by HPLC analysis. In an embodiment, the sesquiterpene lactone is parthenolide or a pharmaceutically acceptable salt thereof, and is provided as a substantially pure compound, for example, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.9% pure, measured, e.g, by HPLC analysis. In an embodiment, the sesquiterpene lactone is provided with less than 10%, 7.5%, 5%, 2.5%, 1%, 0.5%, or 0.1% of another sesquiterpene lactone present. In an embodiment, the sesquiterpene lactone is parthenolide and is provided with less than 10%, 7.5%, 5%, 2.5%, 1%, 0.5%, or 0.1% of another sesquiterpene lactone present. In an embodiment, the sesquiterpene lactone is parthenolide and is provided with less than 10%, 7.5%, 5%, 2.5%, 1%, 0.5%, or 0.1% of costunolide present. In an embodiment, the sesquiterpene lactone is provided with less than 10%, 7.5%, 5%, 2.5%, 1%, 0.5%, or 0.1% of another plant material, such as a plant metabolite or plant lipid. In an embodiment, the sesquiterpene lactone is parthenolide and is provided with less than 10%, 7.5%, 5%, 2.5%, 1%, 0.5%, or 0.1% of another plant material, such as a plant metabolite or plant lipid. A composition useful for the treatment of inflammation or an inflammatory disease or disorder may contain a sesquiterpene lactone (e.g., parthenolide) or a plurality of sesquiterpene lactones. For example, a composition comprising a sesquiterpene lactone may contain only parthenolide, e.g., synthetically prepared or extracted from a natural source, in the absence of another sesquiterpene lactone. In contrast, a composition comprising a sesquiterpene lactone may
Attorney Docket No.: M2199-7017WO also contain a combination of parthenolide and a closely related analog or variant thereof, e.g., a sesquiterpene lactone shown in Table 1, e.g., costunolide. The flavonoids and sesquiterpene lactones provided herein may contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. Further, the flavonoids and sesquiterpene lactones may exist as one of many tautomeric forms. All such isomeric and tautomeric forms of these compounds are expressly included within the scope. Unless otherwise indicated when a compound is named or depicted by a structure without specifying the stereochemistry and has one or more chiral centers or tautomeric structures, it is understood to represent all possible stereoisomers or tautomers of the compound. The compounds provided herewith may also contain linkages (e.g., carbon-carbon bonds, phosphorus-oxygen bonds, or phosphorus-sulfur bonds) or substituents that can restrict bond rotation, e.g., restriction resulting from the presence of a ring or double bond. Inflammatory Diseases and Disorders Described herein are methods for treating inflammation or an inflammatory disease or disorder in a subject, tissue, or cell, e.g., by administration of a sesquiterpene lactone and a flavonoid. In embodiments, the cell is an isolated cell (e.g., a cell in a cell culture or a cell isolated from a tissue or intact organism). In embodiments, the cell is located in a tissue or organ. An inflammatory disease or disorder relates to any disease or disorder that affects the immune system and may result in a modulation of the inflammatory pathway. Exemplary inflammatory diseases and disorders include dermatological conditions (e.g., psoriasis, dermal hypersensitivity, eczema, burns, atopic dermatitis, or abnormal proliferation of hair follicle cells), fibrosis (e.g., kidney or lung fibrosis), allergic rhinitis, respiratory distress syndrome, asthma, bronchitis, tendinitis, bursitis, fever, migraine headaches, gastrointestinal conditions (e.g., inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome, colitis and colorectal cancer), vascular diseases (e.g., atherosclerosis), periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's Disease, rheumatic fever, osteoarthritis, autoimmune diseases (e.g., type I diabetes, myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis), sarcoidosis, nephrotic syndrome, renal failure, Behcet's Syndrome,
Attorney Docket No.: M2199-7017WO polymyositis, gingivitis, hypersensitivity (e.g., delayed type hypersentivity or immediate hypersensitivity), graft and transplant rejections, graft versus host disease (GVHD), conjunctivitis, swelling occurring after injury, myocardial ischemia, and endotoxin shock syndrome. Psoriasis is a chronic skin disorder that afflicts about 2 percent of the population. The disease is associated with the rapid turnover of skin cells (hyperproliferation) accompanied by a loss of differentiation so that silvery white scales form on the surface of the skin. Additionally, the capillaries become tortuous and dilated and an inflammatory reaction occurs, so that the skin reddens. The elevated silvery white scales on a contrasting red background produce the unsightly lesions characteristic of psoriasis. Psoriasis most commonly appears on the scalp, knees, elbows, hands and feet, but can affect any part of the skin. The cause of the disease is unknown, though it is believed to have a genetic component, and it has been suggested to be a T-cell mediated autoimmune skin disorder. In an embodiment, the inflammatory disease or disorder comprises psoriasis. Dermal hypersensitivity is a nonspecific histological reaction pattern that may be seen in multiple clinical conditions. Symptoms may include pruritis, lesions, and in idiopathic cases, urticarial or eczematous papules or plaques. In an embodiment, the inflammatory disease or disorder comprises dermal hypersensitivity. Eczema is a general term for many types of skin inflammation, also known as dermatitis. The most common form of eczema is atopic eczema or dermatitis. Eczema occurs in people of all races and can affect people of any age, although the condition is most common in infants, and about 85% of people have an onset prior to five years of age. Typically, eczema will permanently resolve by age three in only about one-half of affected infants. In others, the condition tends to recur throughout life. People with eczema often have a family history of the condition or a family history of other allergic conditions, such as asthma and/or hay fever. While eczema is not known to be contagious, it is believed to be at least partially inherited. In an embodiment, the inflammatory disease or disorder comprises eczema. Approximately 140 million people suffer burns per year in the United States alone. Of these, 54,000 to 180,000 people are estimated to be hospitalized. A burn is an injury to the skin or other tissue caused by heat, cold, electricity, chemicals, friction, or radiation. Most burns are caused by heat generated by hot liquids (burns), solids, or fire. The skin is composed of three
Attorney Docket No.: M2199-7017WO major tissue layers: epidermis, dermis, and subcutaneous tissue. Burns that affect only the outermost skin are called superficial or first-order burns. They appear red, free of blisters, and pain usually lasts for about three days. When the damage extends to some underlying skin layer, it is called a local thickness or secondary burn. Blisters often occur and are often painful. Healing may take up to eight weeks and scarring may occur. In full thickness or third degree burns, the damage extends to all layers of the skin. Usually without pain and the burned area is stiff. It does not heal itself normally and skin grafting is required. Fourth degree burns also involve damage to deeper tissues such as muscles, tendons or bones. Such burns are usually black and often result in loss of the burn site. In an embodiment, the inflammatory disease or disorder comprises burns. Atopic dermatitis is the most common form of eczema. It is a condition that causes dry, itchy and inflamed skin. It is common in young children but can occur at any age. Atopic dermatitis is a chronic condition that can cause flare ups throughout a patient’s life and is not contagious. People with atopic dermatitis are at risk of developing food allergies, hay fever, and asthma. Symptoms of atopic dermatitis may include dry, cracked skin, itchiness (pruritis), small, raised bumps, thickened skin, darkening of the skin around the eyes, and raw, sensitive skin. In an embodiment, the inflammatory disease or disorder comprises atopic dermatitis. Fibrosis is a process characterized by an excessive accumulation of the extracellular matrix as a response to different types of tissue injuries, which leads to organ dysfunction. The process can be initiated by multiple and different stimuli and pathogenic factors which trigger the cascade of reparation converging in molecular signals responsible of initiating and driving fibrosis. Though fibrosis can play a defensive role, in several circumstances at a certain stage, it can progressively become an uncontrolled irreversible and self-maintained process, named pathological fibrosis. Such fibrosis can occur in any organ in the body, e.g., in the kidney(s) (kidney fibrosis), or in the lung(s) (lung fibrosis). In an embodiment, the inflammatory disease or disorder comprises fibrosis, e.g., kidney fibrosis and lung fibrosis. Allergic rhinitis, also called hay fever, is an allergic reaction that causes sneezing, congestion, itchy nose and sore throat. Pollen, pet dander, mold and insects can lead to hay fever symptoms. Symptoms of hay fever include sneezing, nasal congestion and irritation of the nose, throat, mouth and eyes. In an embodiment, the inflammatory disease or disorder comprises allergic rhinitis.
Attorney Docket No.: M2199-7017WO Respiratory distress syndrome is a disease involving increased pulmonary capillary permeability. The consequent accumulation of protein-rich fluid inside the alveoli is the result of the damage to the capillary endothelium and alveolar epithelium; this causes the release of cytokines, producing diffuse alveolar damage. Common risk factors for ARDS include: pneumonia, sepsis, gastric content aspiration, trauma, pancreatitis, inhalation injury, burns, non- cardiogenic shock, drug overdose, transfusion related acute lung injury (TRALI), and drowning. The characteristic pathological features of ARDS have classically been described by three overlapping phases: an exudative or inflammatory phase, a proliferative phase, and a fibrotic phase. In an embodiment, the inflammatory disease or disorder comprises respiratory distress syndrome. Asthma is a chronic inflammatory disease of the airways characterized by airway hyper responsiveness, acute and chronic bronchoconstriction, airway edema, and mucus plugging. The inflammation component of asthma is thought to involve many cell types, including mast cells, eosinophils, T lymphocytes, neutrophils, and epithelial cells, and their biological products. Patients with asthma most often present with symptoms of wheezing, shortness of breath, cough, and chest tightness. In an embodiment, the inflammatory disease or disorder comprises asthma. Bronchitis is an inflammation of the mucous membrane of the trachea and bronchi caused by bacterial and viral infections or irritations caused by physical and chemical factors. As a rule, this disease is mainly characterized by cough, sputum, discomfort or pain behind the sternum, shortness of breath and the usual cold symptoms that accompany them. In accordance with the duration of bronchitis can be divided into two forms: acute tracheobronchitis and chronic bronchitis. Chronic bronchitis is bronchitis which lasts more than two months and worsens for two consecutive years or lasts three consecutive months for one year, causing inflammation of the mucous membrane and peripheral tissues. Most patients are adults, and the incidence of bronchitis increases in the winter and spring. In an embodiment, the inflammatory disease or disorder comprises bronchitis. Tendinitis is a tendon inflammation referring to the inflammatory changes of the tendon tissue. It often results in degenerative changes of the tissue affected, possibly including calcium deposits at a later time. In general, tendinitis can affect any tendon of the body. Since tendinitis is mainly caused by mechanical stress (sports), tendinitis affects in particular certain body regions, such as e.g., in the region of the shoulder, the tibia, or the foot. Tendinitis can also occur in the
Attorney Docket No.: M2199-7017WO context of inflammatory rheumatoid diseases (in particular Reiter's syndrome, spondylitis ankylosans, and arthritis psoriatica). In an embodiment, the inflammatory disease or disorder comprises tendinitis. Bursitis is an inflammation of a bursa or protecting sac that is located in or near the patients joints. Bursitis can be acute resulting in a sudden, sharp pain following an injury, or it can be chronic as a result of a recurrent inflammation in the same area. Most commonly, bursitis is caused by trauma, infection and crystal deposits. Bursitis typically results from overuse or injury of a joint as a consequence of intensive working or playing, poor conditioning before exercising or sporting, systematic incorrect posture at work or rest, or an abnormal positioned joint as a result of for instance arthritis or bone length differences that stress soft tissue structures in the human or animal body. In an embodiment, the inflammatory disease or disorder comprises bursitis. Fever is a commonly used medical indicator characterized by elevation of body temperature above a normal range. In an embodiment, the inflammatory disease or disorder comprises fever. Migraine comprises a complex, common neurological condition that is characterized by severe, episodic attacks of headache and associated features, which may include nausea, vomiting, sensitivity to light, sound or movement. In some patients, the headache is preceded or accompanied by sensory warning signs or symptoms (i.e., auras). The headache pain may be severe and may also be unilateral in certain patients. Migraine attacks are disruptive to daily life and cost billions of dollars each year in missed work days and impaired performance. Migraine is a highly prevalent disease worldwide with approximately 15% of the European population and 12% of the United States population suffering from migraine attacks. Additionally, migraines have been found to be associated with a number of psychiatric and medical comorbidities such as depression and vascular disorders. In an embodiment, the inflammatory disease or disorder comprises migraine headaches. Inflammatory bowel disease (IBD) is a chronic inflammatory autoimmune condition of the gastrointestinal (GI) tract, which presents clinically as either ulcerative colitis (UC) or Crohn's disease (CD). CD is a chronic transmural inflammatory disease with the potential to affect any part of the entire GI tract, and UC is a mucosal inflammation of the colon. Both conditions are characterized clinically by frequent bowel motions, malnutrition, and dehydration,
Attorney Docket No.: M2199-7017WO with disruption in the activities of daily living. CD is frequently complicated by the development of malabsorption, strictures, and fistulae and may require repeated surgery. UC, less frequently, may be complicated by severe bloody diarrhea and toxic megacolon, also requiring surgery. Both IBD conditions are associated with an increased risk for malignancy of the GI tract. The etiology of IBD is complex, and many aspects of the pathogenesis remain unclear. In an embodiment, the inflammatory disease or disorder comprises inflammatory bowel disease (e.g., Crohn’s disease or ulcerative colitis). Gastritis is a general term for a group of conditions comprising inflammation of the stomach lining. The inflammation of gastritis is most often the result of infection with the same bacterium that causes most stomach ulcers or the regular use of certain pain relievers. Drinking too much alcohol also can contribute to gastritis. Gastritis may occur suddenly (acute gastritis) or appear slowly over time (chronic gastritis). In some cases, gastritis can lead to ulcers and an increased risk of stomach cancer. In an embodiment, the inflammatory disease or disorder comprises gastritis. Irritable bowel syndrome (IBS) is the most common of all gastrointestinal disorders, affecting 11-14% of adults and accounting for more than 50% of all patients with digestive complaints. It is thought that only a minority of people with IBS actually seek medical treatment. Patients with IBS present with disparate symptoms, for example, abdominal pain predominantly related to defecation, alternating diarrhea and constipation, abdominal distention, gas, and excessive mucus in the stool. A number of possible causes for IBS have been proposed, but none has been fully accepted. These hypotheses included a fiber-poor Western diet, intestinal motility malfunction, abnormal pain perception, abnormal psychology or behavior, or psychophysiological response to stress. In an embodiment, the inflammatory disease or disorder comprises IBS. Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, is the development of cancer from the colon or rectum (parts of the large intestine). Signs and symptoms may include blood in the stool, a change in bowel movements, weight loss, and fatigue. Most colorectal cancers are due to old age and lifestyle factors, with only a small number of cases due to underlying genetic disorders. Risk factors include diet, obesity, smoking, and lack of physical activity. Another risk factor is inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis. Some of the inherited genetic disorders that can cause colorectal
Attorney Docket No.: M2199-7017WO cancer include familial adenomatous polyposis and hereditary non-polyposis colon cancer; however, these represent less than 5% of cases. It typically starts as a benign tumor, often in the form of a polyp, which over time becomes cancerous. In an embodiment, the inflammatory disease or disorder comprises colorectal cancer. Atherosclerosis is a chronic disease that causes thickening of the innermost layer (intima) of the aorta or middle artery. This reduces blood flow and can cause ischemia and tissue destruction in organs supplied by affected blood vessels. Atherosclerosis is a major cause of heart disease including myocardial infarction, stroke and surrounding arterial disease. The disease begins with the accumulation of lipoproteins, mainly low density lipoprotein (LDL), in the extracellular matrix of blood vessels. These LDL particles aggregate and promote oxidative modification. Oxidized LDL is toxic and causes vascular damage. Atherosclerosis represents a response to this wound in the form of inflammation and fibrosis. In an embodiment, the inflammatory disease or disorder comprises atherosclerosis. Polyarteritis nodosa (PAN) is a systemic necrotizing inflammation of blood vessels (vasculitis) affecting medium-sized muscular arteries, typically involving the arteries of the kidneys and other internal organs but generally sparing the lungs' circulation. Small aneurysms are strung like the beads of a rosary, therefore making this "rosary sign" an important diagnostic feature of the vasculitis. PAN is sometimes associated with infection by the hepatitis B or hepatitis C virus. The condition may be present in infants. In an embodiment, the inflammatory disease or disorder comprises periarteritis nodosa. Thyroiditis is the inflammation of the thyroid gland. There are many different signs and symptoms for thyroiditis, none of which are exclusively limited to this disease. Many of the signs imitate symptoms of other diseases, so thyroiditis can sometimes be difficult to diagnose. Common hypothyroid symptoms manifest when thyroid cell damage is slow and chronic, and may include fatigue, weight gain, feeling "fuzzy headed", depression, dry skin, and constipation. Other, rarer symptoms include swelling of the legs, vague aches and pains, decreased concentration and so on. If the thyroid cell damage is acute, the thyroid hormone within the gland leaks out into the bloodstream causing symptoms of thyrotoxicosis, which is similar to those of hyperthyroidism. These symptoms include weight loss, irritability, anxiety, insomnia, fast heart rate, and fatigue. Elevated levels of thyroid hormone in the bloodstream cause both conditions, but thyrotoxicosis is the term used with thyroiditis since the thyroid gland is not
Attorney Docket No.: M2199-7017WO overactive, as in the case of hyperthyroidism. In an embodiment, the inflammatory disease or disorder comprises thyroiditis. Aplastic anemia is a severe hematologic condition in which the body fails to make blood cells in sufficient numbers. Aplastic anemia is associated with cancer and various cancer syndromes. Blood cells are produced in the bone marrow by stem cells that reside there. Aplastic anemia causes a deficiency of all blood cell types: red blood cells, white blood cells, and platelets. It occurs most frequently in people in their teens and twenties but is also common among the elderly. It can be caused by heredity, immune disease, or exposure to chemicals, drugs, or radiation. However, in about half of cases, the cause is unknown. In an embodiment, the inflammatory disease or disorder comprises aplastic anemia. Hodgkin’s disease, also known as Hodgkin’s lymphoma (HL) is a type of lymphoma in which cancer originates from a specific type of white blood cell called lymphocytes, where multinucleated Reed–Sternberg cells (RS cells) are present in the patient's lymph nodes. Symptoms may include fever, night sweats, and weight loss. Often, nonpainful enlarged lymph nodes occur in the neck, under the arm, or in the groin. About half of cases of Hodgkin lymphoma are due to Epstein–Barr virus (EBV) and these are generally the classic form. Other risk factors include a family history of the condition and having HIV/AIDS. In an embodiment, the inflammatory disease or disorder comprises Hodgkin’s disease. Rheumatic fever (RF) is an inflammatory disease that can involve the heart, joints, skin, and brain. The disease typically develops two to four weeks after a streptococcal throat infection. Signs and symptoms include fever, multiple painful joints, involuntary muscle movements, and occasionally a characteristic non-itchy rash known as erythema marginatum. The heart is involved in about half of the cases. Damage to the heart valves, known as rheumatic heart disease (RHD), usually occurs after repeated attacks but can sometimes occur after one. The damaged valves may result in heart failure, atrial fibrillation and infection of the valves. In an embodiment, the inflammatory disease or disorder comprises rheumatic fever. Osteoarthritis (OA) is a type of degenerative joint disease that results from breakdown of joint cartilage and underlying bone which affects 1 in 7 adults in the United States. It is believed to be the fourth leading cause of disability in the world. The most common symptoms are joint pain and stiffness. Other symptoms may include joint swelling, decreased range of motion, and, when the back is affected, weakness or numbness of the arms and legs. The most
Attorney Docket No.: M2199-7017WO commonly involved joints are the two near the ends of the fingers and the joint at the base of the thumbs, the knee and hip joints, and the joints of the neck and lower back. Unlike some other types of arthritis, only the joints, not internal organs, are affected. In an embodiment, the inflammatory disease or disorder comprises osteoarthritis. Type 1 diabetes (T1D), formerly known as juvenile diabetes, is an autoimmune disease that originates when cells that make insulin (beta cells) are destroyed by the immune system, resulting in high blood sugar levels. The common symptoms of this elevated blood sugar are frequent urination, increased thirst, increased hunger, weight loss, and other serious complications. Additional symptoms may include blurry vision, tiredness, and slow wound healing. Symptoms typically develop over a short period of time, often a matter of weeks. The underlying mechanism involves an autoimmune destruction of the insulin-producing beta cells in the pancreas. In an embodiment, the inflammatory disease or disorder comprises Type I diabetes. Myasthenia gravis (MG) is a long-term autoimmune neuromuscular junction disease that leads to varying degrees of skeletal muscle weakness. The most commonly affected muscles are those of the eyes, face, and swallowing. It can result in double vision, drooping eyelids, trouble talking, and trouble walking. Onset can be sudden. Those affected often have a large thymus or develop a thymoma. In an embodiment, the inflammatory disease or disorder comprises myasthenia gravis. Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. It typically results in warm, swollen, and painful joints. Pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. The disease may also affect other parts of the body, including skin, eyes, lungs, heart, nerves and blood. This may result in a low red blood cell count, inflammation around the lungs, and inflammation around the heart. Fever and low energy may also be present. In an embodiment, the inflammatory disease or disorder comprises rheumatoid arthritis. Lupus, technically known as systemic lupus erythematosus (SLE), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. Symptoms vary among people and may be mild to severe. Common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, feeling tired, and a red rash which is most commonly on the face. Often there are periods
Attorney Docket No.: M2199-7017WO of illness, called flares, and periods of remission during which there are few symptoms. The cause of SLE is not clear. It is thought to involve a combination of genetics and environmental factors. In an embodiment, the inflammatory disease or disorder comprises systemic lupus erythematosus. Multiple sclerosis (MS) is the most common demyelinating disease, in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to transmit signals, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. Specific symptoms can include double vision, visual loss, muscle weakness, and trouble with sensation or coordination. MS takes several forms, with new symptoms either occurring in isolated attacks (relapsing forms) or building up over time (progressive forms). While the cause is unclear, the underlying mechanism is thought to be either destruction by the immune system or failure of the myelin-producing cells. In an embodiment, the inflammatory disease or disorder comprises multiple sclerosis. Sarcoidosis is a disease involving abnormal collections of inflammatory cells that form lumps known as granulomata. The disease usually begins in the lungs, skin, or lymph nodes. Less commonly affected are the eyes, liver, heart, and brain, though any organ can be affected. The signs and symptoms depend on the organ involved. Often, no, or only mild, symptoms are seen. When it affects the lungs, wheezing, coughing, shortness of breath, or chest pain may occur. In an embodiment, the inflammatory disease or disorder comprises sarcoidosis. Nephrotic syndrome is a collection of symptoms due to kidney damage. This includes protein in the urine, low blood albumin levels, high blood lipids, and significant swelling. Other symptoms may include weight gain, feeling tired, and foamy urine. Complications may include blood clots, infections, and high blood pressure. Causes include a number of kidney diseases such as focal segmental glomerulosclerosis, membranous nephropathy, and minimal change disease. It may also occur as a complication of diabetes or lupus. In an embodiment, the inflammatory disease or disorder comprises nephrotic syndrome. Kidney failure, also known as end-stage kidney disease, is a medical condition in which the kidneys can no longer adequately filter waste products from the blood, functioning at less than 15% of normal levels. Kidney failure is classified as either acute kidney failure, which
Attorney Docket No.: M2199-7017WO develops rapidly and may resolve; and chronic kidney failure, which develops slowly and can often be irreversible. Symptoms may include leg swelling, feeling tired, vomiting, loss of appetite, and confusion. In an embodiment, the inflammatory disease or disorder comprises renal failure. Behçet's disease (BD) is a type of inflammatory disorder which affects multiple parts of the body. The most common symptoms include painful sores on the mucous membranes of the mouth and other parts of the body, inflammation of parts of the eye, and arthritis. The sores can last from a few days, up to a week or more. Less commonly there may be inflammation of the brain or spinal cord, blood clots, aneurysms, or blindness. Often, the symptoms come and go. In an embodiment, the inflammatory disease or disorder comprises Behcet’s disease. Polymyositis is a type of chronic inflammation of the muscles (inflammatory myopathy) related to dermatomyositis and inclusion body myositis. The inflammation of polymyositis is mainly found in the endomysial layer of skeletal muscle, whereas dermatomyositis is characterized primarily by inflammation of the perimysial layer of skeletal muscles. In an embodiment, the inflammatory disease or disorder comprises polymyositis. Gingivitis is a non-destructive disease that causes inflammation of the gums. The most common form of gingivitis, and the most common form of periodontal disease overall, is in response to bacterial biofilms (also called plaque) that is attached to tooth surfaces, termed plaque-induced gingivitis. Most forms of gingivitis are plaque-induced. In an embodiment, the inflammatory disease or disorder comprises gingivitis. Graft-versus-host disease (GVHD) is a syndrome, characterized by inflammation in different organs. GVHD is commonly associated with bone marrow transplants and stem cell transplants. White blood cells of the donor's immune system which remain within the donated tissue (the graft) recognize the recipient (the host) as foreign (non-self). The white blood cells present within the transplanted tissue then attack the recipient's body's cells, which leads to GVHD. This should not be confused with a transplant rejection, which occurs when the immune system of the transplant recipient rejects the transplanted tissue; GvHD occurs when the donor's immune system's white blood cells reject the recipient. In an embodiment, the inflammatory disease or disorder comprises GVHD. Conjunctivitis, also known as pink eye, is inflammation of the outermost layer of the white part of the eye and the inner surface of the eyelid. It makes the eye appear pink or
Attorney Docket No.: M2199-7017WO reddish. Pain, burning, scratchiness, or itchiness may occur. The affected eye may have increased tears or be "stuck shut" in the morning. Swelling of the white part of the eye may also occur. Itching is more common in cases due to allergies. Conjunctivitis can affect one or both eyes. In an embodiment, the inflammatory disease or disorder comprises conjunctivitis. Myocardial ischemia involves the reduction of blood flow to the heart muscle due to build-up of atherosclerotic plaque in the arteries of the heart. It is the most common of the cardiovascular diseases. A common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck, or jaw. Occasionally it may feel like heartburn. Usually symptoms occur with exercise or emotional stress, last less than a few minutes, and improve with rest. Shortness of breath may also occur and sometimes no symptoms are present. In many cases, the first sign is a heart attack. In an embodiment, the inflammatory disease or disorder comprises myocardial ischemia. Endotoxin shock syndrome, also known as toxic shock syndrome (TSS), is an uncommon but life-threatening disease which is caused by the poisonous endotoxin (TSS-1) produced by Staphylococcus aureus bacteria. Infection is caused due to the entrance of bacteria in the body through skin opening such as cuts or wounds or due to poorly conducted skin surgery, skin-burn, and skin infection. Prevalence of S.aureus colonization and antibodies by age, geographical area there was no significant difference found in the rate of toxigenicity and colonization while the population study prevalence was found to be 26%. Symptoms of TSS include skin rashes, headache, fever, vomiting, diarrhea, including neurological disturbance and the central nervous system disturbance along with organ failure. In an embodiment, the inflammatory disease or disorder comprises endotoxin shock syndrome. In an embodiment, the inflammatory disease or disorder is a dermatological condition. For example, the dermatological disease or disorder may be atopic dermatitis, psoriasis, eczema, or dermal hypersensitivity. In an embodiment, the dermatological condition is atopic dermatitis. In an embodiment, the dermatological condition is psoriasis. In an embodiment, the dermatological condition is eczema. In an embodiment, the dermatological condition is dermal hypersensitivity. Combination Therapies
Attorney Docket No.: M2199-7017WO Described herein are combination therapies comprising a flavonoid and a sesquiterpene lactone useful for the treatment of inflammation or an inflammatory disease or disorder. The combination therapy may be administered as a single formulation or as separate formulations. In an embodiment, the flavonoid and sesquiterpene lactone are administered as a single pharmaceutical composition. In an embodiment, the flavonoid and sesquiterpene lactone are administered as separate pharmaceutical compositions. In the case of separate formulations, the flavonoid and sesquiterpene lactone may be administered concomitantly or sequentially. In an embodiment, the flavonoid and sesquiterpene lactone are administered concomitantly. In an embodiment, the flavonoid and sesquiterpene lactone are administered sequentially. For example, the flavonoid may be administered prior to the sesquiterpene lactone or subsequent to the sesquiterpene lactone. In some embodiments, the administration of the flavonoid and sesquiterpene lactone has a synergistic or additive effect. For example, the administration of the flavonoid and sesquiterpene lactone may have an additive effect, in which the therapeutic effect of the flavonoid and sesquiterpene lactone is the total sum of the effects of each of the components individually. In contrast, the administration of the flavonoid and sesquiterpene lactone may have a synergistic effect, in which the therapeutic effect of the flavonoid and sesquiterpene lactone is greater than the sum of the individual components. The synergistic effect of the combination of the flavonoid and sesquiterpene lactone may be 0.1%, 0.25%.0.5%.0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%.90%.95%, or more than the total sum of the effects of the flavonoid and sesquiterpene lactone administered individually. In an embodiment, the synergistic effect of the combination of flavonoid and sesquiterpene lactone is greater than between 5% and 75% of the total sum of the effects of the flavonoid and sesquiterpene lactone administered individually. In an embodiment, the synergistic effect of the combination of the flavonoid and sesquiterpene lactone is greater than 10% of the total sum of the effects of the flavonoid and sesquiterpene lactone administered individually. In an embodiment, the synergistic effect of the combination of the flavonoid and sesquiterpene lactone is greater than 25% of the total sum of the effects of the flavonoid and sesquiterpene lactone administered individually. In an embodiment, the synergistic effect of the combination of the flavonoid and sesquiterpene lactone is greater than 50% of the total sum of the effects of the flavonoid and sesquiterpene lactone
Attorney Docket No.: M2199-7017WO administered individually. In an embodiment, the synergistic effect of the combination of the flavonoid and sesquiterpene lactone is greater than 75% of the total sum of the effects of flavonoid and sesquiterpene lactone administered individually. The synergistic effect of the combination of the flavonoid and sesquiterpene lactone may be 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 40-fold, 50-fold, 75-fold, 100-fold, 200-fold, 500-fold greater or more than the total sum of the effects of the flavonoid and sesquiterpene lactone administered individually. In an embodiment, the synergistic effect of the combination of the flavonoid and sesquiterpene lactone is greater than between 2-fold and 100-fold of the total sum of the effects of the flavonoid and sesquiterpene lactone administered individually. In an embodiment, the synergistic effect of the combination of the flavonoid and sesquiterpene lactone is greater than between 5- fold and 50-fold of the total sum of the effects of the flavonoid and sesquiterpene lactone administered individually. In one aspect, the amount of the flavonoid and the amount of the sesquiterpene lactone are selected such that the molar concentration of the flavonoid is greater than the molar concentration of the sesquiterpene lactone. For example, the molar concentration of the flavonoid is greater than 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15- fold, 20-fold, 25-fold, 30-fold, 40-fold, 50-fold, 75-fold, 100-fold, 200-fold, or 500-fold greater than the molar concentration of the sesquiterpene lactone. In an embodiment, the molar concentration of the flavonoid is greater than 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7- fold, 8-fold, 9-fold, or 10-fold greater than the molar concentration of the sesquiterpene lactone. In an embodiment, the molar concentration of the flavonoid is between 2-fold and 20-fold greater than the molar concentration of the sesquiterpene lactone. In an embodiment, the molar concentration of the flavonoid is between 5-fold and 10-fold greater than the molar concentration of the sesquiterpene lactone. In an embodiment, the molar concentration of the flavonoid is about 5-fold greater than the molar concentration of the sesquiterpene lactone. In an embodiment, the molar concentration of the flavonoid is about 10-fold greater than the molar concentration of the sesquiterpene lactone. In an embodiment, the molar concentration of the flavonoid is about 15- fold greater than the molar concentration of the sesquiterpene lactone. In another aspect, the combination of the flavonoid with a sesquiterpene lactone results in reducing inflammation (e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a)
Attorney Docket No.: M2199-7017WO in a subject or cell. For example, administration of a combination of the flavonoid with a sesquiterpene lactone may result reducing inflammation (e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a) in a subject or cell, compared with the inflammation (e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a) that results when the sesquiterpene lactone is administered to the subject or cell individually. In an embodiment, the inflammation (e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a) in a subject or cell is reduced upon administration of the sesquiterpene lactone in combination with a flavonoid, e.g., by about 0.1%, 0.25%.0.5%.0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%.90%.95%, or more compared with the inflammation (e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a) that results when a sesquiterpene lactone is administered individually. In another aspect, the combination of the flavonoid with a sesquiterpene lactone results in reducing inflammation (e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a) in a subject or cell. For example, administration of a combination of the flavonoid with a sesquiterpene lactone may result in reducing the inflammation (e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a) in a subject or cell, compared with the inflammation (e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a) that results when the flavonoid is administered to the subject or cell individually. In an embodiment, the inflammation (e.g., the level of an inflammatory cytokine, e.g., IL-6, IL-1b, and TNF-a) in a subject or cell is reduced upon administration of a sesquiterpene lactone in combination with a flavonoid, e.g., by about 0.1%, 0.25%.0.5%.0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%.90%.95%, or more compared with the inflammation (e.g., the level of an inflammatory cytokine) that results when the flavonoid is administered individually. In another aspect, the combination of the flavonoid with a sesquiterpene lactone results in increasing the level of an anti-inflammatory cytokine (e.g., IL-4 and IL-10) in a subject or cell. For example, administration of a combination of the flavonoid with a sesquiterpene lactone may result increasing the level of an anti-inflammatory cytokine (e.g., IL-4 and IL-10) in a subject or cell, compared with the level of an anti-inflammatory cytokine (e.g., IL-4 and IL-10) that results when the sesquiterpene lactone is administered to the subject or cell individually. In an embodiment, the level of an anti-inflammatory cytokine (e.g., IL-4 and IL-10) in a subject or cell
Attorney Docket No.: M2199-7017WO is increased upon administration of the sesquiterpene lactone in combination with a flavonoid, e.g., by about 0.1%, 0.25%.0.5%.0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%.90%.95%, or more compared with the level of an anti-inflammatory cytokine (e.g., IL-4 and IL-10) that results when a sesquiterpene lactone is administered individually. In another aspect, the combination of the flavonoid with a sesquiterpene lactone results in increasing the level of an anti-inflammatory cytokine (e.g., IL-4 and IL-10) in a subject or cell. For example, administration of a combination of the flavonoid with a sesquiterpene lactone may result in increasing the level of an anti-inflammatory cytokine (e.g., IL-4 and IL-10) in a subject or cell, compared with level of an anti-inflammatory cytokine that results when the flavonoid is administered to the subject or cell individually. In an embodiment, the level of an anti- inflammatory cytokine (e.g., IL-4 and IL-10) in a subject or cell is increased upon administration of a sesquiterpene lactone in combination with a flavonoid, e.g., by about 0.1%, 0.25%.0.5%. 0.75%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%.90%.95%, or more compared with the level of an inflammatory cytokine hat results when the flavonoid is administered individually. In an embodiment, the flavonoid is administered at a dosage to provide a concentration of between 0.1 µM and 500 µM in a subject or cell. In an embodiment, the flavonoid is administered at a dosage to provide a concentration of between 0.5 µM and 100 µM in a subject or cell. In an embodiment, the flavonoid is administered at a dosage to provide a concentration of between 1 µM and 100 µM in a subject or cell. In an embodiment, the flavonoid is administered at a dosage to provide a concentration of between 1 µM and 50 µM in a subject or cell. In an embodiment, the flavonoid is administered at a dosage to provide a concentration of between 1 µM and 25 µM in a subject or cell. In an embodiment, the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.01 µM and 50 µM in a subject or cell. In an embodiment, the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.1 µM and 25 µM in a subject or cell. In an embodiment, the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.1 µM and 10 µM in a subject or cell. In an embodiment, the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.1 µM and 5 µM in a subject or cell. In an embodiment, the
Attorney Docket No.: M2199-7017WO sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.1 µM and 2.5 µM in a subject or cell. In an embodiment, the flavonoid is administered at a dosage to provide a concentration of between 0.1 µM and 500 µM and the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.01 µM and 50 µM in a subject or cell. In an embodiment, the flavonoid is administered at a dosage to provide a concentration of to provide a concentration of between 1 µM and 100 µM and the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.1 µM and 25 µM in a subject or cell. In an embodiment, the flavonoid is administered at a dosage to provide a concentration of to provide a concentration of between 1 µM and 25 µM and the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.1 µM and 2.5 µM in a subject or cell. Pharmaceutical Compositions The present disclosure features methods for treating a subject having inflammation or an inflammatory disease or disorder, the methods comprising administering a flavonoid, a sesquiterpene lactone, or a combination thereof. While it is possible for a flavonoid (e.g., a compound of Table 1) or a sesquiterpene lactone (e.g., a compound of Table 2) to be administered alone, it is preferable to administer said compound as a pharmaceutical composition or formulation, where the compounds are combined with one or more pharmaceutically acceptable diluents, excipients or carriers. The compounds according to the disclosure may be formulated for administration in any convenient way for use in human or veterinary medicine. In certain embodiments, the compounds included in the pharmaceutical preparation may be active itself, or may be a prodrug, e.g., capable of being converted to an active compound in a physiological setting. Regardless of the route of administration selected, the compounds of the present disclosure, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present disclosure, are formulated into a pharmaceutically acceptable dosage form such as described below or by other conventional methods known to those of skill in the art. The amount and concentration of compounds of the present disclosure, e.g., a flavonoid (e.g., a compound of Table 1) or a sesquiterpene lactone (e.g., a compound of Table 2) in the pharmaceutical compositions, as well as the quantity of the pharmaceutical composition
Attorney Docket No.: M2199-7017WO administered to a subject, can be selected based on clinically relevant factors, such as medically relevant characteristics of the subject (e.g., age, weight, gender, other medical conditions, and the like), the solubility of compounds in the pharmaceutical compositions, the potency and activity of the compounds, and the manner of administration of the pharmaceutical compositions. For further information on Routes of Administration and Dosage Regimes the reader is referred to Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990. Thus, another aspect of the present disclosure provides pharmaceutically acceptable compositions comprising a therapeutically effective amount or prophylactically effective amount of a flavonoid (e.g., a compound of Table 1) or a sesquiterpene lactone (e.g., a compound of Table 2), formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents. As described in detail below, the pharmaceutical compositions of the present disclosure may be specially formulated for administration in solid or liquid form, including those adapted for oral or parenteral administration, for example, by oral dosage, or by subcutaneous, intramuscular or intravenous injection as, for example, a sterile solution or suspension. However, in certain embodiments the subject compounds may be simply dissolved or suspended in sterile water. In certain embodiments, the pharmaceutical preparation is non-pyrogenic, i.e., does not elevate the body temperature of a patient. The phrases "systemic administration," "administered systemically," "peripheral administration" and "administered peripherally" as used herein mean the administration of the compound other than directly into the central nervous system, such that it enters the patient’s system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration. The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. The phrase "pharmaceutically acceptable carrier" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, stabilizing agent, excipient, solvent or encapsulating material, involved in carrying or
Attorney Docket No.: M2199-7017WO transporting the subject antagonists from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) ascorbic acid; (17) pyrogen-free water; (18) isotonic saline; (19) Ringer’s solution; (20) ethyl alcohol; (21) phosphate buffer solutions; (22) cyclodextrins such as Captisol®; and (23) other non-toxic compatible substances such as antioxidants and antimicrobial agents employed in pharmaceutical formulations. As set out above, certain embodiments of the compounds described herein may contain a basic functional group, such as an amine, and are thus capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable acids. The term "pharmaceutically acceptable salts" in this respect, refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the present disclosure. These salts can be prepared in situ during the final isolation and purification of the compounds of the disclosure, or by separately reacting a purified compound of the disclosure in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like (see, for example, Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci.66:1-19). In other cases, the compounds of the present disclosure may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases. The term "pharmaceutically acceptable salts" in these instances refers to the relatively non-toxic, inorganic and organic base addition salts of the
Attorney Docket No.: M2199-7017WO compound of the present disclosure (e.g. of a flavonoid (e.g., a compound of Table 1) or a sesquiterpene lactone (e.g., a compound of Table 2)). These salts can likewise be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary or tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like. Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like (see, for example, Berge et al., supra). Wetting agents, emulsifiers, and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions. Examples of pharmaceutically acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha- tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like. The pharmaceutically acceptable carriers, as well as wetting agents, emulsifiers, lubricants, coloring agents, release agents, coating agents, sweetening, flavoring agents, perfuming agents, preservatives, antioxidants, and other additional components may be present in an amount between about 0.001% and 99% of the composition described herein. For example, said pharmaceutically acceptable carriers, as well as wetting agents, emulsifiers, lubricants, coloring agents, release agents, coating agents, sweetening, flavoring agents, perfuming agents, preservatives, antioxidants, and other additional components may be present from about 0.005%, about 0.01%, about 0.05%, about 0.1%, about 0.25%, about 0.5%, about 0.75%, about 1%, about 1.5%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 85%, about 90%, about 95%, or about 99% of the composition described herein.
Attorney Docket No.: M2199-7017WO Pharmaceutical compositions of the present disclosure may be in a form suitable for oral administration, e.g., a liquid or solid oral dosage form. In some embodiments, the liquid dosage form comprises a suspension, a solution, a linctus, an emulsion, a drink, an elixir, or a syrup. In some embodiments, the solid dosage form comprises a capsule, tablet, powder, dragée, or powder. The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. Pharmaceutical compositions may comprise, in addition to of a flavonoid (e.g., a compound of Table 1) or a sesquiterpene lactone (e.g., a compound of Table 2), a pharmaceutically acceptable carrier, and may optionally further comprise one or more pharmaceutically acceptable excipients, such as, for example, stabilizers (e.g., a binder, e.g., polymer, e.g., a precipitation inhibitor, diluents, binders, and lubricants. In some embodiments, the composition described herein comprises a liquid dosage form for oral administration, e.g., a solution or suspension. In other embodiments, the composition described herein comprises a solid dosage form for oral administration capable of being directly compressed into a tablet. In addition, said tablet may include other medicinal or pharmaceutical agents, carriers, and or adjuvants. Exemplary pharmaceutical compositions include compressed tablets (e.g., directly compressed tablets), e.g., comprising one or more of a flavonoid (e.g., a compound of Table 1) or a sesquiterpene lactone (e.g., a compound of Table 2) or a pharmaceutically acceptable salt thereof. Formulations of the present disclosure include those suitable for parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about 99 percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent. Pharmaceutical compositions of this disclosure suitable for parenteral administration comprise compounds of the disclosure in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable
Attorney Docket No.: M2199-7017WO solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents. In some embodiments, a compound of the present disclosure, such as a flavonoid (e.g., a compound of Table 1), is provided as a composition in combination with a sesquiterpene lactone (e.g., a compound of Table 2). For example, a flavonoid (e.g., a compound of Table 1) may be prepared as a fixed dose composition in combination with or the sesquiterpene lactone (e.g., a compound of Table 2). The fixed dose composition may be formulated for oral administration, e.g., as a solid dosage form or a liquid dosage form. In some embodiments, the liquid dosage form comprises a suspension, a solution, a linctus, an emulsion, a drink, an elixir, or a syrup. In some embodiments, the solid dosage form comprises a capsule, tablet, dragée, or powder. The combination therapy described herein may involve formulation of the component agents for different routes of administration or for the same route of administration. For example, both the flavonoid and sesquiterpene lactone may be formulated for oral administration. In another embodiment, the flavonoid is formulated for oral administration and the sesquiterpene lactone is formulated for parenteral administration. In another embodiment, the flavonoid is formulated for parenteral administration and the sesquiterpene lactone is formulated for oral administration. In an embodiment, the flavonoid and sesquiterpene lactone are formulated as a fixed dose combination (e.g., as a liquid dosage form or solid dosage form, e.g., a capsule or tablet). In some embodiments, the flavonoid and sesquiterpene lactone are formulated as a fixed dose combination (e.g., as a liquid dosage form or solid dosage form, e.g., a capsule or tablet) for oral administration. Examples of suitable aqueous and nonaqueous carriers that may be employed in the pharmaceutical compositions of the disclosure include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben,
Attorney Docket No.: M2199-7017WO chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin. In some cases, in order to prolong the effect of a compound of the present disclosure (e.g., a flavonoid and sesquiterpene lactone , it may be desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered form of the compound of the present disclosure is accomplished by dissolving or suspending compound in an oil vehicle. In some embodiments, it may be advantageous to administer flavonoid or sesquiterpene lactone of the present disclosure in a sustained fashion. It will be appreciated that any formulation that provides a sustained absorption profile may be used. In certain embodiments, sustained absorption may be achieved by combining a compound of the present disclosure with other pharmaceutically acceptable ingredients, diluents, or carriers that slow its release properties into systemic circulation. Routes of Administration The flavonoids and sesquiterpene lactones described herein, as well as other agents and related compositions thereof used in the methods described herein may be administered to a subject in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art. Exemplary routes of administration of the compositions used in the methods described herein include topical, enteral, or parenteral applications. Topical applications include but are not limited to epicutaneous, inhalation, enema, eye drops, ear drops, and applications through mucous membranes in the body. Enteral applications include oral administration, rectal administration, vaginal administration, and gastric feeding tubes. Parenteral administration includes intravenous, intraarterial, intracapsular, intraorbital, intracardiac, intradermal, transtracheal, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, intrastemal, intraperitoneal, subcutaneous, intramuscular, transepithelial,
Attorney Docket No.: M2199-7017WO nasal, intrapulmonary, intrathecal, rectal, and topical modes of administration. Parenteral administration may be by continuous infusion over a selected period of time. In certain embodiments of the disclosure, the compositions described herein comprising a flavonoid and sesquiterpene lactone are administered orally. In other embodiments of the disclosure, the compositions described herein comprising a flavonoid and sesquiterpene lactone are administered systemically. In other embodiments of the disclosure, the compositions described herein comprising a flavonoid and sesquiterpene lactone are administered topically. In certain embodiments of the disclosure, the compositions described herein comprising a flavonoid are administered orally. In certain embodiments of the disclosure, the compositions described herein comprising a sesquiterpene lactone are administered orally. In other embodiments of the disclosure, the compositions described herein comprising a flavonoid are administered systemically. In other embodiments of the disclosure, the compositions described herein comprising a sesquiterpene lactone are administered systemically. In certain embodiments of the disclosure, the compositions described herein comprising a flavonoid are administered topically. In certain embodiments of the disclosure, the compositions described herein comprising a sesquiterpene lactone are administered topically. In other embodiments of the disclosure, the compositions described herein comprising a flavonoid are administered intravenously. In other embodiments of the disclosure, the compositions described herein comprising a sesquiterpene lactone are administered intravenously. In an embodiment, the compositions described herein comprising quercetin is administered orally in combination with parthenolide. In an embodiment, the compositions described herein comprising quercetin is administered orally prior to or after oral administration of parthenolide. In other embodiments of the disclosure, the compositions described herein comprising quercetin is administered topically (e.g., dermally). In an embodiment, the compositions described herein comprising quercetin is administered topically in combination with parthenolide. In an embodiment, the compositions described herein comprising quercetin is administered systemically prior to or after administration of parthenolide. For intravenous, intraperitoneal, or intrathecal delivery or direct injection, the composition must be sterile and fluid to the extent that the composition is deliverable by syringe. In addition to water, the carrier can be an isotonic buffered saline solution, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable
Attorney Docket No.: M2199-7017WO mixtures thereof. Proper fluidity can be maintained, for example, by use of coating such as lecithin, by maintenance of required particle size in the case of dispersion and by use of surfactants. In many cases, it is preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol or sorbitol, and sodium chloride in the composition. Long-term absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate or gelatin. The choice of the route of administration will depend on whether a local or systemic effect is to be achieved. For example, for local effects, the composition can be formulated for topical administration and applied directly where its action is desired. For systemic, long-term effects, the composition can be formulated for enteral administration and given via the digestive tract. For systemic, immediate and/or short-term effects, the composition can be formulated for parenteral administration and given by routes other than through the digestive tract. Dosages The compositions of the flavonoids and sesquiterpene lactones as described herein may be formulated into acceptable dosage forms by conventional methods known to those of skill in the art. Actual dosage levels of the active ingredients in the compositions of the present disclosure (e.g., a flavonoid or a sesquiterpene lactone, e.g., quercetin or parthenolide) may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular subject, composition, and mode of administration, without being toxic to the subject. The selected dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present disclosure employed, the route of administration, the time of administration, the rate of absorption of the particular agent being employed, the duration of the treatment, other drugs, substances, and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the subject being treated, and like factors well known in the medical arts. A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the composition required. For example, the physician or veterinarian can start doses of the flavonoids and/or sesquiterpene lactone s of the disclosure employed in the composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired
Attorney Docket No.: M2199-7017WO effect is achieved. In general, a suitable daily dose of a composition of the present disclosure will be that amount of the substance which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described herein. Preferably, the effective daily dose of a therapeutic composition may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. Preferred therapeutic dosage levels are between about 0.1 mg/kg to about 1000 mg/kg (e.g., about 0.2 mg/kg, 0.5 mg/kg, 1.0 mg/kg, 1.5 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 60 mg/kg, 70 mg/kg, 80 mg/kg, 90 mg/kg, 100 mg/kg, 125 mg/kg, 150 mg/kg, 175 mg/kg, 200 mg/kg, 250 mg/kg, 300 mg/kg, 350 mg/kg, 400 mg/kg, 450 mg/kg, 500 mg/kg, 600 mg/kg, 700 mg/kg, 800 mg/kg, 900 mg/kg, or 1000 mg/kg) of the composition per day administered (e.g., orally or via injection) to a subject afflicted with a disease or disorder described herein (e.g., a inflammation or an inflammatory disease or disorder). Preferred prophylactic dosage levels are between about 0.1 mg/kg to about 1000 mg/kg (e.g., about 0.2 mg/kg, 0.5 mg/kg, 1.0 mg/kg, 1.5 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 60 mg/kg, 70 mg/kg, 80 mg/kg, 90 mg/kg, 100 mg/kg, 125 mg/kg, 150 mg/kg, 175 mg/kg, 200 mg/kg, 250 mg/kg, 300 mg/kg, 350 mg/kg, 400 mg/kg, 450 mg/kg, 500 mg/kg, 600 mg/kg, 700 mg/kg, 800 mg/kg, 900 mg/kg, or 1000 mg/kg) of the composition per day administered (e.g., orally, topically, or systemically) to a subject. The dose may also be titrated (e.g., the dose may be escalated gradually until signs of toxicity appear, such as headache, diarrhea, or nausea). The frequency of treatment may also vary. The subject can be treated one or more times per day (e.g., once, twice, three, four or more times) or every so-many hours (e.g., about every 2, 4, 6, 8, 12, or 24 hours). The flavonoid and/or sesquiterpene lactone concentration can be administered 1 or 2 times per 24 hours. The time course of treatment may be of varying duration, e.g., for two, three, four, five, six, seven, eight, nine, ten, or more days, two weeks, 1 month, 2 months, 4 months, 6 months, 8 months, 10 months, or more than one year. For example, the treatment can be twice a day for three days, twice a day for seven days, twice a day for ten days. Treatment cycles can be repeated at intervals, for example weekly, bimonthly or
Attorney Docket No.: M2199-7017WO monthly, which are separated by periods in which no treatment is given. The treatment can be a single treatment or can last as long as the life span of the subject (e.g., many years). In some embodiments, the dosage of a flavonoid (e.g., a compound of Table 1) is between about 5 mg/kg to about 100 mg/kg (e.g., about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 30 mg/kg, about 40 mg/kg, about 50 mg/kg, about 60 mg/kg, about 70 mg/kg, about 80 mg/kg, about 90 mg/kg, or about 100 mg/kg). In some embodiments, the dosage of a flavonoid (e.g., a compound of Table 1) between about 10 mg/kg to about 50 mg/kg (e.g., about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, or about 50 mg/kg). In some embodiments, the dosage of a flavonoid (e.g., a compound of Table 1) is about 0.1 mg to about 5 mg (e.g., about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, or about 5 mg). In some embodiments, the dosage of a flavonoid (e.g., a compound of Table 1) is between about 0.01 mg/kg to about 10 mg/kg (e.g., about 0.01 mg/kg, about 0.025 mg/kg, about 0.05 mg/kg, about 0.1 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, or about 10 mg/kg). In some embodiments, the dosage of a flavonoid (e.g., a compound of Table 1) is between about 0.1 mg/kg to about 5 mg/kg (e.g., about 0.1 mg/kg, about 0.2 mg/kg, about 0.3 mg/kg, about 0.4 mg/kg, about 0.5 mg/kg, about 0.6 mg/kg, about 0.7 mg/kg, about 0.8 mg/kg, about 0.9 mg/kg, about 1 mg/kg, about 1.25 mg/kg, about 1.5 mg/kg, about 1.75 mg/kg, about 2 mg/kg, about 2.5 mg/kg, about 3 mg/kg, about 3.5 mg/kg, about 4 mg/kg, about 4.5 mg/kg, or about 5 mg/kg). In some embodiments, a course of a flavonoid (e.g., a compound of Table 1) is between about 1 day to about 24 weeks. In some embodiments, the course of a flavonoid (e.g., a compound of Table 1) is administered at least weekly (e.g., once a week, twice a week, three times a week, four times a week, five times a week, six times a week, 7 times a week) throughout a course of treatment. In some embodiments, the course of a flavonoid (e.g., a compound of Table 1) is administered daily throughout a course of treatment. In some embodiments, the dosage of a sesquiterpene lactone (e.g., a compound of Table 2) is between about 5 mg/kg to about 100 mg/kg (e.g., about 5 mg/kg, about 10 mg/kg, about 15
Attorney Docket No.: M2199-7017WO mg/kg, about 20 mg/kg, about 30 mg/kg, about 40 mg/kg, about 50 mg/kg, about 60 mg/kg, about 70 mg/kg, about 80 mg/kg, about 90 mg/kg, or about 100 mg/kg). In some embodiments, the dosage of a sesquiterpene lactone (e.g., a compound of Table 2) is between about 10 mg/kg to about 50 mg/kg (e.g., about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, or about 50 mg/kg). In some embodiments, the dosage of a sesquiterpene lactone (e.g., a compound of Table 2) is about 0.1 mg to about 5 mg (e.g., about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 1.75 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, or about 5 mg). In some embodiments, the dosage of a sesquiterpene lactone (e.g., a compound of Table 2) is between about 0.01 mg/kg to about 10 mg/kg (e.g., about 0.01 mg/kg, about 0.025 mg/kg, about 0.05 mg/kg, about 0.1 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, or about 10 mg/kg). In some embodiments, the dosage of a sesquiterpene lactone (e.g., a compound of Table 2) is between about 0.1 mg/kg to about 5 mg/kg (e.g., about 0.1 mg/kg, about 0.2 mg/kg, about 0.3 mg/kg, about 0.4 mg/kg, about 0.5 mg/kg, about 0.6 mg/kg, about 0.7 mg/kg, about 0.8 mg/kg, about 0.9 mg/kg, about 1 mg/kg, about 1.25 mg/kg, about 1.5 mg/kg, about 1.75 mg/kg, about 2 mg/kg, about 2.5 mg/kg, about 3 mg/kg, about 3.5 mg/kg, about 4 mg/kg, about 4.5 mg/kg, or about 5 mg/kg). In some embodiments, a course of a sesquiterpene lactone (e.g., a compound of Table 2) is between about 1 day to about 24 weeks. In some embodiments, the course of a sesquiterpene lactone (e.g., a compound of Table 2) is administered at least weekly (e.g., once a week, twice a week, three times a week, four times a week, five times a week, six times a week, 7 times a week) throughout a course of treatment. In some embodiments, the course of a sesquiterpene lactone (e.g., a compound of Table 2) is administered daily throughout a course of treatment. Patient Selection and Monitoring The methods of the present disclosure described herein entail administration of a combination of a flavonoid and a sesquiterpene lactone. Accordingly, a patient and/or subject can be selected for treatment using a flavonoid and a sesquiterpene lactone for the treatment of an inflammatory disease or disorder by first evaluating the patient and/or subject to determine
Attorney Docket No.: M2199-7017WO whether the subject has an inflammatory disease or disorder. A subject can be evaluated as having an inflammatory disease or disorder using methods known in the art. The subject can also be monitored, for example, subsequent to administration of a compound described herein (e.g., a flavonoid and a sesquiterpene lactone) or a pharmaceutically acceptable salt thereof. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. In some embodiments, the subject is an adult. In some embodiments, the subject has an acute form of inflammation or an inflammatory disease or disorder. In some embodiments, the subject has a chronic form of inflammation or an inflammatory disease or disorder. In some embodiments, the subject has been diagnosed with an inflammatory disease or disorder. In some embodiments, the subject is treatment naïve. In some embodiments, the subject has previously been treated for inflammation or an inflammatory disease or disorder. For example, the subject may have received an immune therapy. In some embodiments, the subject is suffering from an inflammatory disease or disorder. In some embodiments, the subject has been treated with an agent other than a flavonoid or sesquiterpene lactone described herein and is suffering from a relapsed inflammatory disease or disorder. In some embodiments, the subject has a co-morbidity, such as heart disease, coronary artery disease, a cardiomyopathy, diabetes, obesity, high blood pressure, cancer, cerebrovascular disease, chronic kidney disease, chronic liver disease, cystic fibrosis, an immunodeficiency, and tuberculosis. In some embodiments, the methods described herein further comprise analyzing or receiving analysis of a biopsy specimen from the subject at least once prior to the end of treatment. In some embodiments, the biopsy specimen is analyzed for the levels of a cytokine, antibody, or other hypersensitivity marker. Additional Agents In some embodiments, additional therapeutic agents may be administered with compositions of the present disclosure for the treatment of inflammation or an inflammatory disease or disorder, or any symptom or associated condition thereof. When combination therapy is employed, the additional therapeutic agent(s) can be administered as a separate formulation or may be combined with any of the compositions described herein.
Attorney Docket No.: M2199-7017WO For example, any of the methods described herein may further comprise the administration of a therapeutically effective amount of an additional agent in conjunction with a a flavonoid or a sesquiterpene lactone. Exemplary additional agents include an immune therapy, a vaccine, an anti-inflammatory agent, a pain reliever, a mucolytic agent, a cancer therapy, an antifungal agent, an antibacterial agent, a bronchodilator, or a vasodilator. In some embodiments, the additional agent is an anti-inflammatory agent. For example, the anti-inflammatory agent may be an angiotensin-converting enzyme 2 (ACE-2) inhibitor (e.g., lisinopril, benazepril, captopril, enalapril, fosinopril, moexipril, perindopril, or quinapril), a corticosteroid (e.g., cortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, or hydrocortisone) or a non-steroidal anti-inflammatory drug (NSAID) (e.g., ibuprofen, naproxen, diclofenac, celecoxib, mefenamic acid, etoricoxib, or indomethacin). In some embodiments, the additional agent is a cancer therapy. In some embodiments, the cancer therapy agent is selected from methotrexate, 5-fluorouracil, doxorubicin, vincristine, bleomycin, vinblastine, dacarbazine, toposide, cisplatin, epirubicin, and sorafenib tosylate. The compositions and methods described herein can comprise an immunomodulator. In one embodiment, the immunomodulator is an anti-inflammatory agent described herein, e.g., for treating or preventing a disease or disorder, e.g., a cancer or a fibrotic disorder described herein. The composition and method can include one, two, three or more anti-inflammatory agents, alone or in combination with one or more therapeutic agents described herein (e.g., an AHCM agent, a microenvironment modulator, an immune-checkpoint inhibitor, or an additional therapy, e.g., a cancer or anti-fibrotic therapy). In one embodiment, the anti-inflammatory agent is an agent that blocks, inhibits, or reduces inflammation or signaling from an inflammatory signaling pathway. In one embodiment, the anti-inflammatory agent inhibits or reduces the activity of one or more of any of the following: IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-18, IL-23, interferons (IFNs), e.g., TNF-α, TNF-β, TNF-RI, TNF-RII; CD23, CD30, CD40L, CXCL-1, EGF, G-CSF, GDNF, PDGF-BB, RANTES/CCL5, IKK, NF-kB, TLR2, TLR3, TLR4, TL5, TLR6, TLR7, TLR8, TLR8, TLR9, and/or any cognate receptors thereof. In one embodiment, the anti-inflammatory agent is an IL-1 or IL-1 receptor antagonist, such as anakinra (KINIRET®), rilonacept, or canakinumab.
Attorney Docket No.: M2199-7017WO In one embodiment, the anti-inflammatory agent is an IL-6 or IL-6 receptor antagonist, e.g., an anti-IL-6 antibody or an anti-IL-6 receptor antibody, such as tocilizumab (ACTEMRA®), olokizumab, clazakizumab, sarilumab, sirukumab, siltuximab, or ALX-0061. In one embodiment, the anti-inflammatory agent is a TNF-a antagonist, e.g., an anti- TNFa antibody, such as infliximab (REMICADE®), golimumab (SIMPONI®), adalimumab (HUMIRA®), certolizumab pegol (CIMZIA®) or etanercept. In one embodiment, the anti-inflammatory agent is a corticosteroid. Exemplary corticosteroids include, but are not limited to, cortisone (hydrocortisone, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, ALA-CORT®, HYDROCORT ACETATE®, hydrocortone phosphate LANACORT®, SOLU-CORTEF®), decadron (dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate, DEXASONE®, DIODEX®, HEXADROL®, MAXIDEX®), methylprednisolone (6-methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, DURALONE®, MEDRALONE®, MEDROL®, M-PREDNISOL®, SOLU-MEDROL®), prednisolone (DELTA-CORTEF®, ORAPRED®, PEDIAPRED®, PRELONE®), and prednisone (DELTASONE®, LIQUID PRED®, METICORTEN®, ORASONE®)), and bisphosphonates (e.g., pamidronate (AREDIA®), and zoledronic acid (ZOMETA®). In another embodiment, the anti-inflammatory agent is a non-steroidal anti-inflammatory drug (NSAID). Exemplary anti-inflammatory agents (e.g., NSAIDs) include, but are not limited to, aspirin, ibuprofen, naproxen, celecoxib, , diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ketoprofen, ketorolac, mefenamic acid, meloxicam, nabumetone, oxaprozin, piroxicam, sulindac, and tolmetin. In an embodiment, the anti-inflammatory agent is an immune selective anti-inflammatory derivative (ImSAID). Administration in combination can proceed by any technique apparent to those of skill in the art including, for example, separate, sequential, concurrent, and alternating administration. ENUMERATED EMBODIMENTS 1. A method of reducing the level of an inflammatory cytokine in a cell or subject, wherein the method comprises administering to the cell or subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone,
Attorney Docket No.: M2199-7017WO thereby reducing the level of the inflammatory cytokine in the cell or subject. 2. A method of reducing the level of an inflammatory cytokine in a cell, wherein the method comprises administering to the cell a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing the level of the inflammatory cytokine in the cell. 3. A method of reducing the level of an inflammatory cytokine in a subject, wherein the method comprises administering to the subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing the level of the inflammatory cytokine in the subject. 4. The method of any one of embodiments 1 or 3, wherein the subject is a mammal. 5. The method of any one of embodiments 1-3, wherein the inflammatory cytokine is selected from IL-6, IL-1b, and TNF-a. 6. The method of any one of embodiments 1-3, wherein the inflammatory cytokine is IL-6. 7. The method of any one of embodiments 1-3, wherein the inflammatory cytokine is IL-1b. 8. The method of any one of embodiments 1-3, wherein the inflammatory cytokine is TNF- a. 9. The method of any one of embodiments 1-3 or 5-8, wherein the level of the inflammatory cytokine is reduced by about 10%, 25%, 50%, 75%, 90%, 95%, or more, e.g., relative to a reference standard.
Attorney Docket No.: M2199-7017WO 10. The method of any one of embodiments 1-3 or 5-8, wherein the level of the inflammatory cytokine is reduced by about 10%, e.g., relative to a reference standard. 11. The method of any one of embodiments 1-3 or 5-8, wherein the level of the inflammatory cytokine is reduced by about 25%, e.g., relative to a reference standard. 12. The method of any one of embodiments 1-3 or 5-8, wherein the level of the inflammatory cytokine is reduced by about 50%, e.g., relative to a reference standard. 13. The method of any one of embodiments 1-3 or 5-8, wherein the level of the inflammatory cytokine is reduced by about 75%, e.g., relative to a reference standard. 14. The method of any one of embodiments 1-3 or 5-8, wherein the level of the inflammatory cytokine is reduced by about 90%, e.g., relative to a reference standard. 15. The method of any one of embodiments 1-3 or 5-8, wherein the level of the inflammatory cytokine is reduced by about 95%, e.g., relative to a reference standard. 16. A method of increasing the level of an anti-inflammatory cytokine in a cell or subject, wherein the method comprises administering to the cell or subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing the level of an anti-inflammatory cytokine in the cell or subject. 17. A method of increasing the level of an anti-inflammatory cytokine in a cell, wherein the method comprises administering to the cell a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing the level of an anti-inflammatory cytokine in the cell.
Attorney Docket No.: M2199-7017WO 18. A method of increasing the level of an anti-inflammatory cytokine in a subject, wherein the method comprises administering to the subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing the level of an anti-inflammatory cytokine in the subject. 19. The method of any one of embodiments 16 or 18, wherein the subject is a mammal. 20. The method of any one of embodiments 16-18, wherein the anti-inflammatory cytokine is selected from IL-4 and IL-10. 21. The method of any one of embodiments 16-18, wherein the anti-inflammatory cytokine is IL-4. 22. The method of any one of embodiments 16-18, wherein the anti-inflammatory cytokine is IL-10. 23. The method of any one of embodiments 16-18 or 20-22, wherein the level of the anti- inflammatory cytokine is increased by about 5%, 10%, 25%, 50%, 75%, 90%, 95%, or more, e.g., relative to a reference standard. 24. The method of any one of embodiments 16-18 or 20-22, wherein the level of the anti- inflammatory cytokine is increased by about 5%, e.g., relative to a reference standard. 25. The method of any one of embodiments 16-18 or 20-22, wherein the level of the anti- inflammatory cytokine is increased by about 10%, e.g., relative to a reference standard. 26. The method of any one of embodiments 16-18 or 20-22, wherein the level of the anti- inflammatory cytokine is increased by about 25%, e.g., relative to a reference standard.
Attorney Docket No.: M2199-7017WO 27. The method of any one of embodiments 16-18 or 20-22, wherein the level of the anti- inflammatory cytokine is increased by about 50%, e.g., relative to a reference standard. 28. The method of any one of embodiments 16-18 or 20-22, wherein the level of the anti- inflammatory cytokine is increased by about 75%, e.g., relative to a reference standard. 29. The method of any one of embodiments 16-18 or 20-22, wherein the level of the anti- inflammatory cytokine is increased by about 90%, e.g., relative to a reference standard. 30. The method of any one of embodiments 16-18 or 20-22, wherein the level of the anti- inflammatory cytokine is increased by about 95%, e.g., relative to a reference standard. 31. A method of reducing the level of a hypersensitivity marker in a cell or subject, wherein the method comprises administering to the cell or subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing the level of a hypersensitivity marker in the cell or subject. 32. A method of reducing the level of a hypersensitivity marker in a cell, wherein the method comprises administering to the cell a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing the level of a hypersensitivity marker in the cell. 33. A method of reducing the level of a hypersensitivity marker in a subject, wherein the method comprises administering to the subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing the level of a hypersensitivity marker in the subject. 34. The method of any one of claims 31 or 33, wherein the subject is a mammal.
Attorney Docket No.: M2199-7017WO 35. The method of any one of embodiments 31-33, wherein the hypersensitivity marker is selected from IL-13, IL-14, INF-g, and serum IgE. 36. The method of any one of embodiments 31-33, wherein the hypersensitivity marker is IL- 13. 37. The method of any one of embodiments 31-33, wherein the hypersensitivity marker is IL- 14. 38. The method of any one of embodiments 31-33, wherein the hypersensitivity marker is INF-g. 39. The method of any one of embodiments 31-33, wherein the hypersensitivity marker is serum IgE. 40. The method of any one of embodiments 31-33 or 35-39, wherein the level of the hypersensitivity marker is reduced by about 10%, 25%, 50%, 75%, 90%, 95%, or more, e.g., relative to a reference standard. 41. The method of any one of embodiments 31-33 or 35-39, wherein the level of the hypersensitivity marker is reduced by about 10%, e.g., relative to a reference standard. 42. The method of any one of embodiments 31-33 or 35-39, wherein the level of the hypersensitivity marker is reduced by about 25%, e.g., relative to a reference standard. 43. The method of any one of embodiments 31-33 or 35-39, wherein the level of the hypersensitivity marker is reduced by about 50%, e.g., relative to a reference standard. 44. The method of any one of embodiments 31-33 or 35-39, wherein the level of the hypersensitivity marker is reduced by about 75%, e.g., relative to a reference standard.
Attorney Docket No.: M2199-7017WO 45. The method of any one of embodiments 31-33 or 35-39, wherein the level of the hypersensitivity marker is reduced by about 90%, e.g., relative to a reference standard. 46. The method of any one of embodiments 31-33 or 35-39, wherein the level of the hypersensitivity marker is reduced by about 95%, e.g., relative to a reference standard. 47. A method of inducing expression of an anti-inflammatory macrophage in a cell or subject, wherein the method comprises administering to the cell or subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby inducing expression of the anti-inflammatory macrophage in the cell or subject. 48. A method of inducing expression of an anti-inflammatory macrophage in a cell, wherein the method comprises administering to the cell a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby inducing expression of the anti-inflammatory macrophage in the cell. 49. A method of inducing expression of an anti-inflammatory macrophage in a subject, wherein the method comprises administering to the subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby inducing expression of the anti-inflammatory macrophage in the subject. 50. The method of any one of claims 47 or 49, wherein the subject is a mammal. 51. The method of any one of embodiments 47-49, wherein the anti-inflammatory macrophage is an M2 macrophage.
Attorney Docket No.: M2199-7017WO 52. The method of any one of embodiments 47-49 or 51, wherein the M2 macrophages secrete an anti-inflammatory cytokine (e.g., IL-10). 53. A method of improving skin health in a cell or subject, wherein the method comprises administering to the cell or subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby improving skin health in the cell or subject. 54. A method of improving skin health in a cell, wherein the method comprises administering to the cell a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby improving skin health in the cell. 55. A method of improving skin health in a subject, wherein the method comprises administering to the subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby improving skin health in the subject. 56. The method of any one of embodiments 53 or 55, wherein the subject is a mammal. 57. A method of reducing inflammation in a cell or subject, wherein the method comprises administering to the cell or subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing inflammation in the cell or subject. 58. A method of reducing inflammation in a cell, wherein the method comprises administering to the cell a combination of:
Attorney Docket No.: M2199-7017WO (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing inflammation in the cell. 59. A method of reducing inflammation in a subject, wherein the method comprises administering to the subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing inflammation in the subject. 60. The method of any one of embodiments 57 or 59, wherein the subject is a mammal. 61. The method of any one of embodiments 57-59, wherein the inflammation is dermal inflammation or epithelial cell inflammation. 62. A method of treating a dermatological condition in a cell or subject, wherein the method comprises administering to the cell or subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby treating the dermatological condition in a cell or subject in a cell or subject. 63. A method of treating a dermatological condition in a cell, wherein the method comprises administering to the cell a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby treating the dermatological condition in a cell or subject in a cell. 64. A method of treating a dermatological condition in a subject, wherein the method comprises administering to the subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone,
Attorney Docket No.: M2199-7017WO thereby treating the dermatological condition in a cell or subject in a subject. 65. The method of any one of embodiments 62 or 64, wherein the subject is a mammal. 66. The method of any one of embodiments 62-64, wherein the dermatological condition is selected from atopic dermatitis, psoriasis, and dermal hypersensitivity. 67. A method of treating topical inflammation in a subject, wherein the method comprises administering to the subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby treating topical inflammation in a subject. 68. The method of embodiment 67, wherein the subject is a mammal. 69. The method of embodiment 67, wherein the topical inflammation comprises hives or a rash. 70. A method of treating an inflammatory disease or disorder in a cell or subject, wherein the method comprises administering to the cell or subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby treating an inflammatory disease or disorder in a cell or subject. 71. A method of treating an inflammatory disease or disorder in a cell, wherein the method comprises administering to the cell a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby treating an inflammatory disease or disorder in a cell.
Attorney Docket No.: M2199-7017WO 72. A method of treating an inflammatory disease or disorder in a subject, wherein the method comprises administering to the subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby treating an inflammatory disease or disorder in a subject. 73. The method of any one of embodiments 70 or 72, wherein the subject is a mammal. 74. The method of any one of embodiments 70-72, wherein the inflammatory disease or disorder condition comprises rheumatoid arthritis. 75. A method of reducing a symptom of inflammation or an inflammatory disease or disorder in a subject, wherein the method comprises administering to the subject a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone, thereby reducing a symptom of inflammation or an inflammatory disease or disorder in a subject. 76. The method of embodiment 75, wherein the subject is a mammal. 77. The method of embodiment 75, wherein the symptom comprises swelling, irritation, redness, itching, hives, or sneezing. 78. The method of embodiment 77, wherein the symptom comprises swelling. 79. The method of embodiment 77, wherein the symptom comprises irritation. 80. The method of embodiment 77, wherein the symptom comprises redness. 81. The method of embodiment 77, wherein the symptom comprises itching.
Attorney Docket No.: M2199-7017WO 82. The method of embodiment 77, wherein the symptom comprises hives. 83. The method of embodiment 77, wherein the symptom comprises sneezing. 84. The method of any one of the preceding embodiments, wherein one of the flavonoid and the sesquiterpene lactone comprises an AHR agonist, an NRF2 agonist, or a PPARg agonist. 85. The method of any one of the preceding embodiments, wherein one of the flavonoid and the sesquiterpene lactone comprises an AHR agonist. 86. The method of any one of the preceding embodiments, wherein one of the flavonoid and the sesquiterpene lactone comprises an NRF2 agonist. 87. The method of any one of the preceding embodiments, wherein one of the flavonoid and the sesquiterpene lactone comprises a PPARg agonist. 88. The method of any one of the preceding embodiments, wherein each of the flavonoid and the sesquiterpene lactone independently comprises an AHR agonist, an NRF2 agonist, or a PPARg agonist. 89. The method of any one of the preceding embodiments, wherein each of the flavonoid and the sesquiterpene lactone independently comprises an AHR agonist. 90. The method of any one of the preceding embodiments, wherein each of the flavonoid and the sesquiterpene lactone independently comprises an NRF2 agonist. 91. The method of any one of the preceding embodiments, wherein each of the flavonoid and the sesquiterpene lactone independently comprises a PPARg agonist.
Attorney Docket No.: M2199-7017WO 92. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone has the structure of Formula (B-i): a pharmaceutically acceptable salt thereof, wherein: hydrogen, C1-C6 alkyl, or C1-C6 heteroalkyl,
or with the carbon atom to which they are attached, form C2- C6 alkenyl or C2-C6 alkynyl; R2 is hydrogen or C1-C6 alkyl; R3 is hydrogen or C1-C6 alkyl; each of R4 and R5 is independently absent, hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or - ORA, or R4 and R5, taken together with the carbon atoms to which they are attached, form a heterocyclyl ring; R6 is hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or -ORA; R7 is hydrogen or -ORA, or R2 and R7, taken together with the carbon atoms to which they are attached, form a heterocyclyl ring; RA is hydrogen, C1-C6 alkyl, -C(O)-C1-C6 alkyl, C(O)-C2-C6 alkenyl, or cycloalkyl; and “ ” is a single or double bond, provided that when “ ” is a double bond, each of R4 and R5 is independently absent. 93. The method of embodiment 92, wherein each of R1a and R1b is independently hydrogen, C1-C6 alkyl, or C1-C6 heteroalkyl. 94. The method of embodiment 92, wherein each of R1a and R1b is independently hydrogen. 95. The method of embodiment 92, wherein each of R1a and R1b is independently C1-C6 alkyl.
Attorney Docket No.: M2199-7017WO 96. The method of embodiment 92, wherein each of R1a and R1b is independently C1-C6 heteroalkyl. 97. The method of embodiment 92, wherein R1a and R1b, taken together with the carbon atom to which they are attached, form C2-C6 alkenyl or C2-C6 alkynyl. 98. The method of embodiment 92, wherein R1a and R1b, taken together with the carbon atom to which they are attached, form C2-C6 alkenyl. 99. The method of embodiment 92, wherein R1a and R1b, taken together with the carbon atom to which they are attached, form C2-C6 alkynyl. 100. The method of embodiment 92, wherein each of R1a and R1b is independently hydrogen, C1-C6 alkyl, or C1-C6 heteroalkyl, or R1a and R1b, taken together with the carbon atom to which they are attached, form C2-C6 alkenyl or C2-C6 alkynyl. 101. The method of embodiment 92, wherein R2 is hydrogen or C1-C6 alkyl. 102. The method of embodiment 92, wherein R2 is hydrogen. 103. The method of embodiment 92, wherein R2 is C1-C6 alkyl. 104. The method of embodiment 92, wherein R3 is hydrogen or C1-C6 alkyl. 105. The method of embodiment 92, wherein R3 is hydrogen. 106. The method of embodiment 92, wherein R3 is C1-C6 alkyl. 107. The method of embodiment 92, wherein each of R4 and R5 is independently absent, hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or -ORA.
Attorney Docket No.: M2199-7017WO 108. The method of embodiment 92, wherein each of R4 and R5 is independently absent. 109. The method of embodiment 92, wherein each of R4 and R5 is independently hydrogen. 110. The method of embodiment 92, wherein each of R4 and R5 is independently C1-C6 alkyl. 111. The method of embodiment 92, wherein each of R4 and R5 is independently C1-C6 heteroalkyl. 112. The method of embodiment 92, wherein each of R4 and R5 is independently -ORA. 113. The method of embodiment 92, wherein R4 and R5, taken together with the carbon atoms to which they are attached, form a heterocyclyl ring. 114. The method of embodiment 92, wherein each of R4 and R5 is independently absent, hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or -ORA, or R4 and R5, taken together with the carbon atoms to which they are attached, form a heterocyclyl ring. 115. The method of embodiment 92, wherein R6 is hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or -ORA. 116. The method of embodiment 92, wherein R6 is hydrogen. 117. The method of embodiment 92, wherein R6 is C1-C6 alkyl. 118. The method of embodiment 92, wherein R6 is C1-C6 heteroalkyl. 119. The method of embodiment 92, wherein R6 is -ORA. 120. The method of embodiment 92, wherein R7 is hydrogen or -ORA.
Attorney Docket No.: M2199-7017WO 121. The method of embodiment 92, wherein R7 is hydrogen. 122. The method of embodiment 92, wherein R7 is -ORA. 123. The method of embodiment 92, wherein R2 and R7, taken together with the carbon atoms to which they are attached, form a heterocyclyl ring. 124. The method of embodiment 92, wherein R7 is hydrogen or -ORA, or R2 and R7, taken together with the carbon atoms to which they are attached, form a heterocyclyl ring. 125. The method of embodiment 92, wherein RA is hydrogen, C1-C6 alkyl, -C(O)-C1-C6 alkyl, C(O)-C2-C6 alkenyl, or cycloalkyl. 126. The method of embodiment 92, wherein RA is hydrogen. 127. The method of embodiment 92, wherein RA is C1-C6 alkyl. 128. The method of embodiment 92, wherein RA is -C(O)-C1-C6 alkyl. 129. The method of embodiment 92, wherein RA is C(O)-C2-C6 alkenyl. 130. The method of embodiment 92, wherein RA is cycloalkyl. 131. The method of embodiment 92, wherein “ ” is a single or double bond, provided that when “ ” is a double bond, each of R4 and R5 is independently absent. 132. The method of embodiment 92, wherein “ ” is a single or double bond.
133. The method of embodiment 92, wherein “ ” is a single bond.
134. The method of embodiment 92, wherein “ ” is a double bond.
Attorney Docket No.: M2199-7017WO 135. The method of embodiment 92, wherein “ ” is a double bond and each of R4 and R5 is independently absent.
136. The method of any one of the preceding embodiments, wherein the compound of Formula (B-i) is selected from parthenolide, costunolide, eupatolide, onopordopicrin, and deoxyelepantopin, or a pharmaceutically acceptable salt thereof. 137. The method of any one of the preceding embodiments, wherein the compound of Formula (B-i) is parthenolide or a pharmaceutically acceptable salt thereof. 138. The method of any one of the preceding embodiments, wherein the compound of Formula (B-i) is costunolide or a pharmaceutically acceptable salt thereof. 139. The method of any one of the preceding embodiments, wherein the compound of Formula (B-i) is eupatolide or a pharmaceutically acceptable salt thereof. 140. The method of any one of the preceding embodiments, wherein the compound of Formula (B-i) is onopordopicrin or a pharmaceutically acceptable salt thereof. 141. The method of any one of the preceding embodiments, wherein the compound of Formula (B-i) is deoxyelepantopin or a pharmaceutically acceptable salt thereof. 142. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is a compound of Formula (B-i): a pharmaceutically acceptable salt thereof, wherein R2 is
or C1-C6 alkyl; R6 is hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or -ORA; R7 is hydrogen or -ORA, or R2 and R7, taken together with the carbon
Attorney Docket No.: M2199-7017WO atoms to which they are attached, form a heterocyclyl ring; and RA is hydrogen, C1-C6 alkyl, - C(O)-C1-C6 alkyl, C(O)-C2-C6 alkenyl, or cycloalkyl. 143. The method of embodiment 142, wherein R2 is hydrogen or C1-C6 alkyl. 144. The method of embodiment 142, wherein R2 is hydrogen. 145. The method of embodiment 142, wherein R2 is C1-C6 alkyl. 146. The method of embodiment 142, wherein R3 is hydrogen or C1-C6 alkyl. 147. The method of embodiment 142, wherein R3 is hydrogen. 148. The method of embodiment 142, wherein R3 is C1-C6 alkyl. 149. The method of embodiment 142, wherein R6 is hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or -ORA. 150. The method of embodiment 142, wherein R6 is hydrogen. 151. The method of embodiment 142, wherein R6 is C1-C6 alkyl. 152. The method of embodiment 142, wherein R6 is C1-C6 heteroalkyl. 153. The method of embodiment 142, wherein R6 is -ORA. 154. The method of embodiment 142, wherein R7 is hydrogen or -ORA. 155. The method of embodiment 142, wherein R7 is hydrogen. 156. The method of embodiment 142, wherein R7 is -ORA.
Attorney Docket No.: M2199-7017WO 157. The method of embodiment 142, wherein R2 and R7, taken together with the carbon atoms to which they are attached, form a heterocyclyl ring. 158. The method of embodiment 142, wherein RA is hydrogen, C1-C6 alkyl, -C(O)-C1-C6 alkyl, C(O)-C2-C6 alkenyl, or cycloalkyl. 159. The method of embodiment 142, wherein RA is hydrogen. 160. The method of embodiment 142, wherein RA is C1-C6 alkyl. 161. The method of embodiment 142, wherein RA is -C(O)-C1-C6 alkyl. 162. The method of embodiment 142, wherein RA is C(O)-C2-C6 alkenyl. 163. The method of embodiment 142, wherein RA is cycloalkyl. 164. The method of embodiment 142, wherein R2 is C1-C6 alkyl; R3 is C1-C6 alkyl; R6 is hydrogen; and R7 is hydrogen. 165. The method of embodiment 142, wherein R2 is methyl; R3 is methyl; R6 is hydrogen; and R7 is hydrogen. 166. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is a compound of Formula (C-iii): iii) or a pharmaceutically acceptable salt thereof, wherein R2 is
is hydrogen or C1-C6 alkyl; R6 is hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or -ORA; R7 is hydrogen or -ORA, or R2 and R7, taken together with the carbon
Attorney Docket No.: M2199-7017WO atoms to which they are attached, form a heterocyclyl ring; and RA is hydrogen, C1-C6 alkyl, - C(O)-C1-C6 alkyl, C(O)-C2-C6 alkenyl, or cycloalkyl. 167. The method of embodiment 166, wherein R2 is hydrogen or C1-C6 alkyl. 168. The method of embodiment 166, wherein R2 is hydrogen. 169. The method of embodiment 166, wherein R2 is C1-C6 alkyl. 170. The method of embodiment 166, wherein R3 is hydrogen or C1-C6 alkyl. 171. The method of embodiment 166, wherein R3 is hydrogen. 172. The method of embodiment 166, wherein R3 is C1-C6 alkyl. 173. The method of embodiment 166, wherein R6 is hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or -ORA. 174. The method of embodiment 166, wherein R6 is hydrogen. 175. The method of embodiment 166, wherein R6 is C1-C6 alkyl. 176. The method of embodiment 166, wherein R6 is C1-C6 heteroalkyl. 177. The method of embodiment 166, wherein R6 is -ORA. 178. The method of embodiment 166, wherein R7 is hydrogen or -ORA. 179. The method of embodiment 166, wherein R7 is hydrogen. 180. The method of embodiment 166, wherein R7 is -ORA.
Attorney Docket No.: M2199-7017WO 181. The method of embodiment 166, wherein R2 and R7, taken together with the carbon atoms to which they are attached, form a heterocyclyl ring. 182. The method of embodiment 166, wherein RA is hydrogen, C1-C6 alkyl, -C(O)-C1-C6 alkyl, C(O)-C2-C6 alkenyl, or cycloalkyl. 183. The method of embodiment 166, wherein RA is hydrogen. 184. The method of embodiment 166, wherein RA is C1-C6 alkyl. 185. The method of embodiment 166, wherein RA is -C(O)-C1-C6 alkyl. 186. The method of embodiment 166, wherein RA is C(O)-C2-C6 alkenyl. 187. The method of embodiment 166, wherein RA is cycloalkyl. 188. The method of embodiment 166, wherein R2 is C1-C6 alkyl; R3 is C1-C6 alkyl; R6 is hydrogen; and R7 is hydrogen. 189. The method of embodiment 166, wherein R2 is methyl; R3 is methyl; R6 is hydrogen; and R7 is hydrogen. 190. The method of embodiment 166, wherein R2 is C1-C6 alkyl; R3 is C1-C6 alkyl; R6 is - ORA; R7 is hydrogen; and RA is hydrogen. 191. The method of embodiment 166, wherein R2 is methyl; R3 is methyl; R6 is -ORA; R7 is hydrogen; and RA is hydrogen.
Attorney Docket No.: M2199-7017WO 192. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is selected from parthenolide, costunolide, eupatolide, and onopordopicrin, or a pharmaceutically acceptable salt thereof. 193. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is parthenolide or a pharmaceutically acceptable salt thereof. 194. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is costunolide or a pharmaceutically acceptable salt thereof. 195. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is eupatolide or a pharmaceutically acceptable salt thereof. 196. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is onopordopicrin or a pharmaceutically acceptable salt thereof. 197. The method of any one of the preceding embodiments, wherein the flavonoid has the structure of Formula (A):
salt thereof, wherein: each of R1 and R2 is independently hydrogen or ORA; R3 is hydrogen or ORA; R4 is hydrogen or -ORA; RA is hydrogen, C1-C6 alkyl, or cycloalkyl; and “ ” is a single or double bond.
Attorney Docket No.: M2199-7017WO 198. The method of embodiment 197, wherein each of R1 and R2 is independently hydrogen or ORA. 199. The method of embodiment 197, wherein each of R1 and R2 is independently hydrogen. 200. The method of embodiment 197, wherein each of R1 and R2 is independently ORA. 201. The method of embodiment 197, wherein R3 is hydrogen or ORA. 202. The method of embodiment 197, wherein R3 is hydrogen. 203. The method of embodiment 197, wherein R3 is ORA. 204. The method of embodiment 197, wherein R4 is hydrogen or ORA. 205. The method of embodiment 197, wherein R4 is hydrogen. 206. The method of embodiment 197, wherein R4 is ORA. 207. The method of embodiment 197, wherein RA is hydrogen, C1-C6 alkyl, or cycloalkyl. 208. The method of embodiment 197, wherein RA is hydrogen. 209. The method of embodiment 197, wherein RA is C1-C6 alkyl. 210. The method of embodiment 197, wherein RA is cycloalkyl. 211. The method of embodiment 197, wherein “ ” is a single or double bond. 212. The method of embodiment 197, wherein “ ” is a single bond.
Attorney Docket No.: M2199-7017WO 213. The method of embodiment 197, wherein “ ” is a double bond. 214. The method of any one of the preceding embodiments, wherein the flavonoid is selected from quercetin, luteolin, myricetin, taxifolin, fisetin, and kaempferol, or a pharmaceutically acceptable salt thereof. 215. The method of any one of the preceding embodiments, wherein the flavonoid is quercetin or a pharmaceutically acceptable salt thereof. 216. The method of any one of the preceding embodiments, wherein the flavonoid is luteolin or a pharmaceutically acceptable salt thereof. 217. The method of any one of the preceding embodiments, wherein the flavonoid is myricetin or a pharmaceutically acceptable salt thereof. 218. The method of any one of the preceding embodiments, wherein the flavonoid is taxifolin or a pharmaceutically acceptable salt thereof. 219. The method of any one of the preceding embodiments, wherein the flavonoid is fisetin, and kaempferol, or a pharmaceutically acceptable salt thereof. 220. The method of any one of the preceding embodiments, wherein the flavonoid is kaempferol or a pharmaceutically acceptable salt thereof. 221. The method of any one of the preceding embodiments, wherein the flavonoid is selected from quercetin, myricetin, taxifolin, fisetin, and kaempferol, or a pharmaceutically acceptable salt thereof. 222. The method of any one of the preceding embodiments, wherein the flavonoid is quercetin, luteolin, or a pharmaceutically acceptable salt thereof.
Attorney Docket No.: M2199-7017WO 223. The method of any one of the preceding embodiments, wherein the efficacy of the combination is at least X1-fold greater than the efficacy of the flavonoid alone at the molar amount used in the combination, wherein X1 is 1, 1.25, 1.5, 1.75, 2, 2.5, or greater. 224. The method of any one of the preceding embodiments, wherein the efficacy of the combination is at least X1-fold greater than the efficacy of the flavonoid alone at the molar amount used in the combination, wherein X1 is 1. 225. The method of any one of the preceding embodiments, wherein the efficacy of the combination is at least X1-fold greater than the efficacy of the flavonoid alone at the molar amount used in the combination, wherein X1 is 1.25. 226. The method of any one of the preceding embodiments, wherein the efficacy of the combination is at least X1-fold greater than the efficacy of the flavonoid alone at the molar amount used in the combination, wherein X1 is 1.5. 227. The method of any one of the preceding embodiments, wherein the efficacy of the combination is at least X1-fold greater than the efficacy of the flavonoid alone at the molar amount used in the combination, wherein X1 is 1.75. 228. The method of any one of the preceding embodiments, wherein the efficacy of the combination is at least X1-fold greater than the efficacy of the flavonoid alone at the molar amount used in the combination, wherein X1 is 2. 229. The method of any one of the preceding embodiments, wherein the efficacy of the combination is at least X1-fold greater than the efficacy of the flavonoid alone at the molar amount used in the combination, wherein X1 is 2.5. 230. The method of any one of the preceding embodiments, wherein the efficacy of the combination is at least X1-fold greater than the efficacy of the sesquiterpene lactone alone at the molar amount used in the combination, wherein X1 is 1, 1.25, 1.5, 1.75, 2, 2.5, or greater.
Attorney Docket No.: M2199-7017WO 231. The method of any one of the preceding embodiments, wherein the efficacy of the combination is at least X1-fold greater than the efficacy of the sesquiterpene lactone alone at the molar amount used in the combination, wherein X1 is 1. 232. The method of any one of the preceding embodiments, wherein the efficacy of the combination is at least X1-fold greater than the efficacy of the sesquiterpene lactone alone at the molar amount used in the combination, wherein X1 is 1.25. 233. The method of any one of the preceding embodiments, wherein the efficacy of the combination is at least X1-fold greater than the efficacy of the sesquiterpene lactone alone at the molar amount used in the combination, wherein X1 is 1.5. 234. The method of any one of the preceding embodiments, wherein the efficacy of the combination is at least X1-fold greater than the efficacy of the sesquiterpene lactone alone at the molar amount used in the combination, wherein X1 is 1.75. 235. The method of any one of the preceding embodiments, wherein the efficacy of the combination is at least X1-fold greater than the efficacy of the sesquiterpene lactone alone at the molar amount used in the combination, wherein X1 is 2. 236. The method of any one of the preceding embodiments, wherein the efficacy of the combination is at least X1-fold greater than the efficacy of the sesquiterpene lactone alone at the molar amount used in the combination, wherein X1 is 2.5. 237. The method of any one of the proceeding embodiments, wherein the sesquiterpene lactone is parthenolide and the flavonoid is quercetin. 238. The method of any one of the proceeding embodiments, wherein the sesquiterpene lactone is prepared synthetically.
Attorney Docket No.: M2199-7017WO 239. The method of any one of the proceeding embodiments, wherein the flavonoid is prepared synthetically. 240. The method of any one of the proceeding embodiments, wherein the sesquiterpene lactone and/or the flavonoid is extracted from a natural source (e.g., a plant). 241. The method of any one of the proceeding embodiments, wherein the sesquiterpene lactone is extracted from a natural source (e.g., a plant). 242. The method of any one of the proceeding embodiments, wherein the flavonoid is extracted from a natural source (e.g., a plant). 243. The method of any one of the preceding embodiments, wherein the flavonoid is a compound selected from Table 1 or a pharmaceutically acceptable salt thereof. 244. The method of embodiment 243, wherein the flavonoid is substantially pure. 245. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 99.9% of another compound. 246. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 50% of another compound. 247. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 55% of another compound.
Attorney Docket No.: M2199-7017WO 248. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 60% of another compound. 249. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 65% of another compound. 250. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 70% of another compound. 251. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 75% of another compound. 252. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 80% of another compound. 253. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 85% of another compound. 254. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 90% of another compound. 255. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 95% of another compound.
Attorney Docket No.: M2199-7017WO 256. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 99% of another compound. 257. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 99.9% of another compound. 258. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 99.9% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof. 259. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 50% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof. 260. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 55% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof. 261. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 60% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof. 262. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about
Attorney Docket No.: M2199-7017WO 65% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof. 263. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 70% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof. 264. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 75% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof. 265. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 80% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof. 266. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 85% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof. 267. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 90% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof. 268. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about
Attorney Docket No.: M2199-7017WO 95% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof. 269. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 99% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof. 270. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 99.9% of another flavonoid, e.g., a flavonoid listed in Table 1 or a pharmaceutically acceptable salt thereof. 271. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 99.9% of a plant-derived substance. 272. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 50% of a plant-derived substance. 273. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 55% of a plant-derived substance. 274. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 60% of a plant-derived substance.
Attorney Docket No.: M2199-7017WO 275. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 65% of a plant-derived substance. 276. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 70% of a plant-derived substance. 277. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 75% of a plant-derived substance. 278. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 80% of a plant-derived substance. 279. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 85% of a plant-derived substance. 280. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 90% of a plant-derived substance. 281. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 95% of a plant-derived substance. 282. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 99% of a plant-derived substance.
Attorney Docket No.: M2199-7017WO 283. The method of any one of the preceding embodiments, wherein the flavonoid is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 99.5% of a plant-derived substance. 284. The method of any one of the preceding embodiments, wherein the flavonoid is provided in the combination in the absence of quercetin, luteolin, myricetin, taxifolin, fisetin, or kaempferol, or a pharmaceutically acceptable salt thereof. 285. The method of any one of the preceding embodiments, wherein the flavonoid is provided in the combination in the absence of quercetin or a pharmaceutically acceptable salt thereof. 286. The method of any one of the preceding embodiments, wherein the flavonoid is provided in the combination in the absence of luteolin or a pharmaceutically acceptable salt thereof. 287. The method of any one of the preceding embodiments, wherein the flavonoid is provided in the combination in the absence of myricetin or a pharmaceutically acceptable salt thereof. 288. The method of any one of the preceding embodiments, wherein the flavonoid is provided in the combination in the absence of taxifolin or a pharmaceutically acceptable salt thereof. 289. The method of any one of the preceding embodiments, wherein the flavonoid is provided in the combination in the absence of fisetin or a pharmaceutically acceptable salt thereof. 290. The method of any one of the preceding embodiments, wherein the flavonoid is provided in the combination in the absence of kaempferol or a pharmaceutically acceptable salt thereof. 291. The method of any one of the preceding embodiments, wherein the flavonoid is quercetin or a pharmaceutically acceptable salt thereof.
Attorney Docket No.: M2199-7017WO 292. The method of embodiment 291, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided in the combination in the absence of luteolin, myricetin, taxifolin, fisetin, or kaempferol, or a pharmaceutically acceptable salt thereof. 293. The method of embodiment 291, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided in the combination in the absence of luteolin or a pharmaceutically acceptable salt thereof. 294. The method of embodiment 291, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided in the combination in the absence of myricetin or a pharmaceutically acceptable salt thereof. 295. The method of embodiment 291, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided in the combination in the absence of taxifolin or a pharmaceutically acceptable salt thereof. 296. The method of embodiment 291, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided in the combination in the absence of fisetin or a pharmaceutically acceptable salt thereof. 297. The method of embodiment 291, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided in the combination in the absence of kaempferol or a pharmaceutically acceptable salt thereof. 298. The method of any one of embodiments 291-297, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided as a pharmaceutical composition, and the pharmaceutical composition comprises less than about 90%, 95%, 99%, or 99.9% of another compound in listed in Table 1 or a pharmaceutically acceptable salt thereof. 299. The method of any one of embodiments 291-297, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided as a pharmaceutical composition, and the
Attorney Docket No.: M2199-7017WO pharmaceutical composition comprises less than about 90% of another compound in listed in Table 1 or a pharmaceutically acceptable salt thereof. 300. The method of any one of embodiments 291-297, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided as a pharmaceutical composition, and the pharmaceutical composition comprises less than about 95% of another compound in listed in Table 1 or a pharmaceutically acceptable salt thereof. 301. The method of any one of embodiments 291-297, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided as a pharmaceutical composition, and the pharmaceutical composition comprises less than about 99% of another compound in listed in Table 1 or a pharmaceutically acceptable salt thereof. 302. The method of any one of embodiments 291-297, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided as a pharmaceutical composition, and the pharmaceutical composition comprises less than about 99.9% of another compound in listed in Table 1 or a pharmaceutically acceptable salt thereof. 303. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is a compound selected from Table 1 or a pharmaceutically acceptable salt thereof. 304. The method of embodiment 303, wherein the sesquiterpene lactone is substantially pure. 305. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 99.9% of another compound. 306. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 50% of another compound.
Attorney Docket No.: M2199-7017WO 307. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 55% of another compound. 308. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 60% of another compound. 309. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 65% of another compound. 310. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 70% of another compound. 311. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 75% of another compound. 312. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 80% of another compound. 313. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 85% of another compound.
Attorney Docket No.: M2199-7017WO 314. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 90% of another compound. 315. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 95% of another compound. 316. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 99% of another compound. 317. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 99.9% of another compound. 318. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 99.9% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof. 319. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 50% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof. 320. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 55% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof.
Attorney Docket No.: M2199-7017WO 321. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 60% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof. 322. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 65% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof. 323. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 70% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof. 324. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 75% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof. 325. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 80% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof. 326. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 85% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof.
Attorney Docket No.: M2199-7017WO 327. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 90% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof. 328. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 95% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof. 329. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 99% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof. 330. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 99.9% of another sesquiterpene lactone, e.g., a sesquiterpene lactone listed in Table 2 or a pharmaceutically acceptable salt thereof. 331. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 99.9% of a plant- derived substance. 332. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 50% of a plant-derived substance.
Attorney Docket No.: M2199-7017WO 333. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 55% of a plant-derived substance. 334. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 60% of a plant-derived substance. 335. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 65% of a plant-derived substance. 336. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 70% of a plant-derived substance. 337. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 75% of a plant-derived substance. 338. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 80% of a plant-derived substance. 339. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 85% of a plant-derived substance. 340. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 90% of a plant-derived substance.
Attorney Docket No.: M2199-7017WO 341. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 95% of a plant-derived substance. 342. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 99% of a plant-derived substance. 343. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided as a pharmaceutical composition and the pharmaceutical composition comprises less than about 99.9% of a plant-derived substance. 344. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided in the combination in the absence of costunolide, eupatolide, onopordopicrin, and deoxyelepantopin, or a pharmaceutically acceptable salt thereof. 345. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided in the combination in the absence of costunolide or a pharmaceutically acceptable salt thereof. 346. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided in the combination in the absence of eupatolide or a pharmaceutically acceptable salt thereof. 347. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided in the combination in the absence of onopordopicrin or a pharmaceutically acceptable salt thereof.
Attorney Docket No.: M2199-7017WO 348. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is provided in the combination in the absence of deoxyelepantopin or a pharmaceutically acceptable salt thereof. 349. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is parthenolide or a pharmaceutically acceptable salt thereof. 350. The method of embodiment 349, wherein the parthenolide or a pharmaceutically acceptable salt thereof is provided in the combination in the absence of costunolide, eupatolide, onopordopicrin, and deoxyelepantopin, or a pharmaceutically acceptable salt thereof. 351. The method of embodiment 349, wherein the parthenolide or a pharmaceutically acceptable salt thereof is provided in the combination in the absence of costunolide or a pharmaceutically acceptable salt thereof. 352. The method of embodiment 349, wherein the parthenolide or a pharmaceutically acceptable salt thereof is provided in the combination in the absence of eupatolide or a pharmaceutically acceptable salt thereof. 353. The method of embodiment 349, wherein the parthenolide or a pharmaceutically acceptable salt thereof is provided in the combination in the absence of onopordopicrin or a pharmaceutically acceptable salt thereof. 354. The method of embodiment 349, wherein the parthenolide or a pharmaceutically acceptable salt thereof is provided in the combination in the absence of deoxyelepantopin or a pharmaceutically acceptable salt thereof. 355. The method of any one of embodiments 349-354, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided as a pharmaceutical composition, and the pharmaceutical composition comprises less than about 90%, 95%, 99%, or 99.9% of another compound in listed in Table 1 or a pharmaceutically acceptable salt thereof.
Attorney Docket No.: M2199-7017WO 356. The method of any one of embodiments 349-344, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided as a pharmaceutical composition, and the pharmaceutical composition comprises less than about 90% of another compound in listed in Table 1 or a pharmaceutically acceptable salt thereof. 357. The method of any one of embodiments 349-354, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided as a pharmaceutical composition, and the pharmaceutical composition comprises less than about 95% of another compound in listed in Table 1 or a pharmaceutically acceptable salt thereof. 358. The method of any one of embodiments 349-354, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided as a pharmaceutical composition, and the pharmaceutical composition comprises less than about 99% of another compound in listed in Table 1 or a pharmaceutically acceptable salt thereof. 359. The method of any one of embodiments 349-354, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided as a pharmaceutical composition, and the pharmaceutical composition comprises less than about 99.9% of another compound in listed in Table 1 or a pharmaceutically acceptable salt thereof. 360. The method of any one of the preceding embodiments, wherein each of parthenolide and quercetin is independently formulated as a pharmaceutical composition. 361. The method of any one of the preceding embodiments, wherein the parthenolide and quercetin are formulated together as a pharmaceutical composition. 362. The method of any one of the preceding embodiments, wherein each of the parthenolide and quercetin is provided (e.g., administered) concomitantly to the subject.
Attorney Docket No.: M2199-7017WO 363. The method of embodiment 362, wherein each of the parthenolide and quercetin is provided (e.g., administered) sequentially to the subject. 364. The method of embodiment 362, wherein the parthenolide is provided (e.g., administered) to the subject prior to the quercetin. 365. The method of embodiment 362, wherein the quercetin is provided (e.g., administered) to the subject prior to the parthenolide. 366. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone and the flavonoid are formulated for topical, systemic, or oral administration. 367. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone and the flavonoid are formulated for topical administration. 368. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone and the flavonoid are formulated for systemic administration. 369. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone and the flavonoid are formulated for oral administration. 370. The method of any one of the preceding embodiments, wherein the flavonoid is administered at a dosage to provide a concentration of between 0.1 µM and 500 µM in the subject or a cell. 371. The method of any one of the preceding embodiments, wherein the flavonoid is administered at a dosage to provide a concentration of between 0.1 µM and 500 µM in the subject. 372. The method of any one of the preceding embodiments, wherein the flavonoid is administered at a dosage to provide a concentration of between 0.1 µM and 500 µM in a cell.
Attorney Docket No.: M2199-7017WO 373. The method of any one of the preceding embodiments, wherein the flavonoid is administered at a dosage to provide a concentration of between 1 µM and 25 µM in the subject or a cell. 374. The method of any one of the preceding embodiments, wherein the flavonoid is administered at a dosage to provide a concentration of between 1 µM and 25 µM in the subject. 375. The method of any one of the preceding embodiments, wherein the flavonoid is administered at a dosage to provide a concentration of between 1 µM and 25 µM in a cell. 376. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.01 µM and 25 µM in the subject or a cell. 377. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.01 µM and 25 µM in the subject. 378. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.01 µM and 25 µM in a cell. 379. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.1 µM and 5 µM in the subject or a cell. 380. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.1 µM and 5 µM in the subject.
Attorney Docket No.: M2199-7017WO 381. The method of any one of the preceding embodiments, wherein the sesquiterpene lactone is administered at a dosage to provide a concentration of between 0.1 µM and 5 µM in a cell. 382. The method of any one of the preceding embodiments, wherein the ratio of the amount of flavonoid to the sesquiterpene lactone in the combination is between 200:1 to 1:1. 383. The method of embodiment 382, wherein the ratio of the amount of flavonoid to the sesquiterpene lactone in the combination is between 50:1 to 1:1. 384. The method of any one of embodiments 382-383, wherein the ratio of the amount of flavonoid to the sesquiterpene lactone in the combination is between 50:1 to 2:1. 385. The method of any one of embodiments 382-384, wherein the ratio of the amount of flavonoid to the sesquiterpene lactone in the combination is between 25:1 to 2:1. 386. The method of any one of the preceding embodiments, wherein: (i) the flavonoid is quercetin or a pharmaceutically acceptable salt thereof; (ii) the sesquiterpene lactone is parthenolide or a pharmaceutically acceptable salt thereof; and (iii) the molar amount of the flavonoid in the combination is between 20-fold and 5-fold greater than the molar amount of the sesquiterpene lactone. 387. The method of any one of the preceding embodiments, further comprising administration of an additional agent. 388. The method of any one of the preceding embodiments, wherein the subject is a mammal (e.g., a human). 389. The method of any one of the preceding embodiments, wherein the inflammation is present within an inflamed organ, tissue, or cell in a subject.
Attorney Docket No.: M2199-7017WO 390. The method of embodiment 389, wherein the inflamed organ is selected from the group consisting of the akin, brain, spinal cord, eye, skin, lung, heart, pancreas, large intestine, small intestine, stomach, liver, gall bladder, kidney, or spleen. 391. The method of embodiment 389, wherein the inflamed organ is the akin. 392. The method of embodiment 389, wherein the inflamed organ is the brain. 393. The method of embodiment 389, wherein the inflamed organ is the spinal cord. 394. The method of embodiment 389, wherein the inflamed organ is the eye. 395. The method of embodiment 389, wherein the inflamed organ is the skin. 396. The method of embodiment 389, wherein the inflamed organ is the lung. 397. The method of embodiment 389, wherein the inflamed organ is the large intestine. 398. The method of embodiment 389, wherein the inflamed organ is the small intestine. 399. The method of embodiment 389, wherein the inflamed organ is the stomach. 400. The method of embodiment 389, wherein the inflamed organ is the liver. 401. The method of embodiment 389, wherein the inflamed organ is the gall bladder. 402. The method of embodiment 389, wherein the inflamed organ is the kidney. 403. The method of embodiment 389, wherein the inflamed organ is the spleen.
Attorney Docket No.: M2199-7017WO 404. The method of embodiment 389, wherein the inflamed tissue is selected from the group consisting of lung tissue, tracheal tissue, intestinal tissue, skin tissue, pancreatic tissue, vascular tissue, mucosal tissue, kidney tissue, brain tissue, nervous tissue, or cardiac tissue. 405. The method of embodiment 389, wherein the inflamed tissue is lung tissue. 406. The method of embodiment 389, wherein the inflamed tissue is tracheal tissue. 407. The method of embodiment 389, wherein the inflamed tissue is intestinal tissue. 408. The method of embodiment 389, wherein the inflamed tissue is skin tissue. 409. The method of embodiment 389, wherein the inflamed tissue is pancreatic tissue. 410. The method of embodiment 389, wherein the inflamed tissue is vascular tissue. 411. The method of embodiment 389, wherein the inflamed tissue is mucosal tissue 412. The method of embodiment 389, wherein the inflamed tissue is kidney tissue. 413. The method of embodiment 389, wherein the inflamed tissue is brain tissue. 414. The method of embodiment 389, wherein the inflamed tissue is nervous tissue. 415. The method of embodiment 389, wherein the inflamed tissue is cardiac tissue. EXAMPLES The following examples are provided to further illustrate some embodiments of the present disclosure but are not intended to limit the scope of the disclosure. It will be understood
Attorney Docket No.: M2199-7017WO by their exemplary nature that other procedures, methodologies, or techniques known to those skilled in the art may alternatively be used. Example 1: In vitro assay to determine anti-inflammatory properties of exemplary compounds - THP1 cytokine secretion assay AhR, NRF2, or PPARG agonism are known to lead to downstream inhibition of the secretion of various inflammatory cytokines (e.g., TNFa, IL6). Given that AhR, NRF2, or PPARG agonism were observed, the purpose of this example was to demonstrate the ability of quercetin and parthenolide, alone or in combination, to impact various downstream, functional inflammatory processes. Human THP-1 cells were plated and differentiated into macrophages through treatment with phorbol 12-myristate 13-acetate and beta-mercaptoethanol for 72 hours. Differentiated THP-1 macrophages were then stimulated with IFN-gamma (20 ng/mL) and LPS (50 ng/mL) to induce an inflammatory response and co-treated with Parthenolide and/or Quercetin at 0, 0.2, 0.5, 2, 5, 10 uM. Various secreted cytokines were measured from the media using the Ella Automated Immunoassay System (ProteinSimple). Parthenolide alone (0-5 uM) led to dose-dependent inhibition of TNFa secretion, with the greatest TNFa inhibition to 1.3% seen at 5 uM. Quercetin alone (0-10 uM) also led to dose- dependent inhibition of TNFa secretion, with the greatest TNFa inhibition to 38.1% seen at 10 uM. Parthenolide and Quercetin synergized when screened in combination at certain concentrations to lead to even greater TNFa inhibition than the max impact of each compound alone. As an example, Parthenolide (5 uM) in combination with Quercetin (0.2-10 uM) led to complete TNFa inhibition to 0%. Example 2: In vitro assay to determine anti-inflammatory properties of exemplary compounds – Primary T cell cytokine secretion assay CD4+CD25- T-responder cells T-cells can be isolated from human PBMC (STEMCELL Technologies, Cat# 70025) using the CD4+CD127lowCD25+ regulatory T-cell isolation kit (Cat# 18063, STEMCELL Technologies). For CD4+ T-responder cell cytokine release, cells can be seeded at 25000/well in a V-bottom 96-well plate and exposed to IL-2 (100 U/mL) to trigger cytokine secretion. Parthenolide and Quercetin (5 uM + 5 uM) ability to prevent cytokine secretion may be evaluated. A cytokine panel analysis may be performed using Ella Automated Immunoassay System (ProteinSimple).
Attorney Docket No.: M2199-7017WO Example 3: Oxazolone-induced dermatitis mouse model: Experimental design and results The purpose of this example was to demonstrate the combinatorial, anti-inflammatory effects of a combination of parthenolide or quercetin applied topically on oxazolone-induced ear swelling in mice, a model of allergic contact dermatitis. Male BALB/c mice weighing 22 ^ 2 g are used and randomly divided into groups of 5 each. Sham treatment group receive no oxazolone sensitization and challenge, but PBS, plus treated with vehicle (Acetone:ethanol 1:1). All other groups’ animals were sensitized by applying oxazolone (100 ^L, 1.5% in acetone) onto their preshaved abdominal surface on Day 0, and challenged by oxazolone (1%, 20 ^L/ear) seven (7) days later.20 µL of either Vehicle, Dexamethasone (5 mg/mL; anti-inflammatory positive control), or a combination of Parthenolide (0.5 – 3 mg/mL) + Quercetin (1.8 – 10.8 mg/mL) were applied topically to the anterior and posterior surfaces of the right ear 30 minutes before and 15 minutes after oxazolone challenge. Left ear was unstimulated and treated as a control. The right and left ear thickness of each mouse were measured at 24 hours after oxazolone challenge as an index of inflammation. The right ear was harvested and snap frozen for cytokine gene expression analysis. Each compound was assessed by calculating the percentage of cytokine gene expression compared to the Vehicle control, with a lower percentage indicating greater anti-inflammatory action of the compound. Vehicle-treated ears exhibited oxazolone-stimulated increases in ear thickness to 0.42 mm. Dexamethasone-treated ears demonstrated a 29% reduction in thickness compared to the Vehicle-treated ears. Parthenolide + Quercetin-treated ears demonstrated a 20% reduction in thickness compared to the Vehicle-treated ears (FIG.1). Vehicle-treated mice exhibited oxazalone-induced increases in expression of Il1b, Il4, Il6, Il11, Il13, and Tnfa compared to the Sham group. Topical treatment with Dexamethasone effectively reduced Il1b, Il4, Il6, Il11, Il13, and Tnfa gene expression down to 5%, 24%, 33%, 55%, 20%, and 14% of the Vehicle control, respectively. Dexamethasone increased Ifng gene expression to 445% of the Vehicle control. Topical treatment with Parthenolide + Quercetin reduced Il1b, Il4, Il6, Il11, Il13, Tnfa down to <1%, <1%, 50%, 50%, 6%, 47% of the Vehicle control, respectively (Table 3).
Attorney Docket No.: M2199-7017WO Table 3. Fold change in gene expression in ears of mice topically stimulated with oxazolone and treated with vehicle, dexamethasone, or combinations of Quercetin + Parthenolide Cytokine gene Dexamethasone Parthenolide + Quercetin (% of Vehicle control) (% of Vehicle control)
xamp e : - n uce system c n ammaton mouse mo e : xpermental design and results C57Bl/6 male mice, 6-8 weeks old, weighing 22 ^ 2 g were randomly divided into groups of 5-6 each. Sham animals were injected intra-peritoneally with PBS only. All other groups were intraperitoneally injected with either Vehicle control, Dexamethasone (5 mg/kg), or a combination of Parthenolide + Quercetin (4 mg/kg + 9 mg/kg) at 1 hour prior to injection with LPS (1 mg/kg), an agent known to trigger systemic inflammation. After LPS injection, blood was collected at different time points: 30 min, 2 h, 4 h and 24 h and the processed serum or plasma were used for further cytokine analysis through LUMINEX or Ella Automated Immunoassay System (ProteinSimple). At 4 h, Dexamethasone reduced MIP1-beta, CXCL1, and TNFa levels down to 29%, 57%, and 12% of the Vehicle in LPS-injected mice, respectively. Parthenolide + Quercetin reduced MIP1-beta, CXCL1, and TNFa levels down to 73%, 63%, and 55% of the Vehicle in LPS-injected mice, respectively (FIGS.2A-2C). INCORPORATION BY REFERENCE AND EQUIVALENTS The entire contents of all patents, published applications, and references cited herein are incorporated by reference in their entirety. While example embodiments have been particularly shown and described, it will be understood by those skilled in the art that various changes in
Attorney Docket No.: M2199-7017WO form and details may be made therein without departing from the scope of the embodiments encompassed by the appended claims.
Claims
Attorney Docket No.: M2199-7017WO CLAIMS 1. A composition for use in reducing inflammation in a mammal comprising a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone. 2. The composition for use of claim 2, wherein the inflammation is dermal inflammation or epithelial cell inflammation. 3. A composition for use in treating a dermatological condition in a cell or subject, comprising a combination of: (i) a flavonoid; and (ii) a sesquiterpene lactone. 4. The composition for use of claim 3, wherein the dermatological condition is selected from atopic dermatitis, psoriasis, and dermal hypersensitivity. 5. The composition for use of any one of the preceding claims, wherein one of the flavonoid and the sesquiterpene lactone comprises an AHR agonist, an NRF2 agonist, or a PPARg agonist. 6. The composition for use of any one of the preceding claims, wherein one of the flavonoid and the sesquiterpene lactone independently comprises an AHR agonist, an NRF2 agonist, or a PPARg agonist. 7. The composition for use of any one of the preceding claims, wherein the sesquiterpene lactone has the structure of Formula (C-i):
Attorney Docket No.: M2199-7017WO a pharmaceutically acceptable salt thereof, wherein: independently hydrogen, C1-C6 alkyl, or C1-C6 heteroalkyl,
or together with the carbon atom to which they are attached, form C2- C6 alkenyl or C2-C6 alkynyl; R2 is hydrogen or C1-C6 alkyl; R3 is hydrogen or C1-C6 alkyl; each of R4 and R5 is independently absent, hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or - ORA, or R4 and R5, taken together with the carbon atoms to which they are attached, form a heterocyclyl ring; R6 is hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, or -ORA; R7 is hydrogen or -ORA, or R2 and R7, taken together with the carbon atoms to which they are attached, form a heterocyclyl ring; RA is hydrogen, C1-C6 alkyl, -C(O)-C1-C6 alkyl, C(O)-C2-C6 alkenyl, or cycloalkyl; and “ ” is a single or double bond, provided that when “ ” is a double bond, each of R4 and R5 is independently absent. 8. The composition for use of any one of the preceding claims, wherein the compound of Formula (C-i) is selected from a compound in Table 2. 9. The composition for use of any one of the preceding claims, wherein the sesquiterpene lactone is selected from parthenolide, costunolide, eupatolide, and onopordopicrin, or a pharmaceutically acceptable salt thereof. 10. The composition for use of any one of the preceding claims, wherein the sesquiterpene lactone is parthenolide or a pharmaceutically acceptable salt thereof.
Attorney Docket No.: M2199-7017WO 11. The composition for use of any one of the preceding claims, wherein the flavonoid has the structure of Formula (A-i): salt thereof, wherein:
hydrogen or ORA; R3 is hydrogen or ORA; R4 is hydrogen or -ORA; RA is hydrogen, C1-C6 alkyl, or cycloalkyl; and “ ” is a single or double bond. 12. The composition for use of any one of the preceding claims, wherein the compound of Formula (A-i) is selected from a compound Table 1. 13. The composition for use of any one of the preceding claims, wherein the flavonoid is selected from quercetin, myricetin, taxifolin, fisetin, and kaempferol, or a pharmaceutically acceptable salt thereof. 14. The composition for use of any one of the preceding claims, wherein the flavonoid is quercetin, luteolin, or a pharmaceutically acceptable salt thereof. 15. The composition for use of any one of the preceding claims, wherein the flavonoid is quercetin or a pharmaceutically acceptable salt thereof. 16. The composition for use of any one of the preceding claims, wherein the efficacy of the combination is at least X1-fold greater than the efficacy of the flavonoid alone at the molar amount used in the combination, wherein X1 is 1, 1.25, 1.5, 1.75, 2, 2.5, or greater.
Attorney Docket No.: M2199-7017WO 17. The composition for use of any one of the preceding claims, wherein the efficacy of the combination is at least X1-fold greater than the efficacy of the sesquiterpene lactone alone at the molar amount used in the combination, wherein X1 is 1, 1.25, 1.5, 1.75, 2, 2.5, or greater. 18. The composition for use of any one of the proceeding claims, wherein the sesquiterpene lactone is parthenolide and the flavonoid is quercetin. 19. The composition for use of any one of the preceding claims, wherein the flavonoid is provided in the combination in the absence of quercetin, luteolin, myricetin, taxifolin, fisetin, or kaempferol, or a pharmaceutically acceptable salt thereof. 20. The composition for use of any one of the preceding claims, wherein the sesquiterpene lactone is provided in the combination in the absence of costunolide, eupatolide, onopordopicrin, and deoxyelepantopin, or a pharmaceutically acceptable salt thereof. 21. The composition for use of any one of the preceding claims, wherein the sesquiterpene lactone is parthenolide or a pharmaceutically acceptable salt thereof. 22. The composition for use of claim 21, wherein the parthenolide or a pharmaceutically acceptable salt thereof is provided in the combination in the absence of of costunolide, eupatolide, onopordopicrin, and deoxyelepantopin, or a pharmaceutically acceptable salt thereof. 23. The composition for use of any one of claims 21-22, wherein the quercetin or a pharmaceutically acceptable salt thereof is provided as a pharmaceutical composition, and the pharmaceutical composition comprises less than about 90%, 95%, 99%, or 99.9% of another compound in listed in Table 1 or a pharmaceutically acceptable salt thereof. 24. The composition for use of any one of the preceding claims, wherein each of parthenolide and quercetin is independently formulated as a pharmaceutical composition.
Attorney Docket No.: M2199-7017WO 25. The composition for use of any one of the preceding claims, wherein the parthenolide and quercetin are formulated together as a pharmaceutical composition. 26. The composition for use of any one of the preceding claims, wherein each of the parthenolide and quercetin is provided (e.g., administered) concomitantly to the subject. 27. The composition for use of claim 26, wherein each of the parthenolide and quercetin is provided (e.g., administered) sequentially to the subject. 28. The composition for use of claim 26, wherein the parthenolide is provided (e.g., administered) to the subject prior to the quercetin. 29. The composition for use of claim 26, wherein the quercetin is provided (e.g., administered) to the subject prior to the parthenolide. 30. The composition for use of any one of the preceding claims, wherein the sesquiterpene lactone and the flavonoid are formulated for topical, systemic, or oral administration. 31. The composition for use of any one of the preceding claims, wherein the flavonoid is administered at a dosage to provide a concentration of between 0.1 µM and 500 µM in the subject or a cell. 32. The composition for use of any one of the preceding claims, wherein the ratio of the amount of flavonoid to the sesquiterpene lactone in the combination is between 200:1 to 1:1. 33. The composition for use of any one of the preceding claims, wherein: (i) the flavonoid is quercetin or a pharmaceutically acceptable salt thereof; (ii) the sesquiterpene lactone is parthenolide or a pharmaceutically acceptable salt thereof; and (iii) the molar amount of the flavonoid in the combination is between 20-fold and 5-fold greater than the molar amount of the sesquiterpene lactone.
Attorney Docket No.: M2199-7017WO 34. The composition for use of any one of the preceding claims, further comprising administration of an additional agent. 35. The composition for use of any one of the preceding claims, wherein the mammal is a human. 36. The composition for use of any one of the preceding claims, wherein the inflammation is present within an inflamed organ, tissue, or cell in a subject. 37. The composition for use of claim 36, wherein the inflamed organ is selected from the group consisting of the akin, brain, spinal cord, eye, skin, lung, heart, pancreas, large intestine, small intestine, stomach, liver, gall bladder, kidney, or spleen. 38. The composition for use of claim 37, wherein the inflamed tissue is selected from the group consisting of lung tissue, tracheal tissue, intestinal tissue, skin tissue, pancreatic tissue, vascular tissue, mucosal tissue, kidney tissue, brain tissue, nervous tissue, or cardiac tissue.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263396940P | 2022-08-10 | 2022-08-10 | |
US63/396,940 | 2022-08-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024035864A1 true WO2024035864A1 (en) | 2024-02-15 |
Family
ID=88068762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/029963 WO2024035864A1 (en) | 2022-08-10 | 2023-08-10 | Combination of quercetin and pathenolide as anti-inflammatory agents for use in the treatment of dermatitis |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024035864A1 (en) |
-
2023
- 2023-08-10 WO PCT/US2023/029963 patent/WO2024035864A1/en unknown
Non-Patent Citations (4)
Title |
---|
BERGE ET AL.: "Pharmaceutical Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19, XP002675560, DOI: 10.1002/jps.2600660104 |
KARUPPAGOUNDER VENGADESHPRABHU ET AL: "Molecular targets of quercetin with anti-inflammatory properties in atopic dermatitis", DRUG DISCOVERY TODAY, ELSEVIER, AMSTERDAM, NL, vol. 21, no. 4, 22 February 2016 (2016-02-22), pages 632 - 639, XP029500419, ISSN: 1359-6446, DOI: 10.1016/J.DRUDIS.2016.02.011 * |
KEYWAN MORTEZAEE ET AL: "NF-[kappa]B targeting for overcoming tumor resistance and normal tissues toxicity", JOURNAL OF CELLULAR PHYSIOLOGY, WILEY SUBSCRIPTION SERVICES, INC, US, vol. 234, no. 10, 25 March 2019 (2019-03-25), pages 17187 - 17204, XP071323631, ISSN: 0021-9541, DOI: 10.1002/JCP.28504 * |
RIOS J. ET AL: "Effects of Natural Products on Contact Dermatitis", CURRENT MEDICINAL CHEMISTRY. ANTI-INFLAMMATORY & ANTI-ALLERGYAGENTS, vol. 4, no. 1, 1 February 2005 (2005-02-01), NL, pages 65 - 80, XP093097428, ISSN: 1568-0142, DOI: 10.2174/1568014053005273 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7339296B2 (en) | Enhancement of autophagy or extension of lifespan by administration of urolithins or their precursors | |
Wu et al. | Geraniol-mediated osteoarthritis improvement by down-regulating PI3K/Akt/NF-κB and MAPK signals: In vivo and in vitro studies | |
EP3458448B1 (en) | Fasn inhibitors for use in treating non-alcoholic steatohepatitis | |
EA014070B1 (en) | Use of a herbal composition for the treatment of inflammatory disorders | |
AU2018392985A1 (en) | Compositions and methods of treatment for neurological disorders comprising motor neuron diseases | |
US20180311302A1 (en) | Cxcr antagonistic peptides and uses thereof | |
JP2018503637A (en) | Biphenyl derivatives and uses thereof | |
TWI798320B (en) | Therapeutic agent for nervous system disease | |
CN109937053B (en) | Pharmaceutical composition for the treatment of macular degeneration comprising an mTOR inhibitor | |
CN116019813B (en) | Use of Vesatolimod in the preparation of a medicament for the prophylaxis and/or treatment of disorders of the central nervous system | |
WO2024035864A1 (en) | Combination of quercetin and pathenolide as anti-inflammatory agents for use in the treatment of dermatitis | |
WO2020132378A2 (en) | Compositions and methods of treatment for neurological disorders comprising depression | |
WO2024035859A1 (en) | Combination therapies for treating inflammation | |
TW202416945A (en) | Combination therapies for treating inflammation | |
TW202416948A (en) | Combination therapies for treating inflammation | |
KR101706868B1 (en) | A composition for preventing or treating steatohepatitis comprising 2-amino-2-norbornanecarboxylic acid | |
CN114699410A (en) | Application of cepharanthine in preparing medicine for treating rheumatoid arthritis | |
CN109045107B (en) | Medicine for treating rheumatoid arthritis and preparation method thereof | |
KR20210094753A (en) | Novel compound and uses of the same | |
JP7343902B2 (en) | Compounds for use in the prevention and/or treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis | |
RU2564907C1 (en) | Method of treating patients with lichen planus | |
US20160193180A1 (en) | Composition for preventing and treating immune diseases containing daurinol compound as active ingredient | |
JP2007055900A (en) | Medicinal composition for treating and preventing inflammatory disease | |
US11911358B2 (en) | Dicarboxylic acid esters for inducing an analgesic effect | |
TW201343161A (en) | Ameliorative or preventive effect of Antrodia cinnamomea in arthritis, cartilage destruction, or chondrocyte death |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23771987 Country of ref document: EP Kind code of ref document: A1 |